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Background: People with cystic fibrosis are susceptible to pulmonary infection with Pseudomonas
aeruginosa. This may become chronic and lead to increased mortality and morbidity. If treatment is
commenced promptly, infection may be eradicated through prolonged antibiotic treatment.
Objective: To compare the clinical effectiveness, cost-effectiveness and safety of two eradication regimens.
Design: This was a Phase IV, multicentre, parallel-group, randomised controlled trial.
Setting: Seventy UK and two Italian cystic fibrosis centres.
Participants: Participants were individuals with cystic fibrosis aged > 28 days old who had never had a
P. aeruginosa infection or who had been infection free for 1 year.
Interventions: Fourteen days of intravenous ceftazidime and tobramycin or 3 months of oral ciprofloxacin.
Inhaled colistimethate sodium was included in both regimens over 3 months. Consenting patients were
randomly allocated to either treatment arm in a 1 : 1 ratio using simple block randomisation with random
variable block length.
Main outcome measures: The primary outcome was eradication of P. aeruginosa at 3 months and
remaining free of infection to 15 months. Secondary outcomes included time to reoccurrence, spirometry,
anthropometrics, pulmonary exacerbations and hospitalisations. Primary analysis used intention to treat
(powered for superiority). Safety analysis included patients who had received at least one dose of any of
the study drugs. Cost-effectiveness analysis explored the cost per successful eradication and the cost per
quality-adjusted life-year.
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Results: Between 5 October 2010 and 27 January 2017, 286 patients were randomised: 137 patients
to intravenous antibiotics and 149 patients to oral antibiotics. The numbers of participants achieving
the primary outcome were 55 out of 125 (44%) in the intravenous group and 68 out of 130 (52%)
in the oral group. Participants randomised to the intravenous group were less likely to achieve the
primary outcome; although the difference between groups was not statistically significant, the clinically
important difference that the trial aimed to detect was not contained within the confidence interval
(relative risk 0.84, 95% confidence interval 0.65 to 1.09; p = 0.184). Significantly fewer patients in
the intravenous group (40/129, 31%) than in the oral group (61/136, 44.9%) were hospitalised in the
12 months following eradication treatment (relative risk 0.69, 95% confidence interval 0.5 to 0.95;
p = 0.02). There were no clinically important differences in other secondary outcomes. There were
32 serious adverse events in 24 participants [intravenous: 10/126 (7.9%); oral: 14/146 (9.6%)]. Oral
therapy led to reductions in costs compared with intravenous therapy (–£5938.50, 95% confidence
interval –£7190.30 to –£4686.70). Intravenous therapy usually necessitated hospital admission, which
accounted for a large part of this cost.
Limitations: Only 15 out of the 286 participants recruited were adults – partly because of the smaller
number of adult centres participating in the trial. The possibility that the trial participants may be
different from the rest of the cystic fibrosis population and may have had a better clinical status, and
so be more likely to agree to the uncertainty of trial participation, cannot be ruled out.
Conclusions: Intravenous antibiotics did not achieve sustained eradication of P. aeruginosa in a greater
proportion of cystic fibrosis patients. Although there were fewer hospitalisations in the intravenous
group during follow-up, this confers no advantage over the oral therapy group, as intravenous
eradication frequently requires hospitalisation. These results do not support the use of intravenous
antibiotics to eradicate P. aeruginosa in cystic fibrosis.
Future work: Future research studies should combine long-term follow-up with regimens to reduce
reoccurrence after eradication.
Trial registration: Current Controlled Trials ISRCTN02734162 and EudraCT 2009-012575-10.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 25, No. 65. See the NIHR Journals Library website for further project information.
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MCRN CTU Medicines for Children Research
Network Clinical Trials Unit




NICE National Institute for Health and
Care Excellence
NIHR National Institute for Health Research
PFGE pulsed-field gel electrophoresis
PHE Public Health England
PI principal investigator
PISC patient information sheet and
consent form
PPI patient and public involvement
PSS Personal Social Services
PSSRU Personal Social Services Research Unit
QALY quality-adjusted life-year
REC Research Ethics Committee
SAE serious adverse event
SAR serious adverse reaction
SD standard deviation
SE standard error
SOC System Organ Class
SUSAR suspected unexpected serious
adverse reaction
TMG Trial Management Group
TORPEDO-
CF
Trial of Optimal TheRapy for
Pseudomonas EraDicatiOn in
Cystic Fibrosis
TSC Trial Steering Committee
VNTR variable number tandem repeat
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C ystic fibrosis is a genetic condition that affects mucous glands, causing sticky mucus in the lungsand digestive system. People with cystic fibrosis are prone to lung infection with a bacterium
called Pseudomonas aeruginosa, which can lead to serious long-term complications and death. It is
possible to eradicate P. aeruginosa if antibiotics are started promptly and taken for several months.
The Trial of Optimal TheRapy for Pseudomonas EraDicatiOn in Cystic Fibrosis (TORPEDO-CF) was
designed to find out if intravenous ceftazidime and tobramycin were better at eradicating P. aeruginosa
than oral ciprofloxacin.
A total of 286 children, young people and adults with cystic fibrosis joined the study from 70 UK
and two Italian centres. Approximately half of the participants received treatment with intravenous
antibiotics and half with oral antibiotics. All participants received inhaled colistin for 3 months and
were followed up for a minimum of 15 months.
We studied whether or not either treatment eradicated P. aeruginosa, and if reinfection happened
during follow-up. We also collected data on lung function, other chest infections and hospital
admissions, and examined whether or not one treatment was more cost-effective than the other.
In total, 15 adults joined TORPEDO-CF, so the study population may not totally match the wider cystic
fibrosis population; however, in TORPEDO-CF, we found that intravenous antibiotics did not achieve
persistent eradication of P. aeruginosa in a greater proportion of cystic fibrosis patients. We also found
that oral antibiotics were more cost-effective than intravenous antibiotics. The intravenous antibiotics
group had fewer hospital admissions during follow-up, but, as they were usually admitted for their
initial treatment, this was not considered an advantage over the oral antibiotics group.
The TORPEDO-CF results do not support the use of intravenous antibiotics to eradicate
P. aeruginosa in cystic fibrosis and, when the findings of this trial are applied in routine clinical practice
in the NHS, patients will most likely receive oral treatment as an outpatient, avoiding the need for
hospital admission.
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Cystic fibrosis is the most common life-limiting recessively inherited condition in white populations. It is
a multisystem disorder in which the airways frequently become blocked with mucus, often associated
with respiratory infections. These infections may lead to progressive respiratory failure and ultimately
to death from breathing failure. Pseudomonas aeruginosa is a common infection in the lungs of patients
with cystic fibrosis.
However, there is uncertainty about the best method to eradicate P. aeruginosa from the lower
respiratory tract and several different strategies are used, including oral quinolones such as
ciprofloxacin, and intravenous and nebulised antibiotics.
The Trial of Optimal TheRapy for Pseudomonas EraDicatiOn in Cystic Fibrosis (TORPEDO-CF) was
conducted to assess the effectiveness and safety of two eradication regimens in children, young people
and adults with cystic fibrosis.
Methods
Study design
This was a Phase IV, multicentre, parallel-group, randomised controlled trial that compared the effects
of intravenous therapy with oral therapy in participants with cystic fibrosis.
Participants were randomised in a ratio of 1 : 1 to receive up to 3 months of treatment, and, once
treatment had stopped, they were then followed up for a minimum of 15 months.
The trial also included an economic evaluation to estimate the incremental cost per quality-adjusted
life-year for intravenous therapy compared with oral therapy.
Eligibility criteria
Eligible participants had a confirmed diagnosis of cystic fibrosis and a positive isolation of P. aeruginosa,
were aged > 28 days, were either Pseudomonas naive (i.e. never previously had P. aeruginosa isolated
from samples) or Pseudomonas free (i.e. infection free for at least 1 year), and were able to start
allocated treatment within 21 days from the date of the positive microbiology report. Participants were
excluded if the P. aeruginosa was resistant to one or more of the trial antibiotics, if they had a known
hypersensitivity or other contraindication to any of the trial antibiotics, if they were already receiving
P. aeruginosa suppressive therapy (such as an inhaled antibiotics), if they had received any P. aeruginosa
eradication therapy within the previous 9 months, or if they were pregnant or breastfeeding. Participants
could be randomised into TORPEDO-CF only once and could not be randomised within 4 weeks of
taking part in another intervention trial.
Recruitment
Randomisation and blinding
Participants were randomised in a 1 : 1 ratio; randomisation sequences were computer-generated,
stratified by centre. Owing to the nature of both therapies, blinding was not possible during the course
of the trial.
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The primary outcome of the trial was defined as successful eradication of P. aeruginosa infection
3 months after allocated treatment had started, with the participant remaining infection free through
to 15 months after the start of allocated treatment.
Secondary outcomes
The secondary outcomes of the trial were:
l time to reoccurrence of original P. aeruginosa infection
l reinfection with a different genotype of P. aeruginosa
l lung function (forced expiratory volume in 1 second, forced vital capacity and forced expiratory flow
at 25–75% of forced vital capacity)
l oxygen saturation
l growth and nutritional status – height, weight and body mass index
l number of pulmonary exacerbations
l admission to hospital
l number of days spent as an inpatient in hospital during treatment phase, and between 3 and
15 months after randomisation
l quality of life (as measured using the Cystic Fibrosis Questionnaire)
l utility (as measured using the EuroQol-5 Dimensions)
l adverse events
l other sputum/cough microbiology (meticillin-resistant Staphylococcus aureus, Burkholderia cepacia
complex, Aspergillus spp., Candida spp. infection)
l cost per patient (from an NHS perspective)
l incremental cost-effectiveness ratio (cost per successfully treated patient, cost per quality-adjusted
life-year)
l carer burden (absenteeism from education or work)
l participant burden (absenteeism from education or work).
The protocol wording for the outcome ‘number of days spent as an inpatient in hospital during
treatment phase and between 3 and 15 months after randomisation’ is ‘Number of days spent as
inpatient in hospital over the three-month period after allocated treatment has finished treatment,
and between three months and 15 months after eradication treatment has finished (other than
14 days spent on initial intravenous treatment)’. It has been changed in the list of secondary outcomes
to aid clarity.
Sample size
The total target number of participants was 286 (143 in each treatment group).
Statistical methods
Primary and secondary outcome data were analysed following the intention-to-treat principle. Safety
analyses included participants’ data if they had received at least one dose of the randomised treatment.
The statistical analysis plan was developed prior to the final analyses being conducted.
The number and percentage of participants who were classified as a success or a failure for the
primary outcome were presented for each treatment arm. The difference between the groups
was tested using the chi-squared test, and the relative risk and associated 95% confidence intervals
were presented.
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The secondary outcomes were analysed using the following methods: binary outcomes were analysed
using the chi-squared test, longitudinal data were analysed using mixed models, time-to-event data
were analysed using log-rank tests, and continuous data were analysed using a Mann–Whitney U-test,
as appropriate.
Economic analysis
An economic analysis was conducted that assessed the incremental cost per successful eradication
of P. aeruginosa infection 3 months after allocated treatment had started, and remaining infection free
through to 15 months after the start of allocated treatment, in the oral therapy arm compared with
the intravenous therapy arm. The time horizon for the analysis was 15 months post randomisation,
and an NHS and Personal Social Services perspective was used for the collection and incorporation
of resource use. All costs were calculated in Great British pounds using the price year 2016/17.
Where possible, unit costs were sourced from national databases. To account for missingness in the
data, multiple imputation was used (m = 25). Regression analysis for incremental costs and outcomes
was adjusted for baseline utility and age, with the correlation between costs and patient outcomes
controlled using bootstrap sampling with replacement (n = 2000).
The secondary analysis calculated quality-adjusted life-years by applying preference weights to recorded
EuroQol-5 Dimensions, three-level version, scores from patients or carers (on behalf of patients). Using
a cost-effectiveness threshold (λ) of £20,000 per quality-adjusted life-year, the incremental net benefit
of treating patients with oral therapy compared with intravenous therapy was calculated. Sensitivity
analyses explored key drivers of cost-effectiveness identified a priori, including the use of the specialised
cystic fibrosis reimbursement tariff for patients, societal costs and using different functional forms for the
cost regression-based models.
Results
Participants who were randomised to the intravenous antibiotic therapy group had a reduced likelihood of
successful eradication of P. aeruginosa 3 months after the start of treatment and remaining infection
free through to 15 months after the start of allocated treatment (relative risk 0.84, 95% confidence
interval 0.65 to 1.09; p = 0.184). The results from the sensitivity analysis were robust to changes that
were made. These results did not change the original conclusion.
Owing to the small number of participants with samples available for variable number tandem
repeat typing at both time points, the analysis of the outcome ‘time to reoccurrence of the original
P. aeruginosa infection’ should be interpreted with caution. This also applies to the results of the
analysis of the outcome ‘infection with a different and distinct genotype of P. aeruginosa’.
The results of the analysis of the secondary outcomes did not show an effect over time on percentage
predicted forced expiratory volume in 1 second, percentage predicted forced expiratory flow at 25–75%
of forced vital capacity, or oxygen saturation. Forced vital capacity was significantly better in the
intravenous antibiotic group than in the oral group (mean difference 3.14, 95% confidence interval 0.15
to 6.14; p = 0.040); however, this finding should be interpreted with caution as there was no adjustment
for multiple testing. Similarly, body mass index (adults) was significantly lower in the intravenous group
than in the oral group (mean difference –0.73, 95% confidence interval –1.39 to –0.08; p = 0.029)
but this was based on a small number of adults with available data (13 in total). There was no evidence
of an effect at 15 months on oxygen saturation or on height for age z-score, weight for age z-score or
body mass index z-scores in children.
During 15 months’ follow-up, 52 out of 146 (35.6%) participants in the oral antibiotic group and 38 out
of 137 (27.7%) participants in the intravenous antibiotic group experienced a pulmonary exacerbation.
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The difference was not statistically significant. Significantly fewer participants in the intravenous group
[intravenous 40/129 (31%) vs. oral 61/136 (44.9%)] were hospitalised in the 12 months following
eradication treatment (relative risk 0.69, 95% confidence interval 0.50 to 0.95; p = 0.020). During
the same 12-month period, the median hospital stay for participants in both groups was 0 days
(interquartile range 0–13 days for the oral group and 0–3 days for the intravenous group; p = 0.005).
There were no statistically significant differences between study groups for the number of participants
who had cough or sputum samples containing meticillin-resistant Staphylococcus aureus, Burkholderia
cepacia complex, Aspergillus spp. or Candida spp.
There were no statistically significantly differences between the two treatment groups at 15 months
across any of the domains in each of the quality-of-life questionnaires.
The median number of days of absenteeism from education or work for carers and participants was
not statistically significantly different between the two treatment groups.
There were no significant safety concerns in either of the groups.
Oral therapy led to lower overall costs than intravenous therapy, and had similar or greater clinical
effectiveness. For a threshold of £20,000 per quality-adjusted life-year, oral therapy generated
£6770.80 (95% confidence interval £5027.40 to £7906.20) benefit per patient compared with
intravenous therapy.
Conclusions
Intravenous therapy did not significantly improve the eradication rate of P. aeruginosa when compared
with oral therapy; the clinically important difference that was set at the beginning of the trial was not
contained in the 95% confidence interval, indicating that intravenous therapy is not clinically beneficial
when compared with oral therapy in the treatment of P. aeruginosa. The health economic analysis
also showed that oral therapy was more cost-effective than intravenous therapy, indicating that when
the findings of this trial are implemented in routine clinical practice, most patients will receive oral
treatment as an outpatient and many admissions will be avoided. This will reduce treatment burden
and will reduce health-care costs.
Recommendations for future research
Future research studies should combine long-term follow-up with regimens to reduce reoccurrence
after eradication.
Trial registration
This trial is registered as ISRCTN02734162 and EudraCT 2009-012575-10.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 65.
See the NIHR Journals Library website for further project information.
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Cystic fibrosis (CF) is the most common life-limiting recessively inherited condition in white
populations. It is a multisystem disorder in which the airways frequently become blocked with mucus,
often associated with respiratory infections. These infections may lead to progressive respiratory
failure and ultimately to death from breathing failure. Pseudomonas aeruginosa is a common infection in
the lungs of patients with CF. The age-specific prevalence of P. aeruginosa in pre-school children is 9%,
rising to 32% for 10- to 15-year-olds.1 Early infection can be eradicated in the majority of patients.
However, once chronic infection is established, P. aeruginosa is virtually impossible to eradicate and
is associated with increased morbidity and mortality.2 Long-term infection is associated with poor
outcomes, including more rapid decline in lung function, such as the amount of air expired in 1 second
of forced expiration [forced expiratory volume in 1 second (FEV1)].3,4 New isolation of P. aeruginosa is
treated with antibiotics in an attempt to eradicate the infection and to delay acquisition of chronic
infection.5 However, there is uncertainty about the best method to eradicate P. aeruginosa from the
lower respiratory tract, and several different strategies are used, including oral quinolones such as
ciprofloxacin, and intravenous (i.v.) and nebulised antibiotics.6–10
There are clear differences between the available treatments in terms of the impact on the patient and
their family, the use of resources and the cost of treatment. However, few studies have compared the
efficacy and cost-effectiveness of these treatments.
Fourteen days of i.v. treatment will usually necessitate admission to hospital and siting of one or more
i.v. lines for drug infusion. The siting of lines can be traumatic, especially for children and their families.
Intravenous aminoglycosides are commonly used and they require further blood tests for monitoring
of plasma levels, and can be associated with kidney and inner ear damage.11 No study has yet been
conducted to investigate the therapeutic advantage of i.v. and oral treatment.
In 2005, the NHS National Institute for Health Research (NIHR) commissioned the Medicines for
Children Research Network to assess the feasibility of conducting a randomised controlled trial to
investigate the prevention of colonisation with P. aeruginosa in CF patients. This report was completed
in 2007, having surveyed UK clinical practice, surveyed opinions of CF patients and families, and
assessed the number of potentially eligible patients for such a trial.12 The result of this feasibility study
was to show that, generally, clinicians treat first or new growth of P. aeruginosa in accordance with
the UK CF Trust guidelines13 and 95% of clinicians reported that they would consider i.v. treatment of
first isolation of P. aeruginosa. In addition, 71% of clinician and 43% of consumer respondents would
consider entry for themselves/their patients into a randomised controlled trial comparing oral with
i.v. antibiotics. The conclusion of the study stated ‘[T]he clinical community are in equipoise when
considering effectiveness of eradication therapy for treatment of P. aeruginosa in patients with cystic
fibrosis’ and recommended that it is feasible to consider the initiation of a randomised controlled trial
investigating eradication therapy to treat P. aeruginosa in patients with CF.
This study has been conceived and designed in response to addressing this clinical equipoise and has
been commissioned by the NIHR.
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Rationale for research
There is equipoise about the best method to eradicate P. aeruginosa from the lower respiratory tract.
Several strategies exist to treat early infection with P. aeruginosa. This includes the use of inhaled
antibiotics, such as colistin and tobramycin,9,14,15 oral quinolones, such as ciprofloxacin,6,10 and i.v.
antibiotics, usually consisting of a combination of an aminoglycoside with a beta-lactam.
Antibiotic strategies for eradication of P. aeruginosa in people with CF have been investigated in a
systematic review of randomised clinical trials,16 which concluded that there is an urgent need for
well-designed and well-executed trials. The review made the specific recommendation that any future
trial should investigate the hypothesis to see if antibiotic treatment of early P. aeruginosa infection
prevents or delays chronic infection, and whether or not this then results in an appreciable clinical
benefit to patients, without causing them harm. The systematic review made the recommendation that
the following outcomes be considered for any future randomised controlled trial: spirometric lung
function; nutritional status;11 and socioeconomic outcomes, including quality of life.
The UK CF Trust has published guidance for antibiotic treatment for CF, including treatment for eradication
of newly acquired P. aeruginosa infection.11 This guidance recommends energetic treatment for a patient who
has isolated P. aeruginosa where cultures have previously been negative and the report commented that
there is no evidence favouring any particular regimen for eradication. The guidance states that appropriate
treatment in this situation will include oral ciprofloxacin for the duration of treatment up to 3 months or i.v.
treatment such as a beta-lactam antibiotic (e.g. ceftazidime or meropenem) or an anti-pseudomonal penicillin
in combination with i.v. tobramycin.11 Intravenous antibiotics are usually administered for 10–14 days in
patients with CF, although there have been no randomised controlled trials of shorter treatment durations.
The rationale for choosing 14 days of i.v. treatment and for choosing 3 months for oral treatment is
that both of these regimens are standard practice in many UK CF centres identified in the feasibility
study,12 both are standard recommendations within the published UK guideline11 and they are believed
to represent current best practice.
Interventions
Participants recruited into the study were randomised to one of the following treatment groups.
Group A
In this treatment group, participants received up to 14 days (recommended treatment duration of
14 days; minimum treatment duration 10 days) of i.v. antibiotics as follows:
l Ceftazidime 150 mg/kg/day, in three divided doses (maximum of 3 g three times daily). Some
centres used a once-daily continuous infusion (where the maximum daily dose would usually be
6 g/day) or twice-daily regimen for ceftazidime. These centres were permitted to continue using
this regimen for the study and should have followed their local dosing guidelines.
l Tobramycin 10 mg/kg/day once daily (maximum 660 mg/day). Some centres used a twice-daily
or thrice-daily regimen for tobramycin. These centres were permitted to continue using their
current regimen for the study and should have followed their local dosing guidelines.
Therapeutic drug monitoring was used to guide tobramycin dosing as per national guidelines11 and
usual clinic procedures.
Group B
In this treatment group, participants received 3 months (12 weeks) of treatment oral ciprofloxacin
twice daily. Ciprofloxacin dose was 20 mg/kg twice daily (maximum 750 mg twice daily). This was in
INTRODUCTION
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line with the British National Formulary (BNF) for children.17 Some clinicians preferred to use a lower
dose of 15 mg/kg twice daily for children < 5 years, as used in national CF guidelines.11
Both treatment arms received 3 months (12 weeks) of nebulised colistin in conjunction with the
randomised treatment. The colistin dose was as recommended by the UK CF Trust: 1,000,000 units
twice daily for children aged ≤ 2 years and 2,000,000 units twice daily for children aged > 2 years and
adults. If the colistin was administered using an I-neb™ (Philips Respironics, Murrysville, PA, USA), then
a lower dose of 1,000,000 units twice daily was used for all ages.
It was considered likely that during the study period a small proportion of participants would develop
a further P. aeruginosa infection. These participants were treated as per local centre guidelines.
Objective
This study aimed to establish the superiority of 14 days of i.v. therapy compared with 3 months of
oral therapy.
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Chapter 2 Trial design and methods
Study design
This study was a Phase IV, multicentre, parallel-group, randomised controlled trial comparing 14 days
of i.v. antibiotic therapy with 3 months of oral antibiotic therapy for participants with CF (Figure 1).
Patient seen for routine clinic visit. Sputum/cough sample taken and sent to
microbiology laboratories for analysis (standard practice) 
Randomisation
Microbiology laboratory contacts patient’s clinical team to
notify them that sample is positive for P. aeruginosa. Clinical
team contacts patient and instructs them to return to clinic
If the patient is Pseudomonas naive (has never previously had P. aeruginosa
isolated from samples) or Pseudomonas free [i.e. any cough or sputum samples
within the previous year (365 days) should be P. aeruginosa free], screening is




14 days of i.v. ceftazidime dose as per national clinical
guidelines (maximum 3 g)  three times dailya
and
Intravenous tobramycin dose as per national clinical
guidelines (maximum 660 mg) once dailya
In conjunction with 3 monthsb of nebulised colistin
twice dailyc     
3 monthsb of oral ciprofloxacin
• Aged < 5 years, dose as per national clinical
    guidelines twice dailya
• Aged ≥ 5 years, dose as per national clinical
    guidelines twice daily (maximum dose 750 mg
    twice daily)a
In conjunction with 3 monthsb of nebulised colistin
twice dailyc   
No
T + 3 months 
T0
Pre trial
T + 6 months
to
T + 15/24 months 
Clinic review: height/weight measured, FEV1 , FEF25–75 , FVC,
sputum/cough sample collected,c CFQ and EQ-5D administered
(baseline, T + 3 months, T + 15 months and T + 24 months), concomitant









Clinic review: height/weight measured, FEV1,
FEF25–75, FVC, sputum/cough sample
collected,c concomitant medications reported
and recorded 
FIGURE 1 The TORPEDO-CF study design. a, Sites that are unable to comply with the trial dosing regimen can use their
current dosing regimen as long as the total daily dose administered is within national clinical guidelines; b, 3 months is
defined as 12 weeks; and c, sample stored for genotyping.
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Trial registration and ethics
The trial was registered on the European Union Drug Regulating Authorities Clinical Trials (EudraCT)
database on 5 May 2009 (as EudraCT number 2009-012575-10) and received clinical trials authorisation
from the Medicines and Healthcare products Regulatory Agency on 2 November 2009 (clinical trials
authorisation reference 12893/0220/001). The trial and all subsequent protocol amendments were
reviewed and authorised by the Medicines and Healthcare products Regulatory Agency.
The trial protocol was not initiated until it had received the favourable opinion of the National Research
Ethics Committee (REC) (London REC reference 09/H0718/51) on 16 November 2009. It was then
reviewed at the research and development offices at participating sites. All subsequent amendments
were reviewed and approved by the National Research Ethics Committee, London REC.
The trial was listed on the International Standard Randomised Controlled Trial Number (ISRCTN)
registry on 21 May 2009 as ISRCTN02734162.
Participant inclusion and exclusion criteria
Inclusion criteria
l Individuals with a diagnosis of CF.
l Children over the age of 28 days, older children and adult CF participants (i.e. there was no upper
age limit).
l Competent adults who had provided fully informed written consent to participate in the trial.
l Minors for whom proxy consent had been given by their parent or legal guardian and who had
provided their assent to participate in the trial (where possible).
l Individuals who had isolated P. aeruginosa and were either:
¢ P. aeruginosa naive (i.e. never previously had P. aeruginosa isolated from samples) or
¢ P. aeruginosa free [i.e. any cough or sputum samples within the previous year (365 days) were
P. aeruginosa free].
l Participants were able to commence treatment no later than 21 days from the date of a
P. aeruginosa-positive microbiology report.
Exclusion criteria
l Antibiotic resistance of the current P. aeruginosa sample to any of ciprofloxacin, ceftazidime,
tobramycin or colistin reported by local microbiology laboratory.
l Known participant hypersensitivity to ciprofloxacin, ceftazidime, tobramycin or colistin.
l Other known contraindications to any of ciprofloxacin, ceftazidime, tobramycin or colistin including
previous aminoglycoside hearing or renal damage.
l Participants in receipt of P. aeruginosa-suppressing treatment, in particular nebulised colistin or
tobramycin, or oral ciprofloxacin for the previous 9 calendar months. Short courses of oral
ciprofloxacin or i.v. antibiotics (with an anti-pseudomonal spectrum of action) were not a reason for
exclusion unless given to treat proven infections with P. aeruginosa.
l Treatment with other anti-pseudomonal nebulised antibiotics.
l Pregnant and nursing mothers (women of child-bearing age were counselled on the risks of
becoming pregnant during the trial and were offered a pregnancy test).
l Previous randomisation in the Trial of Optimal TheRapy for Pseudomonas EraDicatiOn in Cystic
Fibrosis (TORPEDO-CF).
l Previous participation in another related intervention trial within 4 weeks of taking part in TORPEDO-CF.
TRIAL DESIGN AND METHODS
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Recruitment
The trial took place in 70 UK CF centres and two CF centres in Italy.
Recruitment commenced on 5 October 2010 and the final participant was randomised on 27 January 2017.
Informed consent
The trial recruited adults and minors (defined in statutory instrument 200418 No. 1031 as aged
< 16 years). Informed consent procedures reflected the legal and ethical requirements for obtaining
valid written informed consent in these populations.
Prior written informed consent was required for all trial participants. In obtaining and documenting
informed consent, the investigator was required to comply with the applicable regulatory requirements,
and adhered to the principles of good clinical practice (GCP) and to the ethical principles that have their
origin in the Declaration of Helsinki.19
Potential participants and their families were provided information regarding the trial both verbally
and in writing using the ethics-approved patient information sheets and consent forms (PISCs). They
were given the opportunity to discuss the trial with the site team. The PISCs took into account the age
of minors and their assent was obtained, where appropriate. Potential participants and their families
were provided with a clear overview of the trial and details of the procedures, and the potential risks
and benefits of all trial medications were carefully discussed.
Adequate time to consider trial entry (generally 24 hours, although it was acknowledged that some
patients/families came to a decision sooner) was allowed and all participants were given the opportunity
to ask questions, had the opportunity to discuss the study with their surrogates and had time to
consider the information prior to agreeing to participate. All PISCs used in TORPEDO-CF were made
available in the native language of the countries participating in the trial (with the exception of Wales,
where the majority language was used).
All of the recruiting investigators were experienced CF physicians familiar with imparting information
to the relevant trial populations. All investigators requesting consent to participate had attended
GCP training. During the screening process, if a potential patient was identified, then they/their parent
or the person with parental responsibility were approached by the investigator or a designated
member of the investigating team. The trial and its objectives were then described to them, at which
point any questions could also be answered. The treatment schedule and trial visits were in line
with standard clinical care. The potential risks and benefits of the trial interventions were discussed,
as well as what would happen if they chose not to enter the trial or had to withdraw from the trial
for any reason.
The right of the patient (non-minors) or parent/legal guardian (for minors) to refuse consent to
participate in the trial without giving reasons was respected. After the patient had entered the trial,
the clinician remained free to give alternative treatment to that specified in the protocol, at any stage,
if they felt that it was in the best interest of the participant. However, the reason for doing so was
recorded and the patient remained within the trial for the purpose of follow-up and data analysis
according to the treatment option to which they had been allocated. Similarly, the patient remained
free to withdraw from the protocol treatment and trial follow-up at any time without giving reasons
and without prejudicing their further treatment.
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Randomisation
Participants were randomised using a secure (24-hour) web-based randomisation programme,
which was controlled centrally by the Liverpool Clinical Trials Centre (LCTC), to ensure allocation
concealment. Randomisation lists were generated in a 1 : 1 ratio using simple block randomisation,
with random variable blocks of length of two and four after an initial block of length of three to reduce
predictability. Randomisation was stratified by site, but this was not disclosed in the protocol to further
reduce predictability.
Participant treatment allocation was displayed on a secure web page and an automated e-mail
confirmation was sent to the authorised randomiser and the principal investigator (PI) or co-investigator
(where applicable) at the randomising site. It was the responsibility of the PI or delegated research staff
to inform the pharmacy department at their centre of the potential participant prior to randomisation
to ensure that there was a sufficient supply of the study drugs.
In the event of an internet connection failure between the centre and the randomisation system,
the centre contacted the LCTC to resolve the problem. In the event that site access could not be
promptly reinstated, LCTC would attempt to centrally randomise the patient using the web system.
Where this was not possible, LCTC would randomise the participant using a back-up randomisation
envelope. Of the 286 participants who were randomised, four were randomised utilising a back-up
randomisation envelope.
Interventions
Participants recruited into the study were randomised to one of the following treatment groups.
Group A
Up to 14 days (recommended treatment duration of 14 days; minimum treatment duration 10 days) of
i.v. antibiotics as follows:
l Ceftazidime 150 mg/kg/day, in three divided doses (maximum of 3 g three times daily). Some
centres used a once-daily continuous infusion (where the maximum daily dose would usually be
6 g/day) or twice-daily regimen for ceftazidime. These centres were permitted to continue using this
regimen for the study and should have followed their local dosing guidelines.
l Tobramycin 10 mg/kg/day once daily (maximum 660 mg/day). Some centres used a twice-daily or
thrice-daily regimen for tobramycin. These centres were permitted to continue using their current
regimen for the study and should have followed their local dosing guidelines.
Therapeutic drug monitoring was used to guide tobramycin dosing as per national guidelines11 and
usual clinic procedures.
Group B
Three months (12 weeks) of oral ciprofloxacin twice daily. Ciprofloxacin dose was 20 mg/kg twice daily
(maximum 750 mg twice daily). This was in line with the BNF for children.17 Some clinicians preferred
to use a lower dose of 15 mg/kg twice daily for children < 5 years, as used in national CF guidelines.11
Both treatment arms received 3 months (12 weeks) of nebulised colistin in conjunction with the
randomised treatment. Colistin dose was as recommended by the UK CF Trust: 1,000,000 units twice daily
for children aged ≤ 2 years and 2,000,000 units twice daily for children aged > 2 years and adults. If the
colistin was administered using an I-neb™, a lower dose of 1,000,000 units twice daily was used for all ages.
During the study period, it was likely that a small proportion of participants would develop a further
P. aeruginosa infection. These participants were treated as per local centre guidelines.
TRIAL DESIGN AND METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
8
Data collection and management
Outcome measures
Primary outcome
The primary outcome is the successful eradication of P. aeruginosa infection 3 months after allocated
treatment has started, and remaining infection free through to 15 months after the start of allocated
treatment.
Secondary outcomes
l Time to reoccurrence of original P. aeruginosa infection.
l Reinfection with a different genotype of P. aeruginosa.
l Lung function: FEV1, forced vital capacity (FVC), forced expiratory flow at 25–75% of forced vital
capacity (FEF25–75).
l Oxygen saturation.
l Growth and nutritional status: height, weight and body mass index (BMI).
l Number of pulmonary exacerbations. (Definition of pulmonary exacerbation used guidelines
by Rosenfeld.20)
l Admission to hospital.
l Number of days spent as an inpatient in hospital during treatment phase and between 3 and
15 months after randomisation.
l Quality of life [Cystic Fibrosis Questionnaire (CFQ)].
l Utility [EuroQol-5 Dimensions (EQ-5D)].
l Adverse events (AEs).
l Other sputum/cough microbiology [meticillin-resistant Staphylococcus aureus (MRSA), Burkholderia
cepacia complex, Aspergillus, Candida spp. infection].
l Cost per patient (from an NHS perspective).
l Incremental cost-effectiveness ratio (ICER) [cost per successfully treated patient, cost per
quality-adjusted life-year (QALY)].
l Carer burden (absenteeism from education or work).
l Participant burden (absenteeism from education or work).
The protocol wording for the outcome ‘[N]umber of days spent as an inpatient in hospital during
treatment phase and between 3 and 15 months after randomisation’ is: ‘[N]umber of days spent as
inpatient in hospital over the three-month period after allocated treatment has finished treatment, and
between three months and 15 months after eradication treatment has finished-finished (other than




The CFQ is the only published, disease-specific measure of health-related quality of life (HRQoL) for
children (aged 6–13 years), adults and adolescents (aged ≥ 14 years) with CF.21 Twelve domains of
HRQoL are covered in a 44-item survey, which includes physical functioning, role functioning, vitality,
health perceptions, emotional functioning and social functioning, as well as domains specific to CF:
body image, eating disturbances, treatment burden, and respiratory and digestive symptoms.22
Quality-of-life questionnaires (i.e. CFQs) were completed at baseline, and at 3, 15 and 24 months
after the allocated treatment was started. (Note that the 24-month scores were collected for only
those trial participants who started allocated treatment before 1 January 2016.)
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Health Utility (EuroQol-5 Dimensions)
The EuroQol-5 Dimensions, three-level version (EQ-5D-3L)23 scores were collected at baseline, and at
3, 15 and 24 months post treatment commencement (24-month scores were collected for only those
trial participants who started allocated treatment before 1 January 2016). Participants completed the
baseline booklet before their treatment allocation was revealed.
The PI or delegated research staff were required to ensure that the randomisation number and
time point at which the questionnaire booklet was administered were recorded and to notify LCTC
if a participant was too unwell to complete the questionnaire booklet or missed an assessment.
Participants who failed to complete their full treatment allocation were still given the questionnaire
booklet to complete at the protocol-defined time points to avoid bias.
Sample size
Original trial sample size calculation
The sample size calculation was based on the primary outcome of initial eradication of P. aeruginosa
following the start of allocated treatment and continued eradication until 15 months after the start
of allocated treatment. Data dating back to 1995 on the eradication of P. aeruginosa 3 months after
the start of treatment and 12 months following the end of treatment were obtained from an audit
conducted on all current CF participants treated according to a standard UK CF trust protocol at Alder
Hey Children’s Hospital, Liverpool (conducted by Louisa Heaf and Kate Davenport) (Louise Heaf and
Kate Davenport, Alder Hey Children’s Hospital, 2008, personal communication). The data were treated
in accordance with a standard UK CF Trust protocol. Data on 48 children were collected, with infection
eradicated in 77% (37/48) of children at 3 months following the start of treatment and 58% (28/48) of
children continuing to remain infection free at 12 months after the end of treatment (i.e. equivalent to
15 months after the start of allocated treatment in the proposed trial).
For 90% power, at a 5% level of significance, to detect an absolute difference between the control
group (oral ciprofloxacin) and the treatment group (i.v.) of 20% (a difference of between 55% and 75%),
128 participants were required in each group. A 20% difference between the two treatment regimens
was regarded to be of clinical importance, since the more intensive i.v. treatment would need to be
justified by such a substantial benefit. Based on the experience of the TOPIC trial,24 in which five
out of 244 (2%) participants who were randomised did not provide primary outcome data for the
intention-to-treat (ITT) analysis, it was expected that the number of participants who would not
provide data for the primary outcome during TORPEDO-CF would be quite small. Every effort was
made to follow up all randomised participants, regardless of treatment tolerance, but the sample size
was inflated to allow for 10% of participants not providing primary outcome data, increasing the total
target sample size to 286 participants.
Based on the results of the feasibility study conducted for the Health Technology Assessment
programme,12 it was found that the median rate per annum for the number of first or new growths of
P. aeruginosa was 3% (range 1–8%) in adults and was 10% (range 2.5–23%) in children. Applying these
estimates to the UK CF population (based on figures from 22 adult centres, 28 paediatric centres and
two centres with combined populations) enabled a potential population of eligible adults and children
of approximately 122 and 475, respectively, per annum. From the feasibility report, the consent rate
was estimated to be 44%; therefore, the anticipated number of eligible participants was approximately
54 adults and 209 children per annum.
Patient and public involvement
TORPEDO-CF was conceived as a NIHR-commissioned call and thus had patient and public
involvement (PPI) through this process. In addition, it benefited from a feasibility study that explored
TRIAL DESIGN AND METHODS
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the importance, and acceptability, of the research question for children, young people and their
parents, and adults with CF.
In its set-up, TORPEDO-CF profited from PPI involvement through the Young Persons Advisory Group of
theMedicines for Children Research Network, which provided input on the design of documentation intended
for the use of trial participants (e.g. information sheets and promotional materials).
During its conduct, TORPEDO-CF received support from the CF Trust and PPI representation within
the Trial Management Group (TMG) was in the form of ad hoc representation through the CF Trust
Special Adviser on Research and Patient Involvement, who advised on activities to enhance
engagement with the CF community generally and with potentially eligible individuals in particular.
An important element of PPI involvement was provided by the independent Trial Steering Committee
(TSC). PPI representation on the committee provided reassurance that TORPEDO-CF remained of
relevance to and in the interests of the CF community.
Changes to the protocol
The first site was opened to recruitment on 18 June 2010 and version 2.0 of the protocol was in
operation at this time.
Over the course of the trial, eight substantial amendments were made to the protocol. Each amendment
was assessed by the TMG and approved by the REC and by the Medicines and Healthcare products
Regulatory Agency. The main corrections to the protocol included changes to the management of the
trial and the addition of further guidance for participating sites. The definition of the primary outcome
was also amended from ‘[S]uccessful eradication of P. aeruginosa infection at three months post
randomisation, remaining infection free through to 15 months post randomisation’ to ‘[S]uccessful
eradication of P. aeruginosa infection three months after allocated treatment has started, remaining
infection free through to 15 months after the start of allocated treatment’ to eliminate any systematic
bias due to the inevitable delay in starting i.v. treatment compared with oral treatment (caused by the
need for the patient to be admitted to hospital to receive i.v. treatment).
The initial changes to the protocol were to provide clarification of the exclusion criteria and the
secondary outcomes. Following site set up, several sites raised an issue with regard to differences in
site dosing regimens compared with that specified in the protocol. The TMG confirmed that the
changes were acceptable clinically and from a trial perspective.
Please refer to the trial protocol for a full list of protocol amendments (see NIHR Journals Library;
www.journalslibrary.nihr.ac.uk). A summary of amendments follows.
Protocol version 1.0 (21 August 2009) to version 2.0 (15 February 2010)
l The length of treatment for the i.v. group was changed from 10 to 14 days to reflect
clinical practice.
l Inclusion criteria 1 and 3 clarified.
l The inclusion criteria were amended: the text ‘has not isolated P. aeruginosa from cough, sputum
or bronchoalvelolar lavage’ was replaced with ‘[A] minimum number of four consecutive cough or
sputum samples should be P. aeruginosa free within a 12 month period to satisfy eligibility’ and the
text ‘three weeks after the clinical team has been informed that P. aeruginosa has been isolated’ was
replaced with ‘21 days’.
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l Clarification of text in exclusion criteria 1–5.
l An extra exclusion criterion was added: ‘[P]revious participation in another intervention trial within
four weeks of taking part in TORPEDO-CF’.
l Secondary outcome ‘[T]ime to reoccurrence of P. aeruginosa infection’ amended to ‘[T]ime to reoccurrence
of original P. aeruginosa infection’.
l Secondary outcome ‘time to new P. aeruginosa infection’ replaced with ‘re-infection with a different
genotype of P. aeruginosa’.
l Secondary outcome ‘[C]arer burden (absenteeism from school or work)’ was clarified by changing to
‘[C]arer burden (absenteeism from education or work)’.
l Clarifications made to section 6, ‘Trial treatments’.
l Clarifications made to section 7, ‘Assessments and Procedures’.
Protocol version 2.0 (15 February 2010) to version 3.0 (1 September 2010)
l Clarification text added to exclusion criterion 4: ‘[P]lease note, short courses of oral ciprofloxacin or
intravenous antibiotics (with an anti-pseudomonal spectrum of action) are not an exclusion unless
they are given to treat proven infections with P. aeruginosa’.
l Primary end-point text amended from ‘[S]uccessful eradication of P. aeruginosa infection at three
months post randomisation, remaining infection free through to 15 months post randomisation’
changed to read ‘[S]uccessful eradication of P. aeruginosa infection three months after allocated
treatment has started, remaining infection free through to 15 months after the start of
allocated treatment’.
l Secondary end point 8 changed from ‘[N]umber of days spent as inpatient in hospital over the
three-month period post-treatment and between three months and 15 months post-treatment
(other than 14 days spent on initial intravenous treatment)’ to ‘[N]umber of days spent as inpatient
in hospital over the three-month period post-randomisation and between three months and
15 months post-randomisation (other than 14 days spent on initial intravenous treatment)’.
l In section 8.4 of the protocol, text in sample size calculation changed to reflect change in analysis
from post randomisation to post treatment.
l In section 9.7 of the protocol, change in the reporting timelines for AEs/serious adverse events
(SAEs), beginning from the time allocation treatment started up to 28 days after
treatment cessation.
Protocol version 3.0 (1 September 2010) to version 4.0 (13 December 2011)
l Inclusion criterion 1 changed from ‘[D]iagnosis of cystic fibrosis (CF) (clinical feature + sweat chloride
> 60mmol/l and/or 2 CFTR [cystic fibrosis transmembrane conductance regulator] mutations)’ to
‘[D]iagnosis of cystic fibrosis (CF)’.
l Trial treatment text (arm A) changed from ‘[F]ourteen days intravenous ceftazidime 50 mg/kg/dose
(maximum three grams) three times daily and intravenous tobramycin 10 mg/kg/d (maximum
660mg) once daily’ to ‘[F]ourteen days intravenous ceftazidime dose as per national clinical
guidelines (maximum three grams) three times daily and intravenous tobramycin dose as per
national clinical guidelines (maximum 660 mg) once daily’.
l Trial treatment text (arm B) changed from ‘[T]hree months oral ciprofloxacin < 5 years, 15 mg/kg
twice daily, ≥ 5 years, 20 mg/kg twice daily (maximum dose 750 mg twice daily)’ to ‘[T]hree months
oral ciprofloxacin, < 5 years, dose as per national clinical guidelines twice daily, ≥ 5 years, dose as
per national clinical guidelines twice daily (maximum dose 750 mg twice daily)’.
Protocol version 4.0 (13 December 2011) to version 5.0 (11 January 2012)
l Changes made to section 6, ‘Trial Treatments’, in relation to the provision of drug by home
care companies.
TRIAL DESIGN AND METHODS
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Protocol version 5.0 (11 January 2012) to version 6.0 (17 October 2013)
l Inclusion criterion 5b changed from ‘P. aeruginosa free (i.e. a minimum of four consecutive cough
or sputum samples should be P. aeruginosa free within a 12 month period to satisfy eligibility.)’ to
‘P. aeruginosa free (i.e. any cough or sputum samples within the previous year (365 days) should be
P. aeruginosa free.)’.
l Exclusion criterion 4 changed from ‘previous 9 months’ to ‘previous 9 calendar months’.
l Removing requirement for all SAEs to be reported on a SAE report form. Replaced with ‘[A]ll AEs
that has been assessed and judged by the investigator to be not serious to be reported on an AE
form and returned to MCRN CTU [Medicines for Children Research Network Clinical Trials Unit]
as per routine schedule. All SAEs that have been assessed and judged by the investigator to be
unrelated or unlikely to be related to be reported on an AE form and returned to MCRN CTU as
per routine schedule. All serious adverse reactions (SARs) and Suspected unexpected serious
adverse reactions (SUSARs) must be reported immediately by the investigator to the MCRN CTU on
a SAR report form.’
Protocol version 6.0 (17 October 2013) to version 7.0 (12 August 2014)
l Addition of University of Liverpool as co-sponsor; it will act as sole sponsor for international sites.
Protocol version 7.0 (12 August 2014) to version 8.0 (23 December 2015)
l Clarifying follow-up period: patients who start randomised treatment before 1 January 2016
will continue follow-up for 24 months, patients who start randomised treatment on or after
1 January 2016 will continue follow-up for 15 months.
l Clarification to section 6, ‘Trial Treatments’.
Protocol version 8.0 (23 December 2015) to version 9.0 (12 October 2016)
l Updated number of patients to be enrolled.
Compliance with intervention
Participants’ compliance with trial treatment was monitored using participant-completed treatment
diaries to record their daily treatment routine.
The majority of the trial treatment for participants in the i.v. antibiotic therapy group was anticipated
to be administered during hospital in-patient visits, ensuring accurate monitoring of investigational
medicinal product (IMP) compliance. Participants who had experience of administering i.v. antibiotics
at home or those who preferred to have home i.v. were allowed to self-administer i.v. antibiotics at the
discretion of their local PI. In this event, participants were asked to complete a home i.v. treatment
diary each day to ensure compliance with the study medication. Any unused medication and the
packaging of all used medication were to be returned at the next scheduled follow-up visit. All
returned medication/packaging was destroyed as per local procedures.
Trial management and oversight
University Hospitals Bristol NHS Foundation Trust was the sponsoring organisation, and delegated
responsibilities to LCTC, the University of Liverpool and the chief investigator. LCTC was responsible
for co-ordination of the trial (see Appendix 1).
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University of Liverpool was co-sponsor, having no responsibility for the conduct of the trial in the UK,
but acting as sole sponsor for non-UK centres (i.e. the University of Liverpool was legally responsible
for the non-UK conduct of the trial).
Trial Management Group
The TMG was a multidisciplinary team comprising the chief investigators, scientific co-investigators,
PPI representatives, sponsor representative, health economists and members of LCTC (see Appendix 1).
The TMG was responsible for the day-to-day clinical and practical aspects of the trial.
Independent Data and Safety Monitoring Committee
The Independent Data and Safety Monitoring Committee (IDSMC) comprised two independent
clinicians and a statistician (see Appendix 2). The main responsibilities of the IDSMC were to safeguard
the interests of the TORPEDO-CF participants, assess the safety and efficacy of the interventions
during the trial, and monitor the overall progress and conduct of the trial. The IDSMC met at least
annually during the trial and provided recommendations to the TSC. Reports to the IDSMC were
produced by the statistical team at LCTC.
Trial Steering Committee
The TSC comprised an independent chairperson, two independent physicians, two PPI representatives,
an independent statistician and representatives from the TMG (see Appendix 2). An observer from the
sponsor and from the funder were also invited to meetings. The TSC met at least annually throughout
the trial, both by teleconference and by e-mail, shortly after the IDSMC met and its main role was to
provide overall oversight of the trial.
TRIAL DESIGN AND METHODS
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Chapter 3 Statistical methods
General statistical considerations
The analysis and reporting of the study were undertaken in accordance with the Consolidated Standards
of Reporting Trials (CONSORT)25 and the International Conference on Harmonisation E9 Guidelines.26
The main features of the statistical analysis plan are included here with a full and detailed statistical
analysis plan (available at www.uhbristol.nhs.uk/media/3933191/torpedo_final_analysis_statistical_
analysis_plan_v2.pdf; accessed 8 October 2021). All statistical analyses were undertaken using SAS®
software version 9.3 or later (SAS Institute Inc., Cary, NC, USA).
A two-sided p-value ≤ 0.05 was used to declare statistical significance for all analyses, and all
confidence intervals (CIs) were calculated at the 95% level. There were no adjustments for multiple
testing; rather, all secondary analyses were treated as hypothesis generating.
The primary analysis followed the ITT principle as far as practically possible; all randomised participants
were analysed on the basis of the treatment to which they were randomised, regardless of whether or
not they received it. If consent for treatment was withdrawn but the participant was happy to remain
in the study for follow-up, then they were followed up until completion. However, if they decided to
withdraw consent completely, then the reasons for withdrawal of consent were collected (when possible)
and reported for both groups.
Analysis of baseline data
Demographic and baseline characteristics were summarised for each treatment group using descriptive
statistics. No formal statistical testing was performed on these data. Descriptive statistics, including
the number of observations, mean and standard deviation (SD) for continuous variables, and counts
and percentages for discrete variables, were presented, as appropriate.
Analysis of compliance data
For i.v. antibiotic therapy, the number of daily doses that participants received varied by site.
The protocol stated that patients should receive at least 10 days of treatment. For these reasons,
compliance is presented in terms of the number of days on treatment rather than in terms of the
number of doses received.
For oral antibiotic therapy, compliance is presented in terms of the number of doses received and a
compliance rate [the percentage of the total doses (n = 168: two doses per day for three lots of 28 days)
that were received].
For nebulised therapy, compliance is presented in the same way as oral antibiotic therapy. Data are
presented split by treatment group.
All compliance data are presented descriptively [total (n), mean, SD, median, interquartile (IQR) range,
range, minimum and maximum]. No formal statistical testing was undertaken.
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Analysis of primary outcome
The primary outcome, successful eradication of P. aeruginosa 3 months after the start of treatment,
and remaining infection free through to 15 months after the start of treatment, was a binary outcome.
Participants were classified as a success if there was no record of P. aeruginosa on their microbiology
case report form between 3 and 15 months after treatment commencement, and a failure if there was
at least one record of P. aeruginosa on their microbiology report during this time.
To determine if a participant had eradicated P. aeruginosa at 3 months, they must have had a sample
within 28 days on either side of their expected 3-month visit date (treatment commencement
date + 84 days), which was at least 2 days after the last date of any anti-pseudomonal treatment.
To determine if a patient had remained P. aeruginosa free at 15 months, they must have had either a
positive sample within the primary outcome window (3–15 months) or a sample within 28 days either
side of their expected 15-month visit date (treatment commencement date + 420 days). Participants
who had not regrown P. aeruginosa and did not have a sample within the 15-month window (defined above)
were not included in the primary analysis. If a patient was withdrawn before 15 months of follow-up was
completed, they were included in the primary outcome analysis only if they had isolated P. aeruginosa; if there
was no evidence that they had isolated P. aeruginosa prior to being withdrawn they were not included in the
primary analysis.
The number and percentage of participants who were classified as a success and a failure for the
primary outcome were presented for each treatment group. The difference between the groups was
tested using the chi-squared test, and the relative risk and associated 95% CI are presented. The
number and percentage of patients who had a positive sample at their 3-month follow-up visit are
also presented for each treatment group. As a post hoc analysis, the difference between the groups
at 3 months was also tested using the chi-squared test, the relative risk and associated 95% CI were
calculated, and a sensitivity analysis was also carried out that extended the 3-month window to
– 4 weeks/+ 10 weeks.
Six sensitivity analyses were conducted to determine the robustness of the results of the primary analysis:
1. All participants followed up past 3 months, but with no 15-month sample were classified
as successes.
2. All participants followed up past 3 months, but with no 15-month sample were classified as failures.
3. All patients followed up past 3 months, but with no 15-month sample were classified as successes/
failures according to the next sample taken after the end of the 15-month window.
4. Primary analysis adjusted for centre effect – a logistic regression model was fitted to investigate
heterogeneity across centres and adjusted for centre as a random effect.
5. Analysis as per the primary analysis, but 3- and 15-month windows extended to 10 weeks either
side of the expected visit dates: post hoc analysis.
6. Analysis as per the primary analysis, but 15-month window removed (any sample after 3-month
window included): post hoc analysis.
Analysis of secondary outcomes
Time to reoccurrence of the original P. aeruginosa infection was presented graphically using
Kaplan–Meier curves stratified by treatment. The difference between the two treatment groups
was tested using the log-rank test. Two analyses of this outcome were performed as a result of blind
review. The first assumed that all patients who had had a reoccurrence of P. aeruginosa but did not
have both a baseline and a follow-up sample (between 3 and 24 months) sent for genotyping did
not have a reoccurrence of the original P. aeruginosa strain. The second assumed that these patients
did have a reoccurence of the original P. aeruginosa strain.
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Reinfection with a different genotype of P. aeruginosa and admission to hospital were analysed using
the chi-squared test. The relative risk and 95% CI are also presented.
Lung function [percentage predicted FEV1, percentage predicted FVC and percentage predicted FEF25–75
(not measured in participants < 5 years)], oxygen saturation and growth and nutritional status [height
z-scores (children only), weight z-scores (children only), BMI z-scores (children only) and BMI (adults
only)] were analysed using a repeated-measures random effects model with a special power covariance
structure. The baseline measurement, treatment group and time were included in the model as
coefficients and a treatment-by-time interaction was also fitted. The treatment difference at 15 months
and 95% CI are presented.
For the number of pulmonary exacerbations and the number of days spent in hospital, a
Mann–Whitney U-test was used to test whether or not the distribution was the same in each
treatment arm.
Quality of life (as measured by the CFQ – Revised) was analysed using a mixed-effects model for
repeated measures with an unstructured covariance matrix. The baseline measurement, treatment group
and time were included in the model as coefficients and a treatment-by-time interaction was also fitted.
The treatment difference at 15 months and 95% CI are presented.
Whether or not participants had grown at least one positive culture of MRSA, Burkholderia cepacia
complex, Aspergillus or Candida was analysed using the chi-squared test (where there were sufficient
events), and the relative risk and 95% CI are presented. Other sputum microbiology was presented
descriptively; no formal analysis was undertaken.
Carer and participant burden was analysed in two ways. Whether or not carers/participants had been
absent from work/education was analysed using the chi-squared test and presented with a relative risk
and 95% CI. The Mann–Whitney U-test was used to determine whether or not there was a difference
in the distributions of the number of days carers/participants were absent from work/education in
each treatment group.
Analysis of safety data
The safety analysis data set contained all participants who were randomised and had commenced
treatment. All events were coded using the Medical Dictionary for Regulatory Activities (MedDRA).
The number of occurrences of each AE [at the preferred term and System Organ Class (SOC) levels]
and the number (and percentage) of patients experiencing each AE are presented for each treatment
arm and overall. A similar table was produced for all SAEs reported under all versions of the protocol.
Each SAE reported under versions 1.0–5.0 of the protocol and each SAR reported under version 6.0 of





l date of onset
l serious criteria (reporting of all that apply from seven possible options) (PI and chief
investigator assessment)
l severity (mild/moderate/severe) (PI assessment)
l relationship to study drug (PI and chief investigator assessment)
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l expectedness (chief investigator assessment)
l most likely cause (disease under study/other illness/prior or concomitant treatment/protocol
procedure/lack of efficacy) (PI assessment)
l outcome.
There was no formal statistical analysis of any safety data.
Post hoc analyses
Time to P. aeruginosa reoccurrence is presented graphically using Kaplan–Meier curves stratified
by treatment. The difference between the two treatment groups was tested using the log-rank test.
Two analyses of this outcome were performed; the first included all positive samples after 3 months
and the second included samples post 3 months and prior to 15 months. The hazard ratio (HR) and
95% CI were also calculated for the second analysis.
Additional analyses were performed on the lung function, oxygen saturation, growth and nutritional
status, and quality-of-life outcomes. Where the interaction term was not significant in the original model,
it was removed and an overall treatment difference and 95% CI are presented. Treatment differences at
3 and 24 months and the associated 95% CIs were also presented from the original model.
STATISTICAL METHODS
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Chapter 4 Genotyping of Pseudomonas
aeruginosa isolates
Variable number tandem repeats (VNTRs) are short nucleotide sequences that vary in copy numberin bacterial genomes and are thought to occur through deoxyribonucleic acid (DNA) strand
slippage during replication. This variation in copy number may be exploited to generate a VNTR typing
scheme comprising between 9 and 15 selected ‘loci’, or regions of the bacterial genome. Variation in
the number of repeats at each locus generates a numerical code (representing the number of repeat
units at each locus) that may be used to correlate with a bacterial strain type. This method of bacterial
strain typing has been widely used for a range of different bacterial organisms such as Mycobacterium
tuberculosis, Mycobacteroides abscessus, Klebsiella pneumoniae, Acinetobacter baumannii and P. aeruginosa.27–31
Selecting suitable loci for a VNTR typing scheme is critical for defining the scheme’s capacity for
strain discrimination. Usually, loci are selected following specialised computer software analysis of
whole-genome sequence(s) of isolate(s) of the species of interest.32 Factors such as a small repeat size,
choosing non-coding parts of the genome as well as areas that are not likely to contain insertions or
deletions, and whole-genome coverage are important when choosing potential loci.
Use of variable number tandem repeat in a reference laboratory setting
Public Health England (PHE) has used VNTR analysis at nine loci as a method for P. aeruginosa strain
typing since 2010 and, to date (May 2019), PHE has a national database of 31,028 profiles comprising
CF, non-CF and environmental isolates from hospitals across the UK, providing a good national picture.
Good concordance of this methodology was found on comparison with the gold standard, pulsed-field
gel electrophoresis (PFGE).31 In addition, as it is a polymerase chain reaction-based method, results can
be generated rapidly and are portable between laboratories, making it preferable to PFGE, which is
more laborious and not easily comparable between laboratories. Of the nine loci chosen for this
scheme, the ninth is particularly discriminatory and may be used to evaluate relatedness between
isolates from hospital outbreaks and in other settings among non-CF patients,33–36 but this locus is
not always useful for CF isolate discrimination, as variation in copy number may be found in different
colonies from the same sputum sample.
Examining the UK Pseudomonas aeruginosa population structure using
variable number tandem repeat analysis
A study conducted by PHE in 2013 used VNTR analysis to examine the population structure of
P. aeruginosa among UK CF patients, non-CF patients and hospital environmental isolates over a
2-year period.37 In total, 3870 isolates were examined, comprising 726 environmental isolates from
47 hospitals and 2325 isolates from 2230 patients (of whom approximately 54% were CF patients)
from 143 centres. The study highlighted the existence of VNTR profiles representing common
clones present in both patient and environmental specimens, submitted from hospitals across the
UK. Fourteen common types, each found in more than 24 patients within this 2-year period, were
described. Among these were three well-characterised strains associated with transmissibility, which
have been isolated almost exclusively from CF patients, namely the Liverpool, Manchester and
Midlands 1 strains.38,39 These were isolated from 6%, 1.7% and 1.5%, respectively, of 1204 CF patient
isolates in the above-named study.37
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Four of the most common profiles were examined in more detail. Two of these correlated with
previously well-established international clonal lineages, namely ‘PA14’ (VNTR profile: 12, 2, 1, 5, 5,
2, 4, 5, x, where the ninth locus is variable) and ‘clone C’ (VNTR profile: 11, 6, 2, 2, 1, 3, 7/8, 2/3, x,
where the seventh, eighth and ninth loci may vary in copy number),40,41 which correspond to multilocus
sequence types ST253 and 17, respectively. The other two types were ‘cluster A’ (VNTR profile: 8, 3, 4,
5, 2, 3, 5, 2, x), corresponding to ST27, and ‘cluster D’ (VNTR profile: 10, 3, 5, 5, 4, 1, 3, 7, x), where ‘x’
is variable (ST395). These four types were isolated from 6%, 5%, 3% and 2% of patients, respectively,
and were geographically widespread, although they were not always isolated in large numbers in
individual hospitals. PFGE analysis of representatives of each of these VNTR types from multiple hospitals
separated the isolates into four broad clusters corresponding to their VNTR type with an overall similarity
of approximately 70%. This led to the hypothesis that in most cases patients acquired these strains
independently rather than by patient-to-patient transmission. Further evidence for the clonal nature of
these four common profiles was found by examining the sequences for the intrinsic blaOXA-50-like gene.
To examine the hypothesis that these strains were often acquired independently, whole-genome
sequences for 12 isolates of ‘cluster A’ from nine hospitals comprising six CF, five non-CF and one
environmental isolate from geographically distant sites and separated in time were examined. The
presence and absence of genes from the accessory genome detected 9454 variable sequences across
the 12 isolates and the six reference genomes that were compared. A set of seven accessory genes
were chosen from these, which were found to be variably present among a larger set of ‘cluster A’
isolates. Representatives from patients within a single centre mostly had distinct accessory gene
profiles, suggesting that these patients acquired the strain independently, whereas those with clear
epidemiological links shared the same profile. Profiles also varied between representatives from
different centres.
Challenges in variable number tandem repeat analysis of cystic
fibrosis isolates
Variable number tandem repeat analysis of CF isolates often poses additional challenges compared
with the analysis of non-CF outbreaks, particularly, although not exclusively, among chronically infected
patients. In addition to the variation at the last locus found between different colony types from the
same sputum, variation of up to two repeats at one out of the first eight loci may also be found in some
patient samples. There may also be variation between sequential isolates over time. Caution needs to be
applied when inferring strain relatedness solely using VNTR analysis in certain cases. For example, it is
unlikely to be sufficiently discriminatory when assessing whether isolates with similar profiles pre and
post antibiotic therapy represent reinfection from an environmental/other source or therapeutic failure.
In these cases, the greater discrimination provided through whole-genome sequencing of isolates
may be required. Despite these drawbacks, this method has been successfully used by PHE to type
P. aeruginosa isolates from hospitals throughout the UK since 2010, and has proved invaluable for
highlighting outbreaks and aiding cross-infection decisions in CF clinics.
GENOTYPING OF PSEUDOMONAS AERUGINOSA ISOLATES
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Chapter 5 Clinical effectiveness results
Participant recruitment
The first participant was randomised on 5 October 2010 and the final participant was randomised on
27 January 2017, when the recruitment target was met. The last follow-up visit occurred on 10 April 2018.
Sixty-one out of the 72 sites (see Appendix 3) that screened patients randomised at least one
participant. Twenty-two sites randomised at least five participants.
The flow of participants through the trial is presented in the CONSORT flow diagram (Figure 2). A total
of 1308 patients screened for eligibility (patients could be screened on multiple occasions); 1022 did
In ITT analysis set
(n = 148)
Excluded from ITT analysis as patient’s
data completely removedb
(n = 1)
In safety analysis set
(n = 146)
Excluded from safety analysis because
did not receive any allocated
treatment
(n = 2) 
In ITT analysis set
(n = 137)
In safety analysis set
(n = 126)
Excluded from safety analysis because










Discontinued oral antibiotic therapy
(n = 24)
Follow-up




Did not receive allocated intervention
(n = 11) 




Did not receive allocated intervention
(n = 2)
Unknownb









FIGURE 2 The CONSORT flow diagram for all trial participants. a, Multiple screenings allowed; b, Patient randomised by all
data completely removed as PI sign off could not be obtained.
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not undergo randomisation because they did not meet the eligibility criteria and 286 patients were
randomised (137 to i.v. antibiotic therapy and 149 to oral antibiotic therapy). Detailed information on
recruitment is provided in Appendix 4, Tables 28–32.
Analysis populations
The ITT analysis population included 285 of the 286 participants (99.7%) who were randomised; one
participant’s data could not be included as PI approval could not be obtained despite every effort being
made by the TMG to do so. The safety population included 272 of the 286 randomised participants
(95.1%); 13 patients did not receive any of their allocated treatment and one participant’s data could
not be included as PI approval could not be obtained. The analysis set for the primary outcome included
255 participants: 125 in the i.v. antibiotic therapy group and 130 in the oral antibiotic therapy group.
All participants who withdrew consent for trial continuation contributed outcome data up until the
point of withdrawal.
Premature discontinuations
Premature discontinuation of treatment (either IMP or non-IMP) occurred in 40 of the 137 participants
in the i.v. antibiotic therapy group (29.2%) and 26 of the 148 participants in the oral antibiotic therapy
group (17.6%). The most common reasons for premature discontinuation of treatment in the i.v. antibiotic
therapy group were withdrawal of consent (n = 9; 22.5%), venous access problem (n = 7; 17.5%) and
long-line failure (n = 5; 12.5%), and in the oral antibiotic therapy group the reasons were AE (n = 13;
50%) and withdrawal of consent (n = 4; 15.4%). Reasons for premature discontinuation of treatment are
summarised in Table 1.
TABLE 1 Reasons for premature discontinuation of treatment
Reason
Treatment group, n (%)
Total, n (%)i.v. antibiotic therapy Oral antibiotic therapy
AE 1 (2.5) 13 (50.0) 14 (21.2)
Withdrawn consent 9 (22.5) 4 (15.4) 13 (19.7)
Venous access problem 7 (17.5) 0 (0.0) 7 (10.6)
Long-line failure 5 (12.5) 0 (0.0) 5 (7.6)
Missing 4 (10.0) 1 (3.8) 5 (7.6)
Clinician decision 3 (7.5) 1 (3.8) 4 (6.1)
Othera 3 (7.5) 1 (3.8) 4 (6.1)
SAE/reaction 1 (2.5) 3 (11.5) 4 (6.1)
Errorb 3 (7.5) 0 (0.0) 3 (4.5)
Bed not available 2 (5.0) 0 (0.0) 2 (3.0)
Insufficient medication supplied 0 (0.0) 2 (7.7) 2 (3.0)
Lost to follow-up 1 (2.5) 0 (0.0) 1 (1.5)
Poor adherence 0 (0.0) 1 (3.8) 1 (1.5)
Unknown 1 (2.5) 0 (0.0) 1 (1.5)
Total 40 26 66
a Child behaviour, bacteraemia reclassified, regrew P. aeruginosa so changed treatment, and a few bottles exploded
on mixing.
b Mix-up with dates in pharmacy, clinician not aware that patient needed further medication, and participant forgot to
take nebuliser on holiday.
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Withdrawal from follow-up occurred in 5 of the 137 participants in the i.v. antibiotic therapy group
(3.6%) and 16 of the 148 participants in the oral antibiotic therapy group (10.8%). The most common
reason in both groups was that participants were lost to follow-up [three participants in the i.v. antibiotic
therapy group (60%); nine participants in the oral antibiotic therapy group (56.3%)]. Reasons for withdrawals
from follow-up are summarised in Table 2.
Baseline characteristics
The demographic baseline data of the 285 randomised participants were comparable between the
two groups. The proportion of infants and toddlers was slightly larger in the i.v. antibiotic therapy
group (30.7%, compared with 18.9% in the oral antibiotic therapy group). The proportions of male
and female participants were approximately the same across the two treatment groups, with slightly
more female than male participants (Table 3).
Body mass index, lung function and oxygen saturation were similar across the two treatment groups.
The proportions of patients who were naive or free from P. aeruginosa for the preceding 12 months
and who had experienced a pulmonary exacerbation were also comparable across the two groups.
There were fewer patients in the i.v. antibiotic therapy that had a diagnosis based on a homozygous
delta f508 mutation (60.8%, compared with 51.1% in the oral antibiotic therapy group). Similar numbers
of participants in each treatment group had other microorganisms detected at baseline (see Table 3).
TABLE 2 Reasons for withdrawal from follow-up
Reason
Treatment group, n (%)
Total, n (%)i.v. antibiotic therapy Oral antibiotic therapy
AE 0 (0.0) 1 (6.3) 1 (4.8)
Lost to follow-up 3 (60.0) 9 (56.3) 12 (57.1)
Othera 1 (20.0) 2 (12.5) 3 (14.3)
Withdrawn consent 1 (20.0) 4 (25.0) 5 (23.8)
Total 5 16 21
a Complex family issues, travel problems, and change in family circumstances.
TABLE 3 Demographic baseline data: individual level (all centres)
Baseline characteristic
Treatment group, n (%)
i.v. antibiotic therapy (N= 137) Oral antibiotic therapy (N= 148)
Age groupa
Infants and toddlers (28 days–23 months) 42 (30.7) 28 (18.9)
Children (2–11 years) 71 (51.8) 92 (62.2)
Adolescents (12–17 years) 18 (13.1) 19 (12.8)
Adults (18–64 years) 6 (4.4) 9 (6.1)
Sex
Male 63 (46) 67 (45.3)
Female 74 (54) 81 (54.7)
continued
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Protocol deviations
Protocol deviations were monitored centrally by evaluating inclusion/exclusion criteria at trial entry
and throughout the trial. A total of 284 participants (99.6%) had at least one major protocol deviation.
The most common protocol deviations related to visits occurring outside the protocol-specified visit
windows; 282 participants (98.9%) had a visit outside the window at 3 or 15 months (major deviation)
and 280 participants (98.2%) had a visit outside the window at 6, 9, 12, 18, 21 or 24 months (minor
deviation). All protocol deviations were agreed with the co-chief investigators prior to them seeing any
unblinded results (Table 4).
TABLE 3 Demographic baseline data: individual level (all centres) (continued )
Baseline characteristic
Treatment group, n (%)
i.v. antibiotic therapy (N= 137) Oral antibiotic therapy (N= 148)
P. aeruginosa
Naive 81 (59.1) 93 (62.8)
Free 56 (40.9) 55 (37.2)
Other micro-organisms detected
Candida albicans 11 (8) 17 (11.5)
MRSA 0 (0.0) 2 (1.4)
Burkholderia cepacia complex 0 (0.0) 0 (0.0)
Aspergillus fumigatus 2 (1.5) 2 (1.4)
Other organisms 26 (19) 31 (20.9)
Genotype
p.Phe508del/p.Phe508del 70 (51.1) 90 (60.8)
p.Phe508del/other 40 (29.2) 43 (29.1)
p.Phe508del/unknown 4 (2.9) 5 (3.4)
Other/other 12 (8.8) 7 (4.7)
Unknown 11 (8.0) 3 (2)
Pulmonary exacerbation present 18 (13.1) 17 (11.5)
BMI z-score (paediatric), n, mean (SD) 125, 0.3 (1) 131, 0.3 (0.9)
BMI (adults) (kg/m2), n, mean (SD) 6, 24.6 (1.8) 9, 23.2 (2.3)
Time from P. aeruginosa isolation to
treatment initiation (days), n, mean (SD)
126, 8.8 (5.3) 145, 6.8 (5.3)
FEV1% predicted (l), n, mean (SD) 67, 86.6 (15.8) 70, 85.7 (16)
FVC% predicted (l), n, mean (SD) 67, 92.2 (15.5) 70, 95.1 (14.5)
FEF25–75% predicted (l), n, mean (SD) 44, 72.7 (26.6) 53, 70.6 (30.3)
Oxygen saturation (%), n, mean (SD) 118, 97.7 (1.4) 133, 97.7 (1.7)
a Date of birth was not provided for two participants to allow age to be calculated. Age at randomisation was
provided after database lock and analysis, and was added to the baseline table manually.
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Serum creatinine levels prior to the administration of the first dose of tobramycin are presented in
Table 5, along with tobramycin serum concentrations prior to the administration of the second dose
and after 1 week. Table 6 provides summary statistics for the number of days that participants
received i.v. treatment.
TABLE 4 Protocol deviations
Deviation







Any protocol deviation 137 (100.0) 148 (100.0) 285 (100.0)
At least one major deviation 137 (100.0) 147 (99.3) 284 (99.6)
Consent not obtained 0 (0.0) 0 (0.0) 0 (0.0)
Inclusion of patient previously randomised into
TORPEDO-CF
0 (0.0) 0 (0.0) 0 (0.0)
Treatment non-compliance (< 10 days of i.v. treatment
or 120 doses of ciprofloxacin)
35 (25.5) 6 (4.1) 41 (14.4)
Premature discontinuation of randomised treatment
because of safety
2 (1.5) 16 (10.8) 18 (6.3)
Premature discontinuation of randomised treatment
because of patient preference
15 (10.9) 5 (3.4) 20 (7.0)
Scheduled visits at 3 and 15 months occurring outside
appropriate time frame (3 months should be more
than 48 hours after and no more than 14 days after;
15 months should be no more than 7 days before and
14 days after)
136 (99.3) 146 (98.6) 282 (98.9)
At least one minor deviation 134 (97.8) 146 (98.6) 280 (98.2)
Outside age range 0 (0.0) 0 (0.0) 0 (0.0)
Patient starting treatment > 21 days after a positive
microbiology report
1 (0.7) 3 (2.0) 4 (1.4)
Inclusion of patient who has not been clear of
P. aeruginosa for 12 months
1 (0.7) 0 (0.0) 1 (0.4)
Scheduled visits at 6, 9, 12, 18, 21 and 24 months
occurring outside appropriate time frame (no more
than 7 days either side)
134 (97.8) 146 (98.6) 280 (98.2)
TABLE 5 Serum creatinine (mmol/l) and tobramycin (mg/l) serum levels
Summary statistic
Serum creatinine level (mmol/l)
prior to first tobramycin dose
administration
Tobramycin serum levels (mg/l)
Prior to second dose
administration After 1 week
n 109 112 102
Mean 35.6 0.7 1.2
SD 17.7 1.3 4.3
Minimum 0 0 0
Median 33 0.4 0.4
Maximum 132.6 8.7 41
Missing (n) 28 25 35
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Oral antibiotic therapy
Table 7 provides summary statistics for the number of doses that participants received along with a
compliance rate based on a denominator of 168 doses [two doses per day for 84 days (3 × 28 days)].
As some participants remained on treatment for longer than the required 84 days, this information
was updated (post hoc) to include only those doses taken in the first 84 days.
Colistin therapy
Table 8 provides summary statistics for the compliance rate based on a denominator of 168 doses [two doses
per day for 84 days (3 × 28 days)]. As some participants remained on treatment for longer than the required
84 days, this information was updated (post hoc) to include only those doses taken in the first 84 days.
TABLE 6 Ceftazidime and tobramycin compliance
Summary statistic








Missing (n) 0 0
TABLE 8 Colistin compliance
Summary
statistic
Compliance rate (%) using all doses Compliance rate (%) using doses from the first 84 days
i.v. antibiotic therapy Oral antibiotic therapy i.v. antibiotic therapy Oral antibiotic therapy
n 97 105 97 105
Mean 87.8 97.7 82.1 91.6
SD 34.4 21.4 31.5 19.0
Minimum 0.0 0.0 0.0 0.0
Median 100.6 101.2 98.2 98.2
Maximum 125 136.9 100 100
Missing (n) 40 43 40 43
TABLE 7 Ciprofloxacin compliance
Summary
statistic
All doses Doses from first 84 days
Number of doses Compliance rate (%) Number of doses Compliance rate (%)
n 105 105 105 105
Mean 167.1 99.5 156.6 93.2
SD 32.8 19.5 29 17.27
Minimum 0 0.0 0 0.0
Median 173 103.0 166 98.8
Maximum 230 136.9 168 100
Missing (n) 43 43 43 43
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Time from randomisation to treatment commencement
The median (IQR) time from randomisation to treatment commencement was 3 (1–6) days in the
i.v. antibiotic therapy group and 0 (0–1) days in the oral antibiotic therapy group.
Primary outcome
The primary outcome (successful eradication of P. aeruginosa infection 3 months after allocated
treatment has started and remaining infection free through to 15 months after the start of allocated
treatment) was achieved by 55 of the 125 participants (44.0%) in the i.v. antibiotic therapy group
and by 68 of the 130 participants (52.3%) in the oral antibiotic therapy group. Participants who
were randomised to the i.v. antibiotic therapy group had a reduced chance of having successful
eradication of P. aeruginosa 3 months after the start of treatment and remaining infection free through
to 15 months (relative risk 0.84, 95% CI 0.65 to 1.09; p = 0.184). Results from five of the six sensitivity
analyses to address missing data can be found in Table 9, which details the number of patients included
in each analysis, the number in each treatment group in whom eradication was or was not observed,
the relative risk, 95% CI and the p-value from the chi-squared test. The results from all five sensitivity
analyses are consistent with the results from the primary analysis, indicating that the original results
TABLE 9 Primary outcome results
Analysis
Treatment group, n/N (%)





Primary outcome: successful eradication of P. aeruginosa infection 3 months after allocated treatment has started,
remaining infection free through to 15 months after the start of allocated treatment
Primary analysis 55/125 (44) 68/130 (52.3) 0.84 (0.65 to 1.09) 0.184
Sensitivity analysis 1: all participants followed up
past 3 months with no 15-month sample classified
as success
66/136 (48.5) 85/144 (56.9) 0.85 (0.68 to 1.07) 0.159
Sensitivity analysis 2: all participants followed up
past 3 months with no 15-month sample classified
as failure
55/136 (40.4) 68/144 (47.2) 0.86 (0.66 to 1.12) 0.253
Sensitivity analysis 3: all participants followed up
past 3 months with no 15-month sample classified
as success/failure in accordance with the next
sample taken after 15-month window
66/136 (48.5) 81/144 (56.3) 0.86 (0.69 to 1.08) 0.196
Sensitivity analysis 4: as primary analysis, but
3- and 15-month windows extended to – 4 weeks/
+ 10 weeks of the expected visit dates
61/132 (46.2)a 73/139 (52.5)a 0.88 (0.69 to 1.12)a 0.299a
Sensitivity analysis 5: as per primary analysis,
but 15-month window removed (any sample
after 3-month window included)
58/136 (42.7)a 70/144 (48.6)a 0.88 (0.68 to 1.13)a 0.317a
Subgroup analysis 1: P. aeruginosa free participants 23/49 (46.9) 21/50 (42.0) 1.12 (0.72 to 1.74) NR
Subgroup analysis 2: P. aeruginosa naive
participants
32/76 (42.1) 47/80 (58.8) 0.72 (0.53 to 0.99) NR
Unsuccessful eradication of P. aeruginosa 3 months after allocated treatment has started
Primary analysis 13/110 (11.8) 5/116 (4.3) 2.74 (1.01 to 7.44)a 0.037a
Sensitivity analysis: as primary analysis, but
3-month window extended to –4 weeks/
+10 weeks of the expected visit date
22/124 (17.7)a 12/135 (8.9)a 2.00 (1.03 to 3.86)a 0.035a
NR, not reported.
a Post hoc analysis.
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are robust with regard to the assumptions that were made. The additional sensitivity analysis not
reported in Table 9 applied all of the same assumptions as the primary analysis, but used a logistic
regression model to adjust for centre as a random effect. The adjustment to the model for centre did
not significantly affect the results (p = 0.218), indicating that there was no statistically significant effect
of centre on the primary results. Results from a post hoc subgroup analyses in P. aeruginosa naive and
P. aeruginosa free patients are also reported in Table 9. A Mantel–Haenszel test for interaction was
conducted and the relative risks were not significantly different in the two subgroups (p = 0.19).
The number of participants who did not eradicate P. aeruginosa 3 months after the start of treatment
was 13 (11.8%) in the i.v. antibiotic therapy group and five (4.3%) in the oral antibiotic therapy group.
Participants who were randomised to the i.v. antibiotic therapy had an increased risk of unsuccessful
eradication of P. aeruginosa 3 months after the start of treatment (relative risk 2.74, 95% CI 1.01 to
7.44; p = 0.037) (post hoc analysis). The results of this analysis were supported by a sensitivity analysis
in which the 3-month window was widened to – 4 weeks/+ 10 weeks of the expected 3-month visit
date (relative risk 2.00, 95% CI 1.03 to 3.86; p = 0.035).
A post hoc analysis was performed on time to P. aeruginosa reoccurrence. Figure 3 is the Kaplan–Meier
plot for time to P. aeruginosa reoccurrence up until the end of the 15-month window. This analysis
included the 255 participants included in the primary analysis. Oral antibiotic therapy delayed time to
P. aeruginosa reoccurrence compared with i.v. antibiotic therapy; however, the effect was not statistically
significant (HR 1.31, 95% CI 0.93 to 1.85; p = 0.119). Figure 4 is the Kaplan–Meier plot for time to
P. aeruginosa reoccurrence up until the end of the 24-month follow-up period.
Following database lock and the unblinding of the treatment allocations, it was found that one
participant (who had withdrawn from the trial and was not included in the primary analysis) had a
positive sample for P. aeruginosa on the day that they had stopped treatment. The definition in the
statistical analysis plan stated that any samples taken in the 48-hour window following treatment
cessation should be excluded and this was executed for the primary analysis shown above; however,
this should have stated that only samples that were negative for isolation of P. aeruginosa in this period
should be excluded – positive samples should have been included. Further investigation identified no
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FIGURE 3 Time to reoccurrence of P. aeruginosa infection (any strain) up to the end of the 15-month window.
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Secondary outcomes
Time to reoccurrence of original Pseudomonas aeruginosa infection
A total of 50 participants (n= 28 in the i.v. antibiotic therapy group; n = 22 in the oral antibiotic therapy
group) had P. aeruginosa genotyping performed on both a baseline and a follow-up sample over the course
of the trial. Owing to the limited numbers of participants with genotyping results, two analyses were
performed on this outcome, in which assumptions were made around whether any reoccurring
P. aeruginosa infections were the same strain or different. Both analyses included all 285 participants.
In the first analysis, in which participants who had regrown P. aeruginosa but did not have genotyping
performed were assumed to have regrown the same strain, there was no statistically significant
difference between oral antibiotic and i.v. antibiotic therapy treatment groups in time to reoccurrence
of infection with the original P. aeruginosa strain (HR 1.37, 95% CI 0.99 to 1.91; p = 0.061) (Table 10, and
Appendix 4, Figure 6). The results from a sensitivity analysis using time from treatment commencement,
rather than time from randomisation, confirmed this finding (HR 1.38, 95% CI 0.99 to 1.92; p = 0.060)
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FIGURE 4 Time to reoccurrence of P. aeruginosa infection (any strain) up to the end of the 24-month follow-up period.
TABLE 10 Secondary outcome: time to reoccurrence of original P. aeruginosa infection
Analysis
Treatment group, n (%)





Unknown strains assumed to be the same as baseline
Time from randomisation 74 (54.0%) 66 (44.6%) 1.37 (0.99 to 1.91) 0.061
Time from treatment
commencement
74 (54.0%) 66 (44.6%) 1.38 (0.99 to 1.92) 0.060
Unknown strains assumed to be different from baseline
Time from randomisation 21 (15.3%) 14 (9.5%) 1.85 (0.94 to 3.64) 0.075
Time from treatment
commencement
21 (15.3%) 14 (9.5%) 1.85 (0.94 to 3.64) 0.074
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Similarly, in the second analysis, in which participants who had regrown P. aeruginosa but did not have
genotyping performed were assumed to have regrown a different strain, oral antibiotic therapy delayed
time to reoccurrence of the original P. aeruginosa compared with i.v. antibiotic therapy, but, again, this
was not statistically significant (HR 1.85, 95% CI 0.94 to 3.64; p = 0.075) (see Table 6 and Appendix 4,
Figure 8). The results from a sensitivity analysis using time from treatment commencement rather than
time from randomisation confirmed this finding (HR 1.85, 95% CI 0.94 to 3.64; p = 0.074) (see Table 6
and Appendix 4, Figure 9).
Reinfection with a different strain of Pseudomonas aeruginosa
A total of 42 participants (n = 25 in i.v. antibiotic therapy group; n = 17 in oral antibiotic therapy group)
had genotyping performed on both a baseline and a follow-up sample in the first 15 months of
follow-up. In the i.v. antibiotic therapy group, 19 participants (76%) regrew the same strain and six
participants (24%) regrew a different strain. In the oral antibiotic therapy group, 12 participants
(70.6%) regrew the same strain and five participants (29.4%) regrew a different strain. The risk of
regrowing a different strain was slightly lower in the i.v. antibiotic therapy group than in the oral
antibiotic therapy group, but the difference was not statistically significant (relative risk 0.82, 95% CI
0.30 to 2.25; p = 0.733).
Lung function
Lung function analyses were undertaken on patients aged ≥ 5 years (157/285 randomised patients:
76 in the i.v. antibiotic therapy group and 81 in the oral antibiotic therapy group).
A total of 134 participants had a baseline measurement and at least one follow-up measurement of
FEV1 and FVC, and 96 participants had a baseline and at least one follow-up measurement of FEF25–75
and were therefore included in the models. Table 11 provides the mean and standard error (SE) in each
treatment group predicted by the random effects model that fitted a time-by-treatment interaction
and also those from the model when no time-by-treatment interaction was included (post hoc), along
with the mean treatment difference, 95% CI and the p-value for the model with no interaction term
(overall) and for each time point for the model with the interaction term. All three measures of lung
function were very slightly higher in the i.v. antibiotic therapy than in the oral antibiotic therapy group
across all estimates.
Oxygen saturation
A total of 241 participants had a baseline measurement of oxygen saturation and at least one follow-up
measurement, and these participants were therefore included in the models. Table 11 provides the mean
and SE in each treatment group predicted by the random effects model that fitted a time-by-treatment
interaction and also those from the model when no time-by-treatment interaction was included
(post hoc), along with the mean treatment difference, 95% CI and the p-value for the model with no
interaction term (overall) and for each time point for the model with the interaction term. There was no
difference between the two treatment groups.
Growth and nutritional status
Of the 268 children (recruited at a paediatric centre), 256 were included in the analyses of height and
BMI, as they had a baseline measurement and at least one follow-up measurement. The analysis of
weight was restricted to participants aged ≤ 10 years, so included only 211 children. Table 11 provides
the mean and SE in each treatment group predicted by the random effects model that fitted a time-by-
treatment interaction and also those from the model when no time-by-treatment interaction was
included (post hoc), along with the mean treatment difference, 95% CI and the p-value for the model
with no interaction term (overall) and for each time point for the model with the interaction term. There
was very little difference between the two treatment groups in terms of the height, weight and BMI
z-scores that were measured in children. BMI (measured in adults) was slightly lower in the i.v. antibiotic
therapy group than in the oral antibiotic therapy group, but only 13 participants were included in
this model.
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TABLE 11 Secondary outcomes: lung function, oxygen saturation and growth and nutritional status. Estimates predicted
by random effects models
Outcome n Time point
Treatment group, mean (SE)
Mean treatment






% predicted FEV1 134 3 months 85.68 (1.02) 81.93 (0.98) 3.75 (0.97 to 6.53)
a 0.008a
15 months 86.19 (1.1) 84.11 (1.1) 2.08 (–0.99 to 5.14) 0.184
24 months 86.57 (1.55) 85.75 (1.54) 0.82 (–3.45 to 5.1)a 0.705a
Overall 86.32 (0.99)a 83.16 (0.98)a 3.16 (0.51 to 5.8)a 0.019a
% predicted FVC 134 3 months 91.87 (1.04) 88.01 (0.99) 3.86 (1.03 to 6.69)a 0.008a
15 months 94.08 (1.08) 90.94 (1.08) 3.14 (0.15 to 6.14) 0.039
24 months 95.74 (1.5) 93.13 (1.47) 2.61 (–1.52 to 6.73)a 0.216a
Overall 93.53 (0.97)a 89.98 (0.97)a 3.56 (0.9 to 6.21)a 0.009a
% predicted FEF25–75 96 3 months 74.14 (2.62) 70.38 (2.23) 3.76 (–2.99 to 10.52)
a 0.274a
15 months 72.39 (2.73) 68.93 (2.45) 3.46 (–3.74 to 10.66) 0.345
24 months 71.07 (3.63) 67.84 (3.22) 3.23 (–6.29 to 12.76)a 0.505a
Overall 73.36 (2.5)a 69.71 (2.22)a 3.64 (–2.82 to 10.11)a 0.269a
Oxygen saturation (%) 241 3 months 97.81 (0.1) 97.76 (0.09) 0.05 (–0.21 to 0.3)a 0.728a
15 months 97.83 (0.09) 97.78 (0.09) 0.05 (–0.2 to 0.29) 0.709
24 months 97.84 (0.13) 97.79 (0.12) 0.05 (–0.3 to 0.4)a 0.79a
Overall 97.82 (0.08)a 97.77 (0.08)a 0.05 (–0.18 to 0.27)a 0.686a
Growth and nutritional status
Height z-score 256 3 months –0.34 (0.02) –0.34 (0.02) 0 (–0.06 to 0.05)a 0.952a
15 months –0.34 (0.04) –0.31 (0.04) –0.03 (–0.13 to 0.07) 0.572
24 months –0.34 (0.06) –0.29 (0.06) –0.05 (–0.21 to 0.11)a 0.543a
Overall –0.33 (0.02)a –0.33 (0.02)a 0 (–0.06 to 0.05)a 0.939a
Weight z-score 211 3 months 0.06 (0.02) 0.06 (0.02) 0 (–0.06 to 0.06)a 0.988a
15 months 0.11 (0.05) 0.13 (0.05) –0.02 (–0.15 to 0.11) 0.794
24 months 0.15 (0.08) 0.18 (0.08) –0.03 (–0.24 to 0.18)a 0.78a
Overall 0.09 (0.03)a 0.09 (0.03)a 0 (–0.06 to 0.06)a 0.987a
BMI z-score 256 3 months 0.31 (0.03) 0.32 (0.02) –0.01 (–0.08 to 0.06)a 0.767a
15 months 0.34 (0.05) 0.33 (0.05) 0.01 (–0.14 to 0.16) 0.912
24 months 0.36 (0.09) 0.33 (0.08) 0.02 (–0.22 to 0.26)a 0.854a
Overall 0.32 (0.03)a 0.33 (0.03)a –0.01 (–0.08 to 0.06)a 0.774a
BMI (kg/m2) 13 3 months 23.56 (0.18) 24.04 (0.18) –0.48 (–1.0 to 0.03)a 0.067a
15 months 23.51 (0.22) 24.25 (0.24) –0.73 (–1.39 to –0.08) 0.029
24 months 23.47 (0.37) 24.4 (0.39) –0.92 (–2.01 to 0.16)a 0.093a
Overall 23.58 (0.18)a 24.14 (0.19)a –0.56 (–1.03 to -0.09)a 0.02a
a Post hoc analysis.
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Number of pulmonary exacerbations
A total of 283 participants were included in the analysis of the number of pulmonary exacerbations
within the first 15 months of follow-up. In both treatment groups, most participants did not experience
any pulmonary exacerbations (i.v. 72.3%; oral 64.4%) during this time, but the risk of experiencing
at least one pulmonary exacerbation was lower in the i.v. antibiotic therapy group than in the oral
antibiotic therapy group (relative risk 0.78, 95% CI 0.55 to 1.10; p = 0.155). The median (IQR) number of
exacerbations experienced in each group was 0 (0–1). The distributions of the number of exacerbations
experienced in each treatment group were not significantly different (p = 0.090). Table 12 provides the
results of the additional analyses of this outcome over different time periods of interest. The results of
these analyses were all consistent with the results over the first 15 months of follow-up. The analysis
investigating the time to first pulmonary exacerbation found no significant difference between the two
treatment groups (HR 0.73, 95% CI 0.50 to 1.06; p = 0.1); the Kaplan–Meier plot can be seen in Figure 5.
TABLE 12 Secondary outcomes: number of pulmonary exacerbations and admissions to hospital
Outcome Time period









Up to 15 months 38/137 (27.7) 52/146 (35.6) 0.78 (0.55 to 1.10) 0.155
Up to 3 months 8/135 (5.9) 15/144 (10.4) 0.57 (0.25 to 1.3) 0.173
3–15 months 31/131 (23.7) 46/136 (33.8) 0.7 (0.48 to 1.03) 0.067
15–24 months 14/99 (14.1) 26/103 (25.2) 0.56 (0.31 to 1.01) 0.048
Admission to hospital Up to 3 months 25/135 (18.5) 15/143 (10.5) 1.77 (0.97 to 3.2) 0.057
3–15 months 40/129 (31.0) 61/136 (44.9) 0.69 (0.5 to 0.95) 0.02
15–24 months 33/105 (31.4) 41/107 (38.3) 0.82 (0.57 to 1.19) 0.293
Admission to hospital:
sensitivity analysis
Up to 3 months 24/135 (17.8) 9/143 (6.3) 2.82 (1.36 to 5.86) 0.003
3–15 months 39/129 (30.2) 63/136 (46.3) 0.65 (0.47 to 0.9) 0.007
15–24 months 34/104 (32.7) 41/108 (38.0) 0.86 (0.6 to 1.24) 0.422
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FIGURE 5 Time to first pulmonary exacerbation.
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Admission to hospital
A total of 278 participants were included in the analysis over the 3-month treatment period. During
this time, most participants were not admitted to hospital (i.v. antibiotic therapy, 81.5%; oral antibiotic
therapy, 89.5%). However, the risk of being admitted to hospital (not including admission for the i.v.
treatment if randomised to the i.v. antibiotic therapy group) was higher for participants randomised to
i.v. antibiotic therapy than for participants randomised to oral antibiotic therapy (relative risk 1.77,
95% CI 0.97 to 3.2; p = 0.057). After this time, the risk of being admitted to hospital was reduced for the
i.v. antibiotic therapy group compared with the oral antibiotic therapy group. There were 265 participants
included in the analysis from 3 to 15 months (relative risk 0.69, 95% CI 0.5 to 0.95; p = value 0.02) and
212 participants included in the analysis from 15 to 24 months (relative risk 0.82, 95% CI 0.57 to 1.19;
p = 0.293); the reduced number of patients post 15 months was mainly because of the fact that only
those participants randomised prior to 1 January 2016 were followed up for 24 months. All results are
presented in Table 12, along with information on the proportions of participants with no admissions or
at least one admission. Results from the sensitivity analysis are also presented in Table 13 and are
consistent with the primary analysis of this outcome.
Number of days spent as an inpatient in hospital
A total of 278 participants were included in the analysis over the 3-month treatment period,
265 participants were included over the period from 3 to 15 months’ follow-up and 201 participants
were included from 15 to 24 months’ follow-up. The median number of days spent as an inpatient in
hospital was zero in both treatment groups across all time periods. The distributions of the number of
days in hospital in each group were significantly different over the time period from 3 to 15 months’
follow-up (p = 0.005), but not at the other time points (a p-value of 0.066 for the 3-month treatment
period; a p-value of 0.261 for the 15–24 months’ follow-up). The results from sensitivity analyses were
consistent with these results. All results are provided in Table 13.
Quality of life (Cystic Fibrosis Questionnaire)
For this outcome, the analyses were undertaken on patients aged ≥ 6 years (134/285 patients
randomised: 62 patients to i.v. antibiotic therapy and 72 patients to oral antibiotic therapy). Of these,
62 patients were expected to be in the self-report analyses and 46 patients were expected to be in the
parent analyses for i.v. antibiotic therapy. For oral antibiotic therapy, 72 patients were expected to be
in the self-report analyses and 51 patients were expected to be in the parent analyses.













Number of pulmonary exacerbations Up to 15 months 137 0 (0–1) 146 0 (0–1) 0.087
Number of days spent in hospital Up to 3 months 135 0 (0–29) 143 0 (0–14.8) 0.066
3–15 months 129 0 (0–69) 136 0 (0–64) 0.005
15–24 months 99 0 (0–33) 102 0 (0–28) 0.261
Number of days spent in hospital:
sensitivity analysis 1
Up to 3 months 135 0 (0–29) 143 0 (0–16) 0.050
3–15 months 129 0 (0–69) 136 0 (0–64) 0.007
15–24 months 99 0 (0–28) 102 0 (0–28) 0.273
Number of days spent in hospital:
sensitivity analysis 2
Up to 3 months 135 0 (0–29) 143 0 (0–10) 0.003
3–15 months 129 0 (0–69) 136 0 (0–66) 0.004
15–24 months 99 0 (0–42) 102 0 (0–28) 0.574
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A total of 106 participants were included in the analysis of the majority of domains in the self-report
questionnaire (some domains included 105 participants because of missing data). The analysis of the
domains that were completed by participants aged ≥ 14 years included 27 participants. A total of
73 participants (or 72 participants when missing data occurred) were included in the analyses of the
domains in the parent/carer questionnaire. There were no statistically significant differences between
the two treatment groups at 15 months across any of the domains in each questionnaire (Table 14
shows the treatment difference, associated CI and p-value from the model). The mean score for each
treatment group at each time point for each of the domains is shown in Appendix 4, Figures 10–32.
Other sputum/cough microbiology
Different numbers of participants were included in the analyses of the different organisms, as, if
patients had withdrawn prior to the end of the time point, they were included only if they had
previously had an occurrence of the organism of interest. There were no statistically significant
differences between the two treatment groups in terms of the occurrence of the four organisms of
interest at any time point.
TABLE 14 Secondary outcome: quality of life
Domain Participants (n)
Mean treatment difference at
15 months (95% CI) p-value
Self-report questionnaire
Physical functioning 106 –3.63 (–10.41 to 3.16) 0.292
Role/school functioninga 27 7.66 (–6.21 to 21.52) 0.267
Vitalitya 27 5.4 (–6.88 to 17.69) 0.373
Emotional functioning 106 –1.59 (–7.39 to 4.22) 0.589
Social functioning 106 2.11 (–4.03 to 8.25) 0.498
Body image 105 –4.01 (–11.78 to 3.77) 0.309
Eating problems 106 –0.39 (–6.78 to 6) 0.903
Treatment burden 105 2.86 (–6.19 to 11.92) 0.532
Health perceptionsa 27 5.06 (–13.72 to 23.84) 0.583
Weighta 27 1.4 (–19.02 to 21.83) 0.725
Respiratory symptoms 106 2.82 (–3.44 to 9.08) 0.374
Digestive symptoms 106 –0.01 (–9.95 to 9.93) 0.998
Parent/carer questionnaire
Physical functioning 73 –5.17 (–13.55 to 3.22) 0.223
Role/school functioning 72 –1.47 (–10.22 to 7.28) 0.738
Vitality 72 –0.44 (–9.36 to 8.48) 0.923
Emotional functioning 72 3.32 (–3.56 to 10.2) 0.339
Body image 72 –0.56 (12.03 to 10.9) 0.922
Eating problems 72 6.15 (–2.78 to 15.08) 0.174
Treatment burden 73 –0.28 (–11.25 to 10.69) 0.96
Health perceptions 72 –7.25 (–15.09 to 0.6) 0.07
Weight 73 –1.19 (–17.63 to 15.26) 0.886
Respiratory symptoms 73 –3.33 (–11.71 to 9.93) 0.432
Digestive symptoms 72 3.54 (–4.9 to 11.98) 0.405
a Domain completed by participants aged ≥ 14 years.
CLINICAL EFFECTIVENESS RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
34
Table 15 shows the numbers of participants in each treatment group who did/did not have cough or
sputum samples containing each organism, the relative risks and 95% CIs and the p-values from the
chi-squared tests for each organism over each time period of interest.
The number of participants who had cough or sputum samples containing additional organisms of
interest is reported in Appendix 5, Table 34.
Carer and participant burden (absenteeism from education or work)
A total of 270 carers were included in the analysis of absenteeism from education or work during
the 15 months following randomisation. Approximately one-third of carers had at least one episode
of absence (i.v. antibiotic therapy group, 33.6%; oral antibiotic therapy group, 35.3%), but the risk of
absence was not significantly greater in either treatment group (Table 16). The median (IQR) number of
days of absence experienced in each group for carers was 0 (0–1) and the distributions of the number
of days of absence experienced in each group were not significantly different (p = 0.616).
A total of 271 participants were included in the analysis of absenteeism from education or work during
the 15 months following randomisation. Approximately half of the participants had at least one episode
of absence (i.v. antibiotic therapy group, 49.6%; oral antibiotic therapy group, 54.3%), but the risk of
absence was not significantly greater in either treatment group (see Table 16). The median number of
days of absence for participants in the i.v. antibiotic therapy group was 0 (IQR 0–6.2) and the median
was 1 (IQR 0–10) in the oral antibiotic therapy group, and the distributions of the number of days
absence experienced in each group were not significantly different (p = 0.263).
TABLE 15 Secondary outcome: other sputum/cough microbiology
Outcome Time period
Treatment group, n/N (%)





MRSA Up to 3 months 0/136 (0.0) 1/145 (0.7) – –
Up to 15 months 4/135 (3.0) 2/140 (1.4) 2.07 (0.39 to 11.14) 0.441
Up to 24 months 4/132 (3.0) 4/133 (3.0) 1.01 (0.26 to 3.94) 0.999
Burkholderia cepacia
complex
Up to 3 months 1/136 (0.7) 0/144 (0.0) – –
Up to 15 months 2/135 (1.5) 4/139 (2.9) 0.51 (0.10 to 2.76) 0.684
Up to 24 months 2/132 (1.5) 4/133 (3.0) 0.50 (0.09 to 2.70) 0.684
Candida infection Up to 3 months 26/137 (19.0) 27/146 (18.5) 1.03 (0.63 to 1.67) 0.917
Up to 15 months 55/136 (40.4) 55/142 (38.7) 1.04 (0.78 to 1.40) 0.771
Up to 24 months 66/135 (48.9) 63/137 (45.7) 1.07 (0.83 to 1.38) 0.592
Aspergillus Up to 3 months 6/130 (4.4) 5/144 (3.5) 1.27 (0.40 to 4.07) 0.686
Up to 15 months 14/121 (10.4) 20/139 (14.4) 0.72 (0.38 to 1.37) 0.313
Up to 24 months 21/113 (15.7) 25/134 (18.7) 0.84 (0.50 to 1.42) 0.517
TABLE 16 Number of carers/participants experiencing at least one episode of absence from education or work during
the 15 months following randomisation
Outcome Time period
Treatment group, n/N (%)





Carer burden Up to 15 months 44/131 (33.6) 49/139 (35.3) 1.03 (0.86 to 1.22) 0.774
Participant burden Up to 15 months 65/131 (49.6) 76/140 (54.3) 1.10 (0.86 to 1.41) 0.442
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Safety
Safety reporting at database lock
A complete list of AEs (verbatim) and the original MedDRA code (preferred term and SOC) that was
agreed by the chief investigator prior to the database being locked are shown in Appendix 5, Table 35.
The non-serious AEs and SAEs that were recorded on the locked database are shown, grouped by the
SOC and preferred term, in Appendix 5, Tables 36 and 37, respectively. Line listings of the SAEs are
shown in Appendix 5, Table 38.
Changes made to safety reporting post hoc
After the database was locked and the blind was broken, it was found that there had been several
instances where P. aeruginosa and pulmonary exacerbations had been reported both as an AE and also
as a primary or secondary outcome, respectively.
There were four SAEs reported as both an outcome and a SAE: three SAEs (reported from three
participants in the oral antibiotic therapy group) were included as events for the primary outcome and
one SAE (reported from one participant in the oral antibiotic therapy group) was included as both a
SAE and a secondary outcome. These events have not been included in Table 17 and have been
reported only in each of the secondary outcome analyses.
There were 17 non-serious AEs reported as both an outcome and an AE: 14 AEs (nine AEs reported
from nine participants in the i.v. antibiotic therapy group and five AEs from five participants in the oral
antibiotic therapy group) met the definition of the primary outcome and three AEs (reported from
three participants in the oral antibiotic therapy group) met the definition of the secondary outcome
pulmonary exacerbation. These non-serious AEs have not been included in Table 18.
On reflection, the chief investigator and co-chief investigator also felt that there were descriptions of
non-serious AEs that could be clarified to aid the reader. The original classifications as recorded on the
locked trial database and the clarified classifications (as agreed by both the chief investigator and
co-chief investigator) are shown in Appendix 5, Table 39.
Table 18 uses the clarified classifications.
Safety population
A total of 272 participants received at least one dose of their allocated treatment and were included in
the safety population: 126 participants (91.9%) in the i.v. antibiotic therapy group and 146 participants
(98.6%) in the oral antibiotic therapy group.
Serious adverse events/reactions
In the i.v. antibiotic therapy group, 11 SAEs/SARs were reported from 10 participants (7.9%) and, in the
oral antibiotic therapy group, 21 SAEs/SARs were reported from 14 participants (9.6%). None of the
SARs that was reported met the criteria for SUSAR reporting.
Table 17 indicates the number of events reported for each SOC and the number of participants who
experienced the event.
Non-serious adverse events
In the i.v. antibiotic therapy arm, 126 non-serious AEs were reported from 60 participants (47.6%) and, in
the oral antibiotic therapy group, 136 non-serious AEs were reported from 72 participants (49.3%). The
most common SOCs in which events were reported for both treatment groups were respiratory, thoracic
and mediastinal disorders; infections and infestations; and gastrointestinal disorders. A complete list of all
non-serious AEs [excluding events counted in the analyses of primary and secondary outcomes, and using
clarified terms (Table 39)] can be found in Table 18.
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TABLE 17 Serious adverse events/reactions grouped by SOC and preferred term
SOC Preferred term
Treatment group, n (%)














Chest pain 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
General physical
health deterioration
0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Pyrexia 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Hepatobiliary disorders Hepatic failure 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Infections and
infestationsa,b
Bronchiolitis 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Croup infectious 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)




1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Lower respiratory
tract infectionb
0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Rhinitis 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Upper respiratory
tract infection
0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Viral infection 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Nervous system
disorders
Headache 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Psychiatric disorders Anxietyc 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Renal and urinary
disorders




Dyspnoea 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Lung consolidation 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Pneumothorax 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Productive cough 0 0 (0.0) 3 3 (2.1) 3 3 (1.1)
Skin and subcutaneous
tissue disorders





1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Vascular disorders Deep-vein
thrombosis
1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Thrombophlebitis 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Totala,b,d 11 10 (7.9) 17 12 (8.2) 28 22 (8.1)
a Three additional SAEs were reported by three participants in the oral antibiotic therapy group but have not been
included here as they were the event of interest for the primary outcome so should not have been reported as
a SAE.
b One additional AE was reported by one participant in the oral antibiotic therapy group but has not been included
here as it contributed to the analysis of the outcome ‘Number of pulmonary exacerbations’.
c Event was that after 5 weeks on trial, participant developed voices in their head, obsessive behaviours and anxiety
at night.
d Total number of events may exceed the total number of patients as a patient may report more than one event.
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TABLE 18 All non-SAEs grouped by SOC and preferred term
SOC Preferred term
Treatment group, n (%)





Events Patients Events Patients Events Patients
Ear and labyrinth
disorders
Ear discomfort 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Ear pain 0 0 (0.0) 2 2 (1.4) 2 2 (0.7)
Gastrointestinal
disorders
Abdominal pain 1 1 (0.8) 2 2 (1.4) 3 3 (1.1)
Abdominal pain
upper
1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Constipation 1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Diarrhoea 6 5 (4) 3 3 (2.1) 9 8 (2.9)
Distal intestinal
obstruction syndrome
2 2 (1.6) 3 3 (2.1) 5 5 (1.8)
Haematemesis 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Nausea 1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Pancreatitis 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Paraesthesia oral 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Rectal haemorrhage 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Tongue
discolouration
1 1 (0.8) 0 0 (0.0) 1 1 (0.4)






1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Administration site
pain
1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Adverse drug
reaction
1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Catheter site-related
reaction
1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Chest pain 1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Influenza-like illness 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Malaise 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Pain 1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Pyrexia 2 2 (1.6) 7 7 (4.8) 9 9 (3.3)
Nasal swellinga 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Immune system
disorders






0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Candida infection 1 1 (0.8) 5 5 (3.4) 6 6 (2.2)
Chest infectiona 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Conjunctivitis 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Eczema infected 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
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TABLE 18 All non-SAEs grouped by SOC and preferred term (continued )
SOC Preferred term
Treatment group, n (%)





Events Patients Events Patients Events Patients
Enterobacter cloacae
respiratory infectiona
1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Eye infection 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Hand, foot and
mouth diseasea
0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Hand, foot and
mouth disease
(recorded as foot and
mouth disease)a,b
0 0 (0.0) 1 1 (0.7) 1 1 (0.4)








1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Infectious
mononucleosis




4 3 (2.4) 3 3 (2.1) 7 6 (2.2)
Klebsiella pneumoniae
respiratory infectiona
0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Mycobacterium avium
complex infection
0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Nasal vestibulitis 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Nasopharyngitis 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Oral candidiasis 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Otitis media 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Pneumonia 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Respiratory tract
infection
1 1 (0.8) 2 2 (1.4) 3 3 (1.1)








0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Upper respiratory
tract infection
15 11 (8.7) 3 2 (1.4) 18 13 (4.8)
Urinary tract
infection
1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
continued
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TABLE 18 All non-SAEs grouped by SOC and preferred term (continued )
SOC Preferred term
Treatment group, n (%)





Events Patients Events Patients Events Patients
Varicella 3 3 (2.4) 1 1 (0.7) 4 4 (1.5)
Viral infection 1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Vulvovaginal
candidiasis




Fall 1 1 (0.8) 2 2 (1.4) 3 3 (1.1)
Skull fracture 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Sunburn 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)




1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Blood glucose
increased
1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Chest X-ray abnormal 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Metabolism and
nutrition disorders
Decreased appetite 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Vitamin A deficiency 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Vitamin D deficiency 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)




Arthralgia 0 0 (0.0) 3 3 (2.1) 3 3 (1.1)
Back pain 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Flank pain 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Limb discomfort 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Musculoskeletal
chest pain
0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Musculoskeletal
stiffness
0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Myalgia 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Pain in extremity 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)





Malignant melanoma 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Nervous system
disorders
Dizziness 1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Febrile convulsion 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Headache 3 2 (1.6) 0 0 (0.0) 3 2 (0.7)
Lethargy 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Migraine 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
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TABLE 18 All non-SAEs grouped by SOC and preferred term (continued )
SOC Preferred term
Treatment group, n (%)





Events Patients Events Patients Events Patients
Product issues Device occlusion 2 2 (1.6) 0 0 (0.0) 2 2 (0.7)
Psychiatric disorders Enuresis 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Renal and urinary
disorders
Dysuria 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)




Bronchospasm 1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Cough 26 22 (17.5) 28 23 (15.8) 54 45 (16.5)
Epistaxis 1 1 (0.8) 2 2 (1.4) 3 3 (1.1)
Haemoptysis 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Nasal congestion 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Pharyngeal oedema 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Pulmonary function
decreaseda
1 1 (0.8) 2 2 (1.4) 3 3 (1.1)
Productive cough 5 5 (4) 8 8 (5.5) 13 13 (4.8)
Sputum increased 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Wheezing 3 3 (2.4) 6 6 (4.1) 9 9 (3.3)
Skin and subcutaneous
tissue disorders
Dermatitis diaper 1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Dry skin 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Eczema 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Onychoclasis 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Petechiae 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Photosensitivity
reaction
0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Rash 2 2 (1.6) 1 1 (0.7) 3 3 (1.1)
Skin discolouration 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Urticaria 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Totalc,d 126 60 (47.6) 136 72 (49.3) 262 132 (48.5)
a Wording not consistent with ‘preferred term’ recorded on database; amended based on additional data available.
b Not confirmed in medical notes.
c Three additional AEs were reported by three participants in the oral antibiotic therapy group, but have not been
included here as they contributed to the analysis of the outcome ‘[N]umber of pulmonary exacerbations’.
d Nine additional AEs were reported by nine participants in the i.v. antibiotic therapy group and five AEs were
reported by five participants in the oral antibiotic therapy group, but they have not been included here as they were
the event of interest for the primary outcome so should not have been reported as an AE.
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Chapter 6 Economic evaluation
Overview
A prospective economic evaluation was conducted alongside the randomised controlled trial to assess
the cost-effectiveness of oral antibiotic therapy compared with i.v. antibiotic therapy. The primary
analysis used an NHS and Personal Social Services (PSS) perspective for the collection and incorporation
of resource use, as recommended by the National Institute for Health and Care Excellence (NICE).42
The time horizon for the primary analysis was 15 months from randomisation.
The primary outcome within the economic evaluation was the same as that in the clinical study and
measured the percentage of patients with successful eradication of P. aeruginosa 3 months after the
start of treatment and who remained infection free through 15 months after the start of treatment.
Analysis for the economic evaluation was based on the population with data for the primary outcome;
missing health economic data within that population were multiply imputed.
The primary cost-effectiveness analysis measured the incremental cost per successful eradication of
P. aeruginosa infection 3 months after allocated treatment had started, and of remaining infection free
through to 15 months after the start of allocated treatment, in the oral antibiotic therapy group and
the i.v. antibiotic therapy group. Regression analysis controlled for baseline differences between groups.
Secondary cost-effectiveness analyses were carried out and used the EQ-5D-3L (completed by a
mixture of patients/carers, as appropriate) and QALYs to value health outcomes.
Where the EQ-5D-3L and QALYs were used to value health outcomes, cost–utility analysis was
conducted to measure the incremental net benefit (INB) of treating patients in the oral antibiotic
therapy group and the i.v. antibiotic therapy group. Sensitivity analyses explored factors that were
identified a priori as likely to be key drivers of cost-effectiveness, including assumptions regarding the
incorporation of costs for the intervention.
Resource use and costs
Total resource use and costs for each patient in the clinical trial were calculated. The main resource use
and cost components for both the oral antibiotic therapy and i.v. antibiotic therapy arm comprised (1) the
different modes of antibiotic intervention, information on which was collected through the use of case
report forms and (2) any follow-up interactions with the health and social care system, which information
was captured through patient diaries and collected at 3, 6, 9, 12 and 15 months. All costs were calculated
in Great British pounds with the price year of 2016/17 used. Where possible, unit costs were sourced
from national databases including the BNF43 for medicines; NHS reference costs44 for inpatient, outpatient
and accident and emergency (A&E) visits; and Personal Social Services Research Unit (PSSRU)45 for
primary care consultations (Tables 19 and 20 present the complete list of unit costs). Where relevant
unit costs were not available for the correct price year of 2016/17, unit costs from other price years
were inflated using the Hospital and Community Health Service (HCHS) pay and price inflation index.45
Interventions
Oral antibiotic therapy and intravenous antibiotic therapy drug costs
In both the oral antibiotic therapy arm and i.v. antibiotic therapy arm, the antibiotic dosage and
quantity of all antibiotics prescribed were recorded through data collected in case report forms to
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TABLE 19 Unit costs in primary care or community care
Resource Measurement Unit cost (£) Source Detail
Primary care
GP visit in surgery Per visit 38 PSSRU 201745 With qualification and including
direct care costs
Nurse visit in surgery Per visit 14 PSSRU 201745 With qualification and including
direct care costs. Assuming a
20-minute consultation
Doctor in walk-in centre Per visit 44 NHS reference costs
2016–1744
Weighted average of non-admitted,
type 4 A&E visits
Nurse in walk-in centre Per visit 44 NHS reference costs
2016–1744
Weighted average of non-admitted,
type 4 A&E visits
Other Per visit 35 Average of above
Home visits
GP visit Per home visit 161 PSSRU 201745 With qualification and including
direct care costs, assuming
40 minutes with travel
District nurse Per home visit 29 PSSRU 201046 With qualification and including
direct care costs, inflated to
2016–17 using HCHS index45
Health visitor Per home visit 58 PSSRU 201046 With qualification and including
direct care costs, inflated to
2016–17 using HCHS index45
Nurse Per home visit 44 PSSRU 201046 With qualification and including
direct care costs, inflated to
2016–17 using HCHS index45
Physiotherapist Per home visit 61 PSSRU 201046 With qualification and including
direct care costs, inflated to
2016–17 using HCHS index45
Occupational therapy Per home visit 45 PSSRU 201745 With qualification and including
direct care costs
Other Per home visit 47 Average of all apart from GP visit
Community-based professional
Home care worker Per visit 21 PSSRU 201745 With qualification and including
direct care costs, 1 hour
Nurse Per visit 44 PSSRU 201745 Same as nurse home visit
Physiotherapist Per visit 49 PSSRU 201745 Same as physiotherapist home visit
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TABLE 20 Secondary care unit costs within the analysis
Resource Measurement
Unit








Per visit 149 NHS reference costs 2016–1744 Any paediatric outpatient,
weighted average
Consultant led, adult Per visit 136 NHS reference costs 2016–1744 Any non-paediatric outpatient,
weighted average
Consultant led, child Per visit 196 NHS reference costs 2016–1744 Any paediatric outpatient,
weighted average
Dietitian Per visit 37 PSSRU 201046 With qualification and including
direct care costs, inflated to
2016–17 using HCHS index45
Physiotherapist Per visit 49 NHS reference costs 2016–1744
MDT, adult Per visit 1541 NICE 201747 MDT clinic, based on 250 adult
patients per year, six visits per
person per year
MDT, child Per visit 1254 NICE 201747 MDT clinic, based on 250 child
patients per year, six visits per
person per year
Radiology Per visit 135 NHS reference costs 2016–1744 Interventional radiology
Pharmacy Per visit PSSRU 201046 With qualification and including
direct care costs, inflated to
2016–17 using HCHS index45
A&E, discharged Per visit 128 NHS reference costs 2016–1744 Any A&E discharged, weighted
average
A&E, admitted Per visit 221 NHS reference costs 2016–1744 Any A&E admitted, weighted
average
Intervention
Ceftazidime Per vial 4.25–
17.59
BNF 201743
Tobramycin Per vial 19 BNF 201743




Fixed cost Per course 159 James Sutton, Nottingham
University Hospitals, 2019,
personal communication
Dispensing fee, delivery fee and
ancillaries
Tobramycin Per day 20–27 James Sutton, Nottingham
University Hospitals, 2019,
personal communication
Eclipse or intermate (once per
day infusions)





Eclipse or intermate (once per
day infusions)
Inpatient ward stays
General ward, adult Per day 380 NHS reference costs 2016–1744 Excess bed-days, weighted
average for adults
General ward, child Per day 595 NHS reference costs 2016–1744 Excess bed-day, weighted
average for paediatrics
MDT, multidisciplinary team.
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calculate a cost per course. Drug resource use was calculated assuming that whole vials or ampoules
were used for each dose. Unit costs for the drug resource use were sourced from the BNF for i.v.
antibiotic therapy within hospital and for the oral antibiotic therapy arm. For i.v. antibiotic therapy
within hospital and for oral antibiotic therapy, no dispensing fees or disposable equipment were
included in the cost, as this was assumed to be an overhead for the inpatient stay or outpatient visit
and incorporated within the reference cost.
For patients who started i.v. antibiotic therapy in hospital and then completed treatment at home, the
dose and quantity of drugs prescribed for home i.v. antibiotic therapy were calculated. Dispensing fees,
delivery fees and ancillaries were included for home i.v. antibiotic therapy, with unit costs sourced from
local pharmacy tariffs. Any unused medicines were assumed to become waste.
Inpatient stay for intravenous antibiotic therapy
For the i.v. antibiotic therapy arm, the length of stay in hospital was recorded. A per diem unit cost,
a weighted average of all general ward stays in NHS Reference Costs, stratified by adult or child,
was multiplied by the length of stay in days to generate an inpatient stay cost for i.v. antibiotic
therapy treatment.
Follow-up resource use and costs
Patient diaries collected follow-up resource use for 15 months following randomisation. Resource
use was recorded in diaries when patients interacted with primary care [in general practitioner
(GP) practices and home visits], interacted with secondary care (inpatients, outpatients, A&E, walk-in
centres), had a diagnostic test in primary or secondary care, or met with a community-based
professional (e.g. physiotherapists or social workers). Patients also recorded any medications prescribed
through the NHS, as well as any aids or home modifications.
For patients who had recorded an inpatient stay, the length of stay was calculated. A per diem unit
cost, stratified by adult or child, was multiplied by the length of stay to generate an inpatient stay cost.
The number of visits to A&E and whether the patient was admitted or discharged was calculated with
appropriate unit costs attached. For each patient, the number of outpatient visits, stratified by whether
the consultation was consultant led or non-consultant led, was calculated and unit costs were attached
based on a weighted average of outpatient visits from NHS Reference Costs.48 Any costs associated
with interactions with primary care were based on whether the consultation was with a GP or nurse,
and whether the consultation took place within the practice or at home. The number of visits with
community-based professionals were recorded and costed. Where patients recorded that they had
visited a multidisciplinary team as part of a CF clinic, an appropriate unit cost was attached based on
a previously conducted micro-costing study.47
The dosage and quantity of all drugs prescribed for patients were recorded and unit costs from the
BNF were attached. Drug resource use was calculated assuming that all medications prescribed were
used or became waste.
Wider resource use and costs
To record wider societal costs, patient diaries also recorded:
l out-of-pocket costs for transport to consultations using car, bus or taxi
l out-of-pocket costs for over-the-counter medicines
l out-of-pocket costs for aids and appliances
l time from work lost by the carer or patient.
For patients reporting car, bus or taxi travel, the total travel time in minutes was calculated and
multiplied by appropriate unit costs per minute of travel. Lost productivity was estimated as the
number of minutes lost to work by the care giver or patient multiplied by mean hourly earnings
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
46
reported by the Office for National Statistics.49 Out-of-pocket costs for over-the-counter medicines,
as well as aids and appliances, were calculated using currently available prices.
Outcomes
The primary outcome measure was the percentage of patients with successful eradication of
P. aeruginosa 3 months after the start of treatment and who remained infection free through 15 months
after the start of treatment and this was calculated for both the i.v. antibiotic therapy arm and the oral
antibiotic therapy arm.
The secondary outcome was the QALY, which is a composite of HRQoL, as measured by the EQ-5D-3L,
and length of life. The EQ-5D-3L questionnaire has five domains (i.e. mobility, self-care, usual activities,
pain and discomfort, and anxiety and depression) and three levels (i.e. no problems, some problems
and extreme problems) and was completed by either patients or their carers (if < 13 years) at baseline,
and at 3, 15 and 24 months. It is still unclear what the most appropriate method is to elicit HRQoL
for very young children.50,51 The EQ-5D-3L was selected in this study as it was available at the time
of study design and provides consistency with measures of HRQoL frequently used in economic
evaluations within adult populations. However, although there are now specific measures of HRQoL
developed for children, none of the new measures has a robust evidence base for performance yet.50 In
the primary analysis, the time horizon of 15 months was used to match the collection of resource use
data. In sensitivity analysis, the long-term 24-month horizon for QALYs was assessed. The EQ-5D-3L
utility tariff was applied to the EQ-5D-3L questionnaire responses to generate utility scores for each
time point for each patient. To calculate the QALYs, linear interpolation was assumed between the time
points and the area under the curve method was applied.52
Statistical analysis: bootstrapping and missing data
Missing data were multiply imputed (m = 25) through the use of chained equations.53 The data were
assumed to be missing at random. To account for non-normality in the distributions of costs and HRQoL,
predictive mean matching was used. Missing cost data were imputed at the level of the category (inpatient
care, outpatient visits, A&E visits, primary care, etc.) and total costs were passively imputed as a sum of
the individual cost domains for those with missing data. For HRQoL, missing data were imputed for the
utility score for each of the time points and QALYs were passively calculated. Predictors in both the cost
and HRQoL multiple imputation models were patients’ age, sex, treatment arm, and costs at baseline.
Owing to the large numbers of patients with missing data for wider resource use, missing data were not
imputed and, instead, individuals were assumed to have zero use.
To account for statistical uncertainty and the correlation between costs and patient outcomes, the data
were bootstrap sampled with replacement 2000 times.54 For each bootstrap sample, missing data were
imputed55 and incremental measures of cost and outcome were calculated using regression analysis,
controlling for baseline HRQoL, age and treatment arm. The regression analysis used ordinary least
squares, accounting for the multiply imputed data through the use of Rubin’s rules.56 All regression
analysis, including bootstrapping and multiple imputation, was conducted using Stata® v14 (StatCorp
LP, College Station, TX, USA).
Cost-effectiveness
In the primary analysis, mean incremental costs and outcomes were calculated using the binary
treatment arm variable within the linear regression models. To calculate the uncertainty around mean
incremental costs and outcomes, the percentile method was used, with the 97.5th and 2.5th percentile
DOI: 10.3310/hta25650 Health Technology Assessment 2021 Vol. 25 No. 65
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Langton Hewer et al. under the terms of a commissioning contract issued by the Secretary of
State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be
included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for
commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha
House, University of Southampton Science Park, Southampton SO16 7NS, UK.
47
bootstrap iterations representing the 95% CIs. Each of the 2000 bootstrap iterations were plotted on a
cost-effectiveness plane. If feasible, an ICER was calculated:
ICER =
costOT − costIVT
% infection freeOT −% infection freeIVT
, (1)
where OT is oral therapy and IVT is i.v. therapy.
A cost-effectiveness acceptability curve (CEAC) reflecting the likelihood of either technology being
cost-effective for a decision-maker’s willingness to pay for the outcome variable was also plotted.
In the secondary analysis, mean incremental costs and QALYs were calculated, with 95% CIs estimated
through the percentile method. The INB was estimated from the incremental costs and QALYs for i.v.
antibiotic therapy compared with oral antibiotic therapy using the following formula:
INB = λ × (QALYOT −QALYIVT)− (costOT − costIVT), (2)
with λ representing the opportunity cost of health-care resources used in the NHS, otherwise known
as the cost-effectiveness threshold. NICE uses a threshold range between £20,000 and £30,000 per
QALY.57 A positive INB suggests that i.v. antibiotic therapy is the cost-effective option and a negative
INB suggests oral antibiotic therapy is the cost-effective option. Cost-effectiveness planes and CEACs
were also plotted for the secondary analyses.
Sensitivity analysis
A series of assumptions used in the economic evaluation were explored through one-way sensitivity
analysis. Separate analyses explored:
1. full time horizon of QALYs (24 months) alongside the collection of resource use data (15 months)
2. using generalised linear models (GLMs) for the cost analysis with different link and family functions
3. using yearly health-care resource use codes for CF instead of treatment costs and inpatient stay
per diem
4. using a societal perspective for the collection and incorporation of costs.
Generalised linear models
Owing to the skewed and zero-centred nature of costing data, some analysts have recommended using
more complex models such as GLMs to assess incremental differences.58 GLMs have an associated
link function and family function. The base-case approach for both primary and secondary analyses
involved using an identity link with Gaussian family, equivalent to ordinary least squares regression.
For sensitivity analysis, a range of different family functions were also explored alongside an identity
link and log-link, including inverse Gaussian, Poisson and gamma. The method of recycled predictions
was used to estimate the incremental difference in costs.
Using cystic fibrosis Healthcare Resource Groups
Since 2013–14, the NHS has used specialised tariffs for patients with CF.59 The CF currency uses a
risk-adjusted banding system with seven bands of increasing complexity, with providers reimbursed on
a yearly basis according to the risk-adjusted bands. The CF currency is intended to include all direct
medical costs associated with treatment and bandings are split according to whether patients are
adults (≥ 17 years) or children.
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
48
Patients were placed in bands according to their age, any length of stay associated with the initial
intervention and the recorded length of stay for further hospitalisation.
Appendix 6, Table 40 includes the banding algorithm and Table 41 provides the unit costs for the
bandings. Inpatient costs were then replaced in totality with banding costs for 1 year. All other costing
estimates were included within this separate Healthcare Resource Group (HRG) analysis to calculate a
total NHS and PSS cost.
Societal perspective for the inclusion of costs
A societal perspective included patients’ purchase of home aids or over-the-counter medicines, and
the cost of transport to attend outpatient visits or inpatient stays, as well as work lost by patients or
caregivers during the trial. Unit costs were attached to resource use using costs reported in Appendix 6.
The total societal costs were calculated by adding these wider costs to the NHS and PSS costs.
Results
The analysis for health economics was based on a total of 255 patients, of whom 130 patients were
randomised to the oral antibiotic therapy arm and 125 patients were randomised to the i.v. antibiotic
therapy arm.
Tables 21 and 22 present resource utilisation and levels of missingness for NHS and societal resource
use data, respectively. Most resource use was balanced between the arms. However, the resource use
in the oral antibiotic therapy arm was suggestive of having a larger proportion of inpatient stays than
the i.v. antibiotic therapy arm.
Table 23 presents data for the completion of the EQ-5D-3L for the different time points recorded.
The domains most affected by CF were pain and discomfort, and self-care, with fewer patients having
‘no problems’ in these domains. There was no clear difference between EQ-5D-3L levels between arms
of the trial or over the duration of the trial.
TABLE 21 Mean NHS and PSS resource use and missingness data
Resource use
Treatment group, n (SD)
i.v. antibiotic therapy (N= 125) Oral antibiotic therapy (N= 130)
Secondary care
≥ 3 visits 0.12 (0.42) 0.12 (0.42)
Missing 66 61
A&E attendance, discharged 0.05 (0.29) 0.06 (0.29)
Missing 66 61
Inpatient stay 0.27 (0.61) 0.38 (0.71)
Missing 43 40
Outpatient (visits) 1.57 (0.77) 1.58 (0.79)
Missing 78 82
continued
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TABLE 21 Mean NHS and PSS resource use and missingness data (continued )
Resource use
Treatment group, n (SD)
i.v. antibiotic therapy (N= 125) Oral antibiotic therapy (N= 130)
Primary care
GP at surgery 0.25 (0.62) 0.30 (0.71)
Missing 40 34
Doctor at walk-in centre 0.00 (0.00) 0.05 (0.27)
Missing 40 34
Nurse at surgery 0.09 (0.29) 0.13 (0.42)
Missing 40 34
Nurse at walk-in centre 0.00 (0.00) 0.00 (0.00)
Missing 40 34
Other 0.16 (0.55) 0.14 (0.54)
Missing 40 34
Number of prescriptions 2.02 (2.79) 2.18 (3.02)
Missing 41 39
Home visits
GP 0.39 (0.49) 0.30 (0.46)
Missing 66 57
District nurse 0.44 (0.62) 0.32 (0.50)
Missing 66 57
Health visitor 0.44 (0.62) 0.36 (0.63)
Missing 66 57
Nurse 0.56 (0.82) 0.44 (0.78)
Missing 66 57
Physiotherapy 0.49 (0.73) 0.34 (0.58)
Missing 66 57
Occupational therapy 0.39 (0.49) 0.30 (0.46)
Missing 66 57
Other 0.39 (0.49) 0.30 (0.46)
Missing 66 57
Home care worker 0.07 (0.37) 0.20 (0.60)
Missing 68 60
Community-based professionals
Social worker 0.07 (0.37) 0.20 (0.60)
Missing 68 60
Nurse 0.11 (0.49) 0.06 (0.29)
Missing 68 60
Physiotherapist 0.00 (0.00) 0.07 (0.39)
Missing 68 60
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TABLE 22 Societal resource utilisation and missingness
Resource use
Treatment group, n (%)




No trips 1 (0.8) 5 (4.0)
1–5 trips 51 (41.5) 49 (39.2)
6–10 trips 7 (5.7) 13 (10.4)
> 10 trips 64 (52.0) 58 (46.4)
Missing 2 5
Transport bus
No trips 29 (23.2) 39 (30.0)
0–5 trips 2 (1.6) 3 (2.3)
6–10 trips 0 (0.0) 1 (0.8)
> 10 trips 94 (75.2) 87 (66.9)
Transport taxi
No trips 26 (20.8) 37 (28.5)
0–5 trips 9 (7.2) 10 (7.7)
6–10 trips 1 (0.8) 0 (0.0)
> 10 trips 89 (71.2) 83 (63.8)
Transport other
No trips 21 (16.8) 30 (23.3)
0–5 trips 20 (16.0) 14 (10.9)
6–10 trips 0 (0.0) 2 (1.6)
> 10 trips 84 (67.2) 83 (64.3)
Missing 0 1
Over-the-counter medicines
0 purchases 110 (88.0) 102 (78.5)
1 purchase 7 (5.6) 19 (14.6)
2 purchases 6 (4.8) 8 (6.2)
3 purchases 2 (1.6) 1 (0.8)
Reported as losing time from work (patient)
No 116 (99.1) 124 (100.0)
Yes 1 (0.9) 0 (0.0)
Reported as losing time from work (carer)
No 106 (90.6) 115 (92.7)
Yes 11 (9.4) 9 (7.3)
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No problems 93.8 95.4 93.3 94.1 82.2 93.7 89.8 94.1
Some problems 6.3 4.6 6.7 5.9 17.8 6.3 10.2 5.9
Extreme
problems
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Self-care
No problems 73.6 84.5 77.9 84.8 75.3 86.7 84.2 89.7
Some problems 14.3 4.9 11.6 6.1 16.4 8.9 12.3 5.9
Extreme
problems
12.1 10.7 10.5 9.1 8.2 4.4 3.5 4.4
Usual activities
No problems 84.4 93.5 91.0 89.9 80.3 89.4 91.4 93.9
Some problems 13.5 6.5 7.9 10.1 18.3 10.6 6.9 6.1
Extreme
problems
2.1 0.0 1.1 0.0 1.4 0.0 1.7 0.0
Pain and discomfort
No problems 80.0 81.7 82.0 82.0 74.0 81.9 75.9 86.8
Some problems 20.0 17.4 18.0 18.0 23.3 18.1 24.1 13.2
Extreme
problems
0.0 0.9 0.0 0.0 2.7 0.0 0.0 0.0
Anxiety and depression
No problems 86.3 88.9 85.2 88.9 80.6 87.2 84.7 95.5
Some problems 12.6 11.1 12.5 11.1 18.1 11.7 15.3 3.0
Extreme
problems












































Incremental costs and outcomes
Unit costs used in the analysis are shown in Appendix 6.
In Table 24, mean costs and outcomes are calculated for the arms of the trial. The mean costs for the
intervention were far higher for the i.v. antibiotic therapy arm (£7284.40) than for the oral antibiotic
therapy arm (£264.30). Follow-up inpatient costs and outpatient costs were higher for the oral
TABLE 24 Costs and outcomes between treatment groups (based on multiply imputed data, m = 25)
Cost and outcome




therapy (N= 125) Oral – i.v. Baseline adjusteda




Primary care 25.13 28.42
Home visits 172.00 185.10
Intervention cost 264.30 7284.40
Prescribed medicines 248.20 124.30














Wider resource use (£)
Patient/carer lost work 1.88 7.67




















EQ-5D baseline 0.873 0.820
EQ-5D 3 months 0.893 0.854
EQ-5D 15 months 0.893 0.829













a Baseline EQ-5D, age.
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antibiotic therapy arm than for the i.v. antibiotic therapy arm. Overall, oral antibiotic therapy was less
costly than i.v. antibiotic therapy, with the incremental difference in mean costs between the arms
being –£5938.50 (95% CI –£7190.30 to –£4686.70) after adjusting for baseline covariates. Most of
the total cost difference reflects the difference in intervention costs, with i.v. antibiotic therapy being
associated with high inpatient stay costs. The inclusion of societal costs had a trivial impact on overall
incremental cost differences between the arms of the trial, with the incremental societal cost, after
adjusting for baseline covariates, being –£5938.50 (95% CI –£7190.30 to –£4686.70) for the oral
antibiotic therapy arm compared with the i.v. antibiotic therapy group.
The primary outcome measure showed that the oral antibiotic therapy arm had a larger proportion of
successful eradications of P. aeruginosa 3 months after the start of treatment and remaining infection
free through 15 months after start of treatment than the i.v. antibiotic therapy arm. The incremental
difference in effect after adjusting for baseline covariates was 0.091 (95% CI –0.034 to 0.22).
For a 15-month time horizon, patients in the oral antibiotic therapy arm gained 1.14 QALYs, with
patients in the i.v. antibiotic therapy arm gaining only 1.05 QALYs. There was an overall unadjusted
incremental difference in QALYs of 0.063 (95% CI 0.0074 to 0.12) after 15 months, with an adjusted
incremental difference in QALYs of 0.035 (95% CI –0.015 to 0.086). After 24 months, patients in the
oral antibiotic therapy arm gained 1.8 QALYs and patients in the i.v. antibiotic therapy arm gained 1.7
QALYs. There was an unadjusted incremental difference in QALYs of 0.098 (95% CI 0.013 to 0.18) and
an adjusted incremental difference in QALYs of 0.058 (95% CI –0.020 to 0.14) for the oral antibiotic
therapy arm compared with the i.v. antibiotic therapy arm.
Cost-effectiveness analysis
Table 25 shows incremental cost-effectiveness for the primary and secondary analysis, as well as the
impact of sensitivity analyses on cost-effectiveness. In all scenarios, oral antibiotic therapy was associated
with lower costs than i.v. antibiotic therapy, and was also more effective. Consequently, oral antibiotic
therapy dominated i.v. antibiotic therapy in both the primary and the secondary analyses. In the secondary
analysis, for a threshold of £20,000 per QALY, oral antibiotic therapy generated £6770.80 (95% CI
£5027.40 to £7906.20) benefit per patient, compared with i.v. antibiotic therapy.
The use of specialised HRG costs led to a smaller difference in costs between the two arms, but
the oral antibiotic therapy arm still had a lower incremental cost of –£653.08 (95% CI–£1197.80 to
–£79.80) compared with the i.v. antibiotic therapy arm. Table 26 shows how patients were grouped into
HRG bands. Patients in the oral antibiotic therapy arm were more likely to be in band 1 than patients
in the i.v. antibiotic therapy arm, in which patients tended to be clustered in higher-risk/higher-cost
bands. However, the highest band reported in the data (band 3) included a larger proportion of
patients in the oral antibiotic therapy arm than in the i.v. antibiotic therapy arm as a result of a small
number of patients in the oral antibiotic therapy arm having a long inpatient stay in the follow-up
period. In the secondary analysis with CF HRG costs, the oral antibiotic therapy arm generated
£653.10 (95% CI £79.80 to £1197.80) benefit per patient for a cost-effectiveness threshold of
£20,000 per QALY.
Changes in model function for the cost data and the inclusion of societal costs led to only small
changes in the incremental cost differences between the arms of the trial. The INB was large for oral
antibiotic therapy compared with i.v. antibiotic therapy in each scenario.
Incremental cost-effectiveness planes and CEACs for the primary analysis, secondary analysis and
associated sensitivity analyses are shown in Appendix 6, Figures 33–45.
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TABLE 25 Incremental costs, outcomes, ICERs and INB between treatment groups
Analysis Incremental cost (£) (95% CI)
Incremental outcome
(95% CI) ICER INB (95% CI)
Primary analysis: proportion infection free, NHS and PSS perspective
costs, 15-month horizon, adjusted
–5938.50 (–7107.40 to –4666.30) 0.091 (–0.034 to 0.22) Oral dominates N/A
Sensitivity analysis
Primary analysis: proportion infection free, NHS and PSS perspective
costs, 15-month horizon, covariate adjusted, CF HRG costs used
–653.08 (–1197.80 to –79.80) 0.091 (–0.034 to 0.22) Oral dominates N/A
Primary analysis: clinical effect, societal perspective costs, 15-month
horizon, adjusted
–5937.00 (–7120.80 to –4659.10) 0.091 (–0.034 to 0.22) Oral dominates N/A
Primary analysis: proportion infection free, NHS and PSS perspective
costs, covariate adjusted, GLM cost model [link(log); family (Gaussian)]
–5942.40 (–7054.90 to –4713.10) 0.091 (–0.034 to 0.22) Oral dominates N/A
Primary analysis: proportion infection free, NHS and PSS perspective
costs, covariate adjusted, GLM cost model [link(log); family (Gaussian)]
–6625.50 (–8574.80 to –5196.60) 0.091 (–0.034 to 0.22) Oral dominates N/A
Secondary analysis: 15-month horizon QALYs, NHS and PSS
perspective costs, covariate
–5938.50 (–7107.40 to –4666.30) 0.035 (–0.007 to 0.088) Oral dominates 6770.8 (5027.4 to 7906.2)
Sensitivity analysis
Secondary analysis: 24-month horizon QALYs, NHS and PSS
perspective costs, covariate adjusted
–5938.50 (–7107.40 to –4666.30) 0.058 (–0.004 to 0.140) Oral dominates 7229.8 (5411.8 to 8553.1)
Secondary analysis: 15-month horizon QALYs, NHS and PSS
perspective costs, covariate, CF HRG costs used
–653.08 (–1197.80 to –79.80) 0.035 (–0.007 to 0.088) Oral dominates 653.1 (79.8 to 1197.8)
Secondary analysis: 15-month horizon QALYs, societal perspective
costs, covariate
–5937.00 (–7052.60 to –4713.20) 0.035 (–0.007 to 0.088) Oral dominates 6755.7 (4977.4 to 8409.3)
Secondary analysis: 15-month horizon QALYs, NHS and PSS
perspective costs, covariate adjusted, GLM cost model [link(log);
family (Gaussian)]
–5942.40 (–7054.90 to –4713.10) 0.035 (–0.007 to 0.088) Oral dominates 6684.4 (5057.0 to 8406.9)
Secondary analysis: 15-month horizon QALYs, NHS and PSS
perspective costs, covariate adjusted, GLM cost model [link(log);
family (inverse Gaussian)]
–6625.50 (–8574.80 to –5196.60) 0.035 (–0.007 to 0.088) Oral dominates 7343.0 (5586.8 to 9756.2)
Secondary analysis: 15-month horizon QALYs, NHS and PSS
perspective costs, CF HRG, covariate adjusted, GLM cost model
[link(log); family (Gaussian)]
–656.60 (–1231.00 to –75.33) 0.035 (–0.007 to 0.088) Oral dominates 1518.9 (251.8 to 2678.9)
Secondary analysis: 15-month horizon QALYs, NHS and PSS
perspective costs, CF HRG, covariate adjusted, GLM cost model
[link(log); family (inverse Gaussian)]



















































































































































































































































































































































































































































For each scenario, oral antibiotic therapy was highly likely to be cost-effective, with virtually all of the
bootstrap replicates falling within the south-east quadrant, demonstrating that the oral antibiotic
therapy was both more effective and less costly than i.v. antibiotic therapy. For the secondary analysis
involving a cost-effectiveness threshold of £20,000 per QALY, oral antibiotic therapy had a 100%
chance of being cost-effective compared with i.v. antibiotic therapy in the base-case analysis, and
findings were robust to assumptions regarding the use of CF HRG codes, costing model specification
and inclusion of societal costs.
TABLE 26 Cystic fibrosis HRG bands and mean band costs
HRG band












6263.10 (205.80) 7154.60 (164.30) 843.80 (–1369.30 to –318.30) 894.40 (–1412.60 to –370.20)
a Age, baseline HRQoL.
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Chapter 7 Discussion
We tested the hypothesis that, for eradicating a new infection with P. aeruginosa in people with CF,an i.v. antibiotic regimen (2 weeks of i.v. ceftazidime and tobramycin) is more effective than
an oral antibiotic (12 weeks of oral ciprofloxacin). In line with UK CF antibiotic guidelines,11 inhaled
colistimethate sodium was included in both regimens.We found that the i.v. regimen was not superior in
achieving the primary outcome – eradication of P. aeruginosa at 3 months and remaining free of infection
to 15 months. The clinically important difference that was set at the beginning of the trial, was not
contained in the 95% CI. In the 12 months following completion of the eradication regimen, there was
a statistically significant difference in the length of hospital stay in favour of the i.v. antibiotic therapy
group. However, this is unlikely to be clinically important as the median length of stay was 0 days in both
groups. The proportion of patients who had at least one hospital stay was significantly lower in the i.v.
antibiotic therapy group (30.2%) than in the oral antibiotic therapy group (46.3%). A possible explanation
of this finding is that patients who already had one hospital admission for eradication might be less likely
to be offered or to accept a further admission in the subsequent 12-month period.We found significant
differences in percentage predicted FVC and adult BMI in favour of the i.v. regimen; however, these
differences were based on small numbers, were numerically small and are unlikely to be clinically
important. There were no other significant differences in secondary outcome measures, AEs or
acquisition of new organisms between the two groups.
A recent systematic review pointed out that, although P. aeruginosa infection carries an adverse
prognosis and eradication is an effective approach, there is no evidence to favour one eradication
regimen over another.16 Uncontrolled studies have advocated an i.v. eradication regimen.60 However,
i.v. treatment often entails hospital admission, requires i.v. access (which may be traumatic)61 and carries
the risk of side effects such as nephrotoxicity and, in the case of aminoglycosides such as tobramycin,
ototoxicity.62 Regardless of which regimen is used, regular collection of airways’ specimens is advised to
detect P. aeruginosa early.11 Furthermore, eradication treatment should be initiated as soon as possible
after P. aeruginosa is detected in respiratory secretions.63 A recent crossover trial of eradication in young
children demonstrated a much lower eradication rate in those who received the placebo in the initial
28-day treatment period.64 The TORPEDO-CF protocol mandated that the eradication regimen should
start no more than 21 days from the report demonstrating P. aeruginosa in the airways.
The TORPEDO-CF used a pragmatic design which aimed to minimise the burden of participation.
Respiratory specimens for microbiology were collected at routine clinic visits, which meant that not
all specimens were obtained in the 3-week time window at the end of the 15-month follow-up period.
To address this, we extended the window to include patients with samples 4 weeks on either side of
15 months and conducted a sensitivity analysis using the next sample collected after the 15-month
window. We collected sputum and (where this was not possible) a cough swab. Bronchoscopy has been
used to collect samples for microbiological outcomes in previous eradication trials,9 but it is not used
for this purpose in routine clinical practice, and, hence, was not mandated in TORPEDO-CF.
A strength of our study is the large sample size and the length of follow-up. In the first generation of
placebo-controlled eradication trials, sample size was often small and microbiological eradication was
reported immediately after the end of eradication treatment.9 More recently, a large randomised
controlled trial, evaluating two 28-day eradication regimens, found that > 60% of participants had
further infection with P. aeruginosa during a median follow-up period of 16 months.65 Arguably, with
longer periods of follow-up, reoccurrence of P. aeruginosa will be influenced to a lesser degree by a
single course of eradication treatment. Hence, the 12 months of post-eradication follow-up used in
our study is a reasonable period over which to evaluate the effect of treatment in achieving sustained
eradication of P. aeruginosa.
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There were several limitations of TORPEDO-CF. It took longer than expected to recruit the required
sample size for the trial. Feasibility data suggested that 25% of eligible patients would be adults.12
However, we recruited only 15 adults out of a total sample size of 286 participants, partly because of
a smaller number of adult centres participating in the trial. We advise caution in applying these trial
findings to the adult CF population.
Many patients and families had a strong preference for one eradication regimen; 324 patients/families
declined to participate because they did not want i.v. treatment and 34 patients/families declined because
they did not want an oral regimen. Our feasibility study suggested that 45% of parents and patients
would consider participation. The consent rates achieved in TORPEDO-CF were a little lower: 286 out of
772 (37%) eligible patients approached. A total of 1308 patients were screened for eligibility for the trial;
1022 patients did not meet the eligibility criteria and we randomised 286 patients.
The possibility that the trial participants may be different from the rest of the CF population and
may have had a better clinical status and, therefore, be more likely to agree to the uncertainty of
trial participation cannot be ruled out. Thirty participants were excluded from the primary analysis
(12 participants in the i.v. antibiotic treatment group and 18 participants in the oral antibiotic treatment
group). These were participants in whom P. aeruginosa was not detected following completion of
eradication, but who did not have a sample taken at the 15-month time window. These exclusions will
diminish the power of the study to show superiority of one regimen over another.
Not all participants received their allocated treatment, and a further group did not receive the prescribed
course in full. Of the 137 participants in the i.v. antibiotic therapy group, 11 (8.0%) participants did not
receive treatment (either allocated intervention or colistimethate sodium) and 29 (21.2%) participants
stopped treatment early. In the oral antibiotic therapy group, 2 out of 148 participants (1.4%) did not start
treatment and 24 (16.1%) participants stopped treatment early. The most common reason for not
completing allocated treatment was difficulty with i.v. access. Lack of complete fidelity to allocated
treatment will also reduce the trial’s power to demonstrate superiority.
Recent engagement work from the UK has identified ‘the best way of eradicating pseudomonas’ as one
of the top 10 research priorities for the patient community.66 In the USA, ‘respiratory microorganism
detection and treatment was the top priority’.67 Future research studies should combine long-term
follow-up with regimens to reduce reoccurrence after eradication. The recent OPTIMIZE (Optimizing
Treatment for Early Pseudomonas aeruginosa Infection in Cystic Fibrosis) trial68 used 18 months of
oral azithromycin as an adjunct to eradication with inhaled tobramycin, but found no difference in time
to reoccurrence. In future, a randomised registry design such as used in the ongoing cystic fibrosis (CF)
anti-staphylococcal antibiotic prophylaxis trial (CF-START); ISRCTN18130649] may be applied to
Pseudomonas eradication trials to allow long-term follow-up and to reduce both the cost of trials and
the inconvenience to trial participants.
Engagement work with the CF community both in the UK66 and in the USA67 has highlighted research to
reduce the treatment burden in CF as a priority. When a treatment (such as i.v. antibiotics) is burdensome,
but no more effective, it follows that patients should be offered an eradication regimen that is appropriate
to their clinical condition and personal circumstances. P. aeruginosa may be identified at the time of a
pulmonary exacerbation when i.v. antibiotics are clinically indicated. In other cases, when the patient is
asymptomatic, oral eradication is appropriate. In our trial, only 13.1% of patients in the i.v. group and
11.5% in the oral group had an exacerbation at baseline. If the findings of this trial are implemented in
routine clinical practice, most patients will receive oral treatment as an outpatient and many admissions
will be avoided. This will reduce treatment burden and will reduce health-care costs.
The health economic analysis was partially limited by difficulties associated with gathering HRQoL
data in young children. Although the EQ-5D-3L was selected for consistency and practical reasons, its
completion by young patients or by carers is subject to great uncertainty. Measures of HRQoL in young
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patients have been developed since the inception of this trial, but evidence of their validity is still at an
early stage. As a consequence of the challenges associated with eliciting HRQoL, the health economics
analysis for cost-effectiveness primarily relied on the results that similar proportions of individuals had
a repeat infection over the duration of the trial, while oral antibiotics were considerably cheaper to
administer. Oral therapy was clearly shown to be less expensive than i.v. therapy, with a cost saving
of £5938.50 (equivalent to US$7543.00). Consequently, the most cost-effective strategy was the use of
oral antibiotics. If the trial had found significant clinical benefit from i.v. eradication therapy over oral
therapy, then some additional cost for i.v. therapy could be balanced against this to assist decision-
making. However, there were no important clinical benefits to the use of i.v. over oral therapy and the
large difference in cost suggests that oral therapy should usually be recommended for eradication of
early infection with P. aeruginosa in CF.
Our trial found that, even in the oral arm (which had the better result for our primary outcome), only
around half of participants were free of infection 15 months after randomisation. Future research should
aim to improve rates of eradication through approaches such as earlier detection of P. aeruginosa and
salvage therapy for failed eradication. It should also be a priority to evaluate the effects of CFTR
modulators on acquisition and eradication of P. aeruginosa.
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Appendix 1 Clinical Trials Unit team
The trial was conducted by the LCTC, University of Liverpool, Liverpool, UK.
TABLE 27 Roles of Clinical Trials Unit team
Role Team member
Director Professor Paula Williamsona
Senior statistician Dr Ashley Jones
Senior trial manager Ms Helen Hickey
Senior data managers Ms Sue Howlin
Ms Clare Jackson
Ms Joanne Eatock
Information systems managers Dr Duncan Appelbe
Ms Marie Connor
Trial statistician Mrs Michaela Brown





Trial co-ordinator assistant Ms Sarah Olsen





Data managers Ms Michelle Girvan
Mr Paul Tate
Database developers Mrs Janet Harrison
Mr Meirion Thomas
a Professor Paula Williamson was the director of the Clinical Trials
Research Centre, University of Liverpool at the time that the work
was carried out. The unit has since been rebranded as LCTC and is
now directed by Professor Carrol Gamble.
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Appendix 2 Trial oversight committees
Trial Steering Committee
Independent members: Professor Jonathan Grigg, Dr David Stableforth, Professor Barry Plant,
Professor Duncan Geddes, Mrs Jennifer Wederell, Dr Ranjit Lall, Ms Sophie Lewis and
Mr Dominic Kavanagh.
Non-independent members: Dr Simon Langton Hewer and Professor Alan Smyth.
Independent Data and Safety Monitoring Committee
Dr Robert Dinwiddie, Professor Christiane De Boeck and Mrs Enid Hennessy.
Trial Management Group
Dr Simon Langton Hewer, Professor Alan Smyth, Professor Deborah Ashby, Professor Paula Williamson,
Ms Jessica Bissett, Dr Ashley Jones, Mrs Michaela Brown, Ms Helen Hickey, Ms Sue Howlin,
Ms Farhiya Ashoor and Dr Dervla Kenna.
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Appendix 3 Recruiting centres in centre
number order
TABLE 28 Participating sites and PIs
Centre and clinic Investigators
Addenbrooke’s Hospital – Paediatrics Dr Robert Ross-Russell
Alder Hey Children’s Hospital – Paediatrics Professor Kevin Southern
Barts and The London Children’s Hospital – Paediatrics Dr Chinedu Nwokoro
Belfast City Hospital – Adults Dr Damian Downey
Birmingham Children’s Hospital – Paediatrics Dr Maya Desai
Birmingham Heartlands Hospital – Adults Dr Joanna L Whitehouse
Birmingham Heartlands Hospital – Paediatrics Dr Sarah Denniston
Bradford Royal Infirmary – Paediatrics Dr Eduardo Moya
Bristol Royal Hospital for Children – Paediatrics Dr Simon Langton Hewer
Bristol Royal Infirmary – Adults Dr Simon Langton Hewer
Chesterfield Royal Hospital – Paediatrics Professor Jim Crossley
Conquest Hospital – Paediatrics Dr Geeta Gopal
Countess of Chester Hospital – Paediatrics Dr Ravi Jayaram
Darlington Memorial Hospital – Paediatrics Dr John Furness
Derriford Hospital – Adults Dr David Derry
Derriford Hospital – Paediatrics Dr Alan Cade
Eastbourne District General Hospital – Paediatrics Dr. Geeta Gopal
Genoa CF Centre – Adults Dr Laura Minicucci
Genoa CF Centre – Paediatrics Dr Laura Minicucci
Gloucestershire Royal Hospital – Paediatrics Dr Mike Webb
Great Ormond Street Hospital – Paediatrics Dr Colin Wallis
Hillingdon Hospital – Paediatrics Dr Stephen Goldring
Hull Royal Infirmary – Paediatrics Dr Ashwini Kotwal
James Cook University Hospital – Paediatrics Dr Rajamanickam Jayaraj
James Paget University Hospital – Paediatrics Dr Caroline Kavanagh
Kettering General Hospital – Paediatrics Dr Patti Rao
King’s College Hospital – Paediatrics Dr Gary Ruiz
King’s Mill Hospital – Paediatrics Dr Mike Yanney
Leicester Children’s Hospital – Paediatrics Dr Erol Gaillard
Leighton Hospital – Paediatrics Dr Julie Ellison
Lincoln County Hospital – Paediatrics Dr Amol Chingale
Macclesfield District General Hospital – Paediatrics Dr Surendran Chandrasekaran
Musgrove Park Hospital – Paediatrics Dr Alexandra Powell
New Cross Hospital – Paediatrics Dr Rosie Rayner
continued
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TABLE 28 Participating sites and PIs (continued )
Centre and clinic Investigators
Norfolk and Norwich University Hospital – Paediatrics Dr Caroline Kavanagh
North Devon District Hospital – Paediatrics Dr Dermot Dalton
Nottingham City Hospital – Adults Dr Jane Dewar
Nottingham Children’s Hospital – Paediatrics Professor Alan Smyth
Oxford Children’s Hospital – Paediatrics Dr Jeremy Hull
Pilgrim Hospital – Paediatrics Dr Margaret Crawford
Queen Alexandra Hospital – Paediatrics Dr Hannah Buckley
Royal Alexandra Children’s Hospital – Paediatrics Dr Paul Seddon
Royal Berkshire Hospital – Paediatrics Dr Claire Holt
Royal Brompton Hospital – Adults Dr Nick Simmonds
Royal Brompton Hospital – Paediatrics Professor Andrew Bush
Royal Cornwall Hospital – Paediatrics Dr Anne Prendiville
Royal Derby Hospital – Paediatrics Dr Nigel Ruggins
Royal Devon and Exeter Hospital – Adults Dr Patrick Oades
Royal Devon and Exeter Hospital – Paediatrics Dr Patrick Oades
Royal Hospital for Sick Children – Paediatrics Professor Steve Cunningham
Royal Preston Hospital – Paediatrics Dr Karnam Sugumar
Royal Shrewsbury Hospital – Paediatrics Dr Martyn Rees
Royal United Hospital – Paediatrics Dr Rebecca Winterson
Royal Victoria Infirmary – Adults Dr Simon Doe
Royal Victoria Infirmary – Paediatrics Dr Malcolm Brodie
Salisbury District Hospital – Paediatrics Dr Robert Scott-Jupp
Sheffield Children’s Hospital – Paediatrics Dr Christopher Taylor
Southampton General Hospital – Adults Dr Mary Carroll
Southampton General Hospital – Paediatrics Dr Julian Legg
St James’s University Hospital – Paediatrics Dr Tim Lee
Torbay Hospital – Adults Dr Lee Dobson
Torbay Hospital – Paediatrics Dr Atanu Mukherjee
University Hospital North Staffordshire – Adults Professor Warren Lenny
University Hospital North Staffordshire – Paediatrics Professor Warren Lenny
University Hospital of Wales – Adults Dr Ian Ketchell
University Hospital of Wales – Paediatrics Dr Julian Forton
Walsgrave Hospitals NHS Trust – Paediatrics Dr Edward Simmonds
Warrington Hospital – Paediatrics Dr Christopher Bedford
William Harvey Hospital – Paediatrics Dr Ola Smith
Wythenshawe Hospital – Adults Dr Naveen Rao
Wythenshawe Hospital – Paediatrics Dr Naveen Rao
York Teaching Hospital – Paediatrics Dr Murray Wheeler
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Appendix 4 Additional results
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Consent rate, %n % n % n % n %
Addenbrooke’s Hospital – Paediatrics 22 23 1 4.3 1 4.3 16 69.6 5 21.7 23.8
Alder Hey Children’s Hospital – Paediatrics 53 55 12 21.8 2 3.6 19 34.5 22 40 53.7
Barts and The London Children’s Hospital – Paediatrics 25 26 3 11.5 3 11.5 17 65.4 3 11.5 15
Belfast City Hospital – Adults 3 3 2 66.7 0 0.0 0 0.0 1 33.3 100
Birmingham Children’s Hospital – Paediatrics 75 76 17 22.4 14 18.4 30 39.5 15 19.7 33.3
Birmingham Heartlands Hospital – Adults 4 4 0 0.0 0 0.0 0 0.0 4 100 100
Birmingham Heartlands Hospital – Paediatrics 13 13 5 38.5 1 7.7 6 46.2 1 7.7 14.3
Bradford Royal Infirmary – Paediatrics 2 2 1 50 1 50 0 0.0 0 0.0 –
Bristol Royal Hospital for Children – Paediatrics 48 48 4 8.3 7 14.6 15 31.3 22 45.8 59.5
Bristol Royal Infirmary – Adults 1 1 0 0.0 0 0.0 0 0.0 1 100 100
Chesterfield Royal Hospital – Paediatrics 4 5 0 0.0 0 0.0 3 60 2 40 40
Conquest Hospital – Paediatrics 5 6 1 16.7 0 0.0 2 33.3 3 50 60
Countess of Chester Hospital – Paediatrics 6 6 1 16.7 1 16.7 4 66.7 0 0.0 0.0
Darlington Memorial Hospital – Paediatrics 2 2 1 50 1 50 0 0.0 0 0.0 –
Derriford Hospital – Adults 29 49 39 79.6 1 2 5 10.2 4 8.2 44.4
Derriford Hospital – Paediatrics 17 19 1 5.3 0 0.0 15 78.9 3 15.8 16.7
Eastbourne District General Hospital – Paediatrics 2 2 0 0.0 0 0.0 0 0.0 2 100 100
Genoa CF Centre – Adults 1 1 0 0.0 0 0.0 0 0.0 1 100 100
Genoa CF Centre – Paediatrics 1 1 0 0.0 0 0.0 0 0.00 1 100 100
Gloucestershire Royal Hospital – Paediatrics 37 54 32 59.3 5 9.3 16 29.6 1 1.9 5.9
Great Ormond Street Hospital – Paediatrics 46 46 9 19.6 12 26.1 18 39.1 7 15.2 28
Hillingdon Hospital – Paediatrics 1 1 0 0.0 0 0.0 0 0.0 1 100 100
Hull Royal Infirmary – Paediatrics 13 14 3 21.4 1 7.1 4 28.6 6 42.9 60
James Cook University Hospital – Paediatrics 23 39 26 66.7 1 2.6 5 12.8 7 17.9 58.3














































Consent rate, %n % n % n % n %
Kettering General Hospital – Paediatrics 7 7 1 14.3 0 0.0 2 28.6 4 57.1 66.7
King’s College Hospital – Paediatrics 14 14 1 7.1 1 7.1 1 7.1 11 78.6 91.7
King’s Mill Hospital – Paediatrics 9 9 1 11.1 0 0.0 3 33.3 5 55.6 62.5
Leicester Children’s Hospital – Paediatrics 56 79 48 60.8 10 12.7 13 16.5 8 10.1 38.1
Leighton Hospital – Paediatrics 6 6 0 0.0 3 50 1 16.7 2 33.3 66.7
Lincoln County Hospital – Paediatrics 15 15 1 6.7 0 0.0 9 60 5 33.3 35.7
Macclesfield District General Hospital – Paediatrics 2 3 1 33.3 2 66.7 0 0.0 0 0.0 –
Musgrove Park Hospital – Paediatrics 10 10 3 30 0 0.0 2 20 5 50 71.4
New Cross Hospital – Paediatrics 20 21 6 28.6 2 9.5 10 47.6 3 14.3 23.1
Norfolk and Norwich University Hospital – Paediatrics 18 25 9 36 3 12 9 36 4 16 30.8
North Devon District Hospital – Paediatrics 2 2 0 0.0 0 0.0 0 0.0 2 100 100
Nottingham City Hospital – Adults 9 9 6 66.7 0 0.0 3 33.3 0 0.0 0.0
Nottingham Children’s Hospital – Paediatrics 44 52 12 23.1 3 5.8 24 46.2 13 25 35.1
Oxford Children’s Hospital – Paediatrics 6 6 1 16.7 0 0.0 3 50 2 33.3 40
Pilgrim Hospital – Paediatrics 5 6 1 16.7 0 0.0 2 33.3 3 50 60
Queen Alexandra Hospital – Paediatrics 15 22 9 40.9 1 4.5 3 13.6 9 40.9 75
Royal Alexandra Children’s Hospital – Paediatrics 12 13 0 0.0 0 0.0 8 61.5 5 38.5 38.5
Royal Berkshire Hospital – Paediatrics 3 3 0 0.0 0 0.0 0 0.0 3 100 100
Royal Brompton Hospital – Adults 31 31 19 61.3 3 9.7 8 25.8 1 3.2 11.1
Royal Brompton Hospital – Paediatrics 78 79 4 5.1 14 17.7 55 69.6 6 7.6 9.8
Royal Cornwall Hospital – Paediatrics 25 38 20 52.6 1 2.6 14 36.8 3 7.9 17.6
Royal Derby Hospital – Paediatrics 13 14 3 21.4 2 14.3 9 64.3 0 0.0 0.0
Royal Devon and Exeter Hospital – Adults 11 12 7 58.3 2 16.7 1 8.3 2 16.7 66.7
Royal Devon and Exeter Hospital – Paediatrics 33 33 13 39.4 2 6.1 8 24.2 10 30.3 55.6






























































































































































































































































































































































































































































Consent rate, %n % n % n % n %
Royal Preston Hospital – Paediatrics 14 14 3 21.4 1 7.1 6 42.9 4 28.6 40
Royal Shrewsbury Hospital – Paediatrics 10 13 3 23.1 0 0.0 1 7.7 9 69.2 90
Royal United Hospital – Paediatrics 17 19 10 52.6 0 0.0 5 26.3 4 21.1 44.4
Royal Victoria Infirmary – Adults 3 3 0 0.0 1 33.3 1 33.3 1 33.3 50
Royal Victoria Infirmary – Paediatrics 11 11 3 27.3 2 18.2 4 36.4 2 18.2 33.3
Salisbury District Hospital – Paediatrics 2 2 0 0.0 0 0.0 0 0.0 2 100 100
Sheffield Children’s Hospital – Paediatrics 43 52 18 34.6 3 5.8 25 48.1 6 11.5 19.4
Southampton General Hospital – Adults 2 2 0 0.0 0 0.0 1 50 1 50 50
Southampton General Hospital – Paediatrics 4 4 0 0.0 0 0.0 2 50 2 50 50
St James’s University Hospital – Paediatrics 197 264b 154 58.3 71 26.9 32 12.1 4 1.5 11.1
Torbay Hospital – Adults 1 1 0 0.0 0 0.0 0 0.0 1 100 100
Torbay Hospital – Paediatrics 13 15 13 86.7 0 0.0 2 13.3 0 0.0 0.0
University Hospital North Staffordshire – Adults 6 7 2 28.6 1 14.3 4 57.1 0 0.0 0.0
University Hospital North Staffordshire – Paediatrics 20 20 1 5 2 10 4 20 13 65 76.5
University Hospital of Wales – Adults 2 2 0 0.0 0 0.0 1 50 1 50 50
University Hospital of Wales – Paediatrics 8 8 1 12.5 2 25 2 25 3 37.5 60
Walsgrave Hospitals NHS Trust – Paediatrics 16 18 3 16.7 2 11.1 8 44.4 5 27.8 38.5
Warrington Hospital – Paediatrics 3 3 1 33.3 0 0.0 1 33.3 1 33.3 50
William Harvey Hospital – Paediatrics 3 3 0 0.0 0 0.0 2 66.7 1 33.3 33.3
Wythenshawe Hospital – Adults 12 12 7 58.3 3 25 2 16.7 0 0.0 0.0
Wythenshawe Hospital – Paediatrics 10 10 4 40 1 10 2 20 3 30 60
York Teaching Hospital – Paediatrics 7 7 0 0.0 1 14.3 6 85.7 0 0.0 0.0
a Multiple screenings allowed.




































TABLE 30 Reasons for ineligibility
Reason for ineligibility Number of patientsa
Aged ≤ 28 days 4
Known to be pregnant 5
Not P. aeruginosa free 168
Not able to commence treatment within
21 days from the date of a P. aeruginosa-
positive microbiology report
20
Antibiotic resistance of the current
P. aeruginosa sample to any of the
study drugs
49
Has been receiving P. aeruginosa-
suppressing treatment
211
Known hypersensitivity to any of the
study drugs
29
Other known contraindications to any
of the study drugs
7






Participated in another interventional
trial within last 4 weeks
14
Poor compliance 22
Did not identify P. aeruginosa 18
Unknown whether patient is
P. aeruginosa free/naive
1
a Multiple screenings allowed.
TABLE 31 Reasons patients not approached
Reason patient not approached Number of patientsa
Clinician decision 113
Family circumstances 11




Did not understand English 8
Other reason 4
No reason given 14
a Multiple screenings allowed.
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TABLE 32 Reasons consent not provided
Reason patient not consented Number of patientsa
Did not want i.v. treatment 324
Did not want oral treatment 34
Did not want to attend follow-up 7
Did not want to be involved in research 3
Did not want to be randomised 7






No reason given 80
a Multiple screenings allowed.





















21 February 2011 27 January 2017 5 October 2011 24 November
2016
22





27 January 2017 6 October 2014 9 November 2015 3
Belfast City Hospital –
Adults





27 January 2017 5 October 2010 6 December 2016 15
Birmingham Heartlands
Hospital – Adults
1 June 2012 27 January 2017 21 May 2013 26 February 2014 4
Birmingham Heartlands
Hospital – Paediatrics








18 June 2010 27 January 2017 18 November
2010
18 January 2017 22




27 January 2017 3 June 2014 3 June 2014 1
Chesterfield Royal
Hospital – Paediatrics
19 January 2011 27 January 2017 20 January 2011 24 March 2011 2
Conquest Hospital –
Paediatrics
27 February 2012 27 January 2017 13 April 2012 24 March 2014 3
Derriford Hospital –
Adults
30 July 2010 27 January 2017 16 April 2013 24 February 2015 4
Derriford Hospital –
Paediatrics




25 January 2012 27 January 2017 1 February 2012 3 October 2013 2
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
80












Genoa CF Centre –
Adults
6 October 2016 27 January 2017 11 October 2016 11 October 2016 1
Genoa CF Centre –
Paediatrics
6 October 2016 27 January 2017 25 October 2016 25 October 2016 1
Gloucestershire Royal
Hospital – Paediatrics










21 August 2012 27 January 2017 21 August 2012 21 August 2012 1
Hull Royal Infirmary –
Paediatrics
26 January 2012 27 January 2017 3 February 2014 16 February 2016 6
James Cook University
Hospital – Paediatrics
28 March 2012 27 January 2017 23 July 2012 21 January 2015 7
Kettering General
Hospital – Paediatrics
11 April 2012 27 January 2017 31 August 2012 15 February 2016 4
King’s College Hospital –
Paediatrics
26 October 2011 27 January 2017 18 January 2012 17 October 2016 11
















27 January 2017 3 January 2012 7 August 2014 2
Lincoln County
Hospital – Paediatrics







21 July 2010 27 January 2017 11 March 2011 20 November
2015
5
New Cross Hospital –
Paediatrics






10 February 2012 27 January 2017 30 April 2012 28 July 2016 4
North Devon District
Hospital – Paediatrics
26 April 2013 27 January 2017 24 September
2013
9 September 2014 2
Nottingham Children’s
Hospital – Paediatrics
12 July 2010 27 January 2017 22 February 2011 6 September 2016 13
Oxford Children’s
Hospital – Paediatrics
17 May 2011 27 January 2017 18 October 2012 7 November 2014 2
Pilgrim Hospital –
Paediatrics
6 February 2012 27 January 2017 7 February 2012 25 August 2015 3
Queen Alexandra
Hospital – Paediatrics











27 January 2017 24 February 2015 5 October 2016 3
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6 January 2015 27 January 2017 2 February 2015 2 February 2015 1
Royal Brompton
Hospital – Paediatrics















4 August 2010 27 January 2017 4 January 2011 30 December
2015
10
Royal Hospital for Sick
Children – Paediatrics
25 July 2012 27 January 2017 10 April 2013 8 January 2016 5
Royal Preston Hospital
– Paediatrics
25 October 2011 27 January 2017 15 November
2011
13 February 2014 4
Royal Shrewsbury
Hospital – Paediatrics
6 December 2012 27 January 2017 3 October 2013 27 January 2017 9
Royal United Hospital –
Paediatrics
2 March 2011 27 January 2017 27 March 2013 26 January 2017 4
Royal Victoria Infirmary
– Adults
22 March 2016 27 January 2017 18 May 2016 18 May 2016 1
Royal Victoria Infirmary
– Paediatrics







23 April 2013 27 January 2017 13 October 2015 6 December 2016 2
Sheffield Children’s
Hospital – Paediatrics
23 February 2011 27 January 2017 03 October 2012 7 December 2016 6
Southampton General
Hospital – Adults
19 February 2013 27 January 2017 12 February 2015 12 February 2015 1
Southampton General
Hospital – Paediatrics
4 February 2013 27 January 2017 22 April 2013 24 March 2014 2
St James’s University
Hospital – Paediatrics













26 January 2011 27 January 2017 30 January 2012 9 September 2015 13
University Hospital of
Wales – Adults







20 February 2013 27 January 2017 16 January 2014 2 October 2014 3
Walsgrave Hospitals
NHS Trust – Paediatrics





















27 January 2017 5 August 2013 7 October 2013 3
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FIGURE 6 Time to reoccurrence of original P. aeruginosa infection: unknown strains assumed to be same as baseline.
i.v. antibiotic therapy
Oral antibiotic therapy
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Treatment group
Time (months)



































































FIGURE 7 Time to reoccurrence of original P. aeruginosa infection: unknown strains assumed to be same as baseline
(sensitivity analysis using date of treatment commencement rather than date of randomisation).
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FIGURE 8 Time to reoccurrence of original P. aeruginosa infection: unknown strains assumed to be different from baseline.
i.v. antibiotic therapy
Oral antibiotic therapy
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FIGURE 9 Time to reoccurrence of original P. aeruginosa infection: unknown strains assumed to be different from
baseline (sensitivity analysis using date of treatment commencement rather than date of randomisation).
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FIGURE 11 Role/school functioning (self-report): mean scores over time by treatment group.
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FIGURE 13 Emotional functioning (self-report): mean scores over time by treatment group.
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FIGURE 15 Body image (self-report): mean scores over time by treatment group.
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FIGURE 17 Treatment burden (self-report): mean scores over time by treatment group.
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FIGURE 19 Weight (self-report): mean scores over time by treatment group.
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FIGURE 21 Digestive symptoms (self-report): mean scores over time by treatment group.
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FIGURE 23 Role/school functioning (parent/carer): mean scores over time by treatment group.
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FIGURE 25 Emotional functioning (parent/carer): mean scores over time by treatment group.
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FIGURE 27 Eating problems (parent/carer): mean scores over time by treatment group.
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FIGURE 29 Health perceptions (parent/carer): mean scores over time by treatment group.
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FIGURE 31 Respiratory symptoms (parent/carer): mean scores over time by treatment group.
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FIGURE 32 Digestive symptoms (parent/carer): mean scores over time by treatment group.
TABLE 34 Number of participants with additional organisms of interest during the 15 months post randomisation
Organism
Treatment group, n (%)
i.v. antibiotic therapy (N= 137) Oral antibiotic therapy (N= 148)
Staphylococcus aureus 51 (37.2) 53 (35.8)
Haemophilus influenzae 36 (26.3) 32 (21.6)
Mycobacterium abscessus 0 (0) 1 (0.7)
Mycobacterium avium–intracellulare complex 0 (0) 0 (0)
Other non-tuberculous mycobacteria 0 (0) 0 (0)
Stenotrophomonas maltophilia 6 (4.4) 9 (6.1)
Achromobacter xylosoxidans 1 (0.7) 3 (20.0)
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Appendix 5 Additional safety data
TABLE 35 The MedDRA classifications for all AEs
AE description (verbatim) Preferred term SOC







A and E admission corzal illness Upper respiratory tract
infection
Infections and infestations
Abdominal pain Abdominal pain Gastrointestinal disorders





Abnormal CXR Chest X-ray abnormal Investigations
Achilles tendonitis Tendonitis Musculoskeletal and connective tissue
disorders
Adverse drug reaction to colomycin (i.v.) Adverse drug reaction General disorders and administration
site conditions





Bed wetting Enuresis Psychiatric disorders
Bilateral knee pain Arthralgia Musculoskeletal and connective tissue
disorders
Black tongue Tongue discolouration Gastrointestinal disorders
Bronchospasm caused by colistin Bronchospasm Respiratory, thoracic and mediastinal
disorders




Candidiasis of nappy area Candida infection Infections and infestations
Chest pain Chest pain General disorders and administration
site conditions
Chest infection Lower respiratory tract
infection
Infections and infestations
Chicken pox Varicella Infections and infestations
Cold productive cough Productive cough Respiratory, thoracic and mediastinal
disorders
Corza Rhinitis Infections and infestations
Cough Cough Respiratory, thoracic and mediastinal
disorders





Deterioration over 1 month General physical health
deterioration
General disorders and administration
site conditions
Diarrhoea Diarrhoea Gastrointestinal disorders
continued
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TABLE 35 The MedDRA classifications for all AEs (continued )
AE description (verbatim) Preferred term SOC
Diarrhoea started 3 days after starting cipro Diarrhoea Gastrointestinal disorders
Diarrhoea Diarrhoea Gastrointestinal disorders
Dizzy episodes Dizziness Nervous system disorders
Eczema under dressing Eczema Skin and subcutaneous tissue disorders
Episode of ciprofloxacin-resistant
P. aeruginosa colonisation
Pseudomonas infection Infections and infestations




Fall from cot on ward Fall Injury, poisoning and procedural
complications
Fall whilst at school – painful neck Fall Injury, poisoning and procedural
complications
Fell whilst sledging and hit back of
head on road
Fall Injury, poisoning and procedural
complications
Fever/high temperature Pyrexia General disorders and administration
site conditions
Foot and mount disease Foot and mouth disease Infections and infestations
Fractured skull Skull fracture Injury, poisoning and procedural
complications
Gastroenteritis Gastroenteritis Infections and infestations
Glandular fever Infectious mononucleosis Infections and infestations
H. influenza on cough swab Haemophilus test positive Investigations
H. influenza infection Haemophilus infection Infections and infestations
Hay fever Seasonal allergy Immune system disorders
Headache Headache Nervous system disorders
High temperature Pyrexia General disorders and administration
site conditions
Hospital admission with croup Croup infectious Infections and infestations
i.v. cannula tissued Catheter site-related
reaction
General disorders and administration
site conditions
Increase cough + sputum production Pyrexia General disorders and administration
site conditions
Increased cough Cough Respiratory, thoracic and mediastinal
disorders
Increased cough and sputum production Productive cough Respiratory, thoracic and mediastinal
disorders
Increased cough and sputum production
prior to surgery
Productive cough Respiratory, thoracic and mediastinal
disorders
Increased cough at night Cough Respiratory, thoracic and mediastinal
disorders
Increased faecal loading Constipation Gastrointestinal disorders
Increased temperature Pyrexia General disorders and administration
site conditions
Increased wet cough Productive cough Respiratory, thoracic and mediastinal
disorders
Infected eczema Eczema infected Infections and infestations
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TABLE 35 The MedDRA classifications for all AEs (continued )
AE description (verbatim) Preferred term SOC




Isolate of Pseudomonas Pseudomonas infection Infections and infestations
Isolate of Pseudomonas aeruginosa Pseudomonas infection Infections and infestations
Itchy rash Rash pruritic Skin and subcutaneous tissue disorders
Long line removed as thrombophlebitis
evident
Thrombophlebitis Vascular disorders
Loose stool Diarrhoea Gastrointestinal disorders
Loose stools Diarrhoea Gastrointestinal disorders
MAI in sputum Mycobacterium avium
complex infection
Infections and infestations
Manifestation of anxiety Anxiety Psychiatric disorders
Migraine Migraine Nervous system disorders
Mild epistaxis Epistaxis Respiratory, thoracic and mediastinal
disorders
Nausea Nausea Gastrointestinal disorders
Neck ache/stiffness Pain General disorders and administration
site conditions
New growth of pseudomonas Pseudomonas infection Infections and infestations
Nosebleed Epistaxis Respiratory, thoracic and mediastinal
disorders
Oral thrush Oral candidiasis Infections and infestations
P. aeruginosa at 3-month follow-up Pseudomonas infection Infections and infestations
PR bleed Rectal haemorrhage Gastrointestinal disorders
Pain in knees Arthralgia Musculoskeletal and connective tissue
disorders
Pain in legs Pain in extremity Musculoskeletal and connective tissue
disorders
Pancreatitis Pancreatitis Gastrointestinal disorders
Petechial rash to trunk Petechiae Skin and subcutaneous tissue disorders
Photosensitive rash Photosensitivity reaction Skin and subcutaneous tissue disorders
Positive pseudomonas aeruginosa Pseudomonas infection Infections and infestations
Productive cough Productive cough Respiratory, thoracic and mediastinal
disorders
Prolonged cough Productive cough Respiratory, thoracic and mediastinal
disorders




Pyrexia (high temp) productive cough Pyrexia General disorders and administration
site conditions
RTI Respiratory tract infection Infections and infestations
Re-growth pseudomonas Pseudomonas infection Infections and infestations
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TABLE 35 The MedDRA classifications for all AEs (continued )
AE description (verbatim) Preferred term SOC
Respiratory tract infection Respiratory tract infection Infections and infestations
Right-sided rib pain Musculoskeletal chest pain Musculoskeletal and connective tissue
disorders
Short of breath, coughing with exercise/
spontaneous moist cough, considerably
reduced air entry R side
Dyspnoea Respiratory, thoracic and mediastinal
disorders
Shoulder ache/stiffness Musculoskeletal stiffness Musculoskeletal and connective tissue
disorders
Stomach ache Abdominal pain upper Gastrointestinal disorders
Swollen throat Pharyngeal oedema Respiratory, thoracic and mediastinal
disorders
Thrush Candida infection Infections and infestations
Thrush (nappy area) Candida infection Infections and infestations
Tingling lips, itchy ears and decreased vision Paraesthesia oral Gastrointestinal disorders
Tracheal tug and wheeze Wheezing Respiratory, thoracic and mediastinal
disorders
Tummy pain Abdominal pain upper Gastrointestinal disorders
Tummy pain, loose stools Diarrhoea Gastrointestinal disorders
URTI Upper respiratory tract
infection
Infections and infestations
URTI, cough + wheeze Upper respiratory tract
infection
Infections and infestations
UTI Urinary tract infection Infections and infestations
Viral infection Viral infection Infections and infestations
Viral illness Viral infection Infections and infestations
Vitamin A deficiency Vitamin A deficiency Metabolism and nutrition disorders
Vitamin D deficiency Vitamin D deficiency Metabolism and nutrition disorders
Vitamin E deficiency Vitamin E deficiency Metabolism and nutrition disorders
Vomiting starting 3 days after starting Cipro Vomiting Gastrointestinal disorders
Vulva candidiasis Vulvovaginal candidiasis Infections and infestations
Wet cough Productive cough Respiratory, thoracic and mediastinal
disorders
Wet cough Productive cough Respiratory, thoracic and mediastinal
disorders
Wheeze Wheezing Respiratory, thoracic and mediastinal
disorders
Wheezy 4/52 Wheezing Respiratory, thoracic and mediastinal
disorders
abdominal pain Abdominal pain Gastrointestinal disorders
abdominal pain Abdominal pain Gastrointestinal disorders





admission for i.v. antibiotic for chest infection Lower respiratory tract
infection
Infections and infestations
back/side pain Flank pain Musculoskeletal and connective tissue
disorders
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TABLE 35 The MedDRA classifications for all AEs (continued )
AE description (verbatim) Preferred term SOC
bleeding at site of line insertion Administration site bruise General disorders and administration
site conditions
blocked feeling in ears Ear discomfort Ear and labyrinth disorders
blood in vomit Haematemesis Gastrointestinal disorders
bronchospasm Bronchospasm Respiratory, thoracic and mediastinal
disorders




chest pain (posteria) pain under rt ribs Chest pain General disorders and administration
site conditions
chest pain and tiredness Chest pain General disorders and administration
site conditions
chesty Cough Respiratory, thoracic and mediastinal
disorders
chicken pox Varicella Infections and infestations
cold Nasopharyngitis Infections and infestations
conjunctivitis Conjunctivitis Infections and infestations
constipation Constipation Gastrointestinal disorders
corysal + coughing Upper respiratory tract
infection
Infections and infestations
coryza Upper respiratory tract
infection
Infections and infestations
coryzal illness Upper respiratory tract
infection
Infections and infestations
coryzed and coughing Upper respiratory tract
infection
Infections and infestations
cough Cough Respiratory, thoracic and mediastinal
disorders
cough, runny nose Cough Respiratory, thoracic and mediastinal
disorders
cough/wheeze Cough Respiratory, thoracic and mediastinal
disorders
development of vaginal thrush Vulvovaginal candidiasis Infections and infestations
device blockage Device occlusion Product issues
diarrhoea Diarrhoea Gastrointestinal disorders
distal intestinal obstruction syndrome (DIOS) Distal intestinal
obstruction syndrome
Gastrointestinal disorders
dizzy Dizziness Nervous system disorders
dry cough Cough Respiratory, thoracic and mediastinal
disorders
dry, peeling skin on toes- both feet Dry skin Skin and subcutaneous tissue disorders
dvt proximal left calf Deep vein thrombosis Vascular disorders
earache Ear pain Ear and labyrinth disorders
elevated blood sugars Blood glucose increased Investigations
eye infection Eye infection Infections and infestations
febrile convulsion Febrile convulsion Nervous system disorders
continued
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TABLE 35 The MedDRA classifications for all AEs (continued )
AE description (verbatim) Preferred term SOC
fever Pyrexia General disorders and administration
site conditions
flu-like symptoms (fever/cough) Influenza-like illness General disorders and administration
site conditions
fractured left and right wrist Wrist fracture Injury, poisoning and procedural
complications
gastroenteritis Gastroenteritis Infections and infestations
grown pseudomonas Bacterial disease carrier Infections and infestations
growth haemophilus on cough swab Haemophilus test positive Investigations
growth of ent cloacae Enterobacter test positive Investigations
growth of Klebisella pneumoniae Klebsiella test positive Investigations





haemoptysis (post nasal polyectomy
operation)
Haemoptysis Respiratory, thoracic and mediastinal
disorders
hand foot and mouth Foot and mouth disease Infections and infestations
headache Headache Nervous system disorders
heamophilus influenza infection Haemophilus infection Infections and infestations
high temperature, hoppy dry cough Pyrexia General disorders and administration
site conditions




increase cough Cough Respiratory, thoracic and mediastinal
disorders
increase cough and sputum Productive cough Respiratory, thoracic and mediastinal
disorders
increased cough Cough Respiratory, thoracic and mediastinal
disorders
increased cough and sputum and extra
oral abs
Cough Respiratory, thoracic and mediastinal
disorders
increased cough since 1st May 2015 Cough Respiratory, thoracic and mediastinal
disorders
increased dry cough Cough Respiratory, thoracic and mediastinal
disorders
increased frequency passing urine Polyuria Renal and urinary disorders
increased sputum Sputum increased Respiratory, thoracic and mediastinal
disorders
increased sputum congestion Productive cough Respiratory, thoracic and mediastinal
disorders
increased temperature Pyrexia General disorders and administration
site conditions
increased wheeze Wheezing Respiratory, thoracic and mediastinal
disorders
involved in accident injured, bump to
abdomen with heamaturic
Haematuria Renal and urinary disorders
joint pain Arthralgia Musculoskeletal and connective tissue
disorders
left lower lobe pneumonia Pneumonia Infections and infestations
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TABLE 35 The MedDRA classifications for all AEs (continued )
AE description (verbatim) Preferred term SOC
left side intermittent back pain Back pain Musculoskeletal and connective tissue
disorders
lethargy Lethargy Nervous system disorders
liver failure Hepatic failure Hepatobiliary disorders
long line blocked Device occlusion Product issues
loose stools Diarrhoea Gastrointestinal disorders
loss of appetite Decreased appetite Metabolism and nutrition disorders
lung consolidation Lung consolidation Respiratory, thoracic and mediastinal
disorders
lung function not back to normal values Pulmonary function test Investigations
malaise Malaise General disorders and administration
site conditions
meconium ileus equivalent Distal intestinal
obstruction syndrome
Gastrointestinal disorders
mild cough Cough Respiratory, thoracic and mediastinal
disorders
myalgia Myalgia Musculoskeletal and connective tissue
disorders
nappy rash Dermatitis diaper Skin and subcutaneous tissue disorders
nasal congestion Nasal congestion Respiratory, thoracic and mediastinal
disorders
nasal vestibulitis Nasal vestibulitis Infections and infestations
new diagnosis of melanoma Malignant melanoma Neoplasms benign, malignant and
unspecified (including cysts and polyps)
no improvement in lung function Pulmonary function test Investigations




onset of productive cough Cough Respiratory, thoracic and mediastinal
disorders
otitis media Otitis media Infections and infestations
p. aeruginosa reoccurred Pseudomonas test positive Investigations
pain at site of line insertion Administration site pain General disorders and administration
site conditions
pain and rash from passing urine Dysuria Renal and urinary disorders
persistent cough Cough Respiratory, thoracic and mediastinal
disorders
persisting cough wheeze Productive cough Respiratory, thoracic and mediastinal
disorders
playground collision – sore arm Limb discomfort Musculoskeletal and connective tissue
disorders
productive cough Productive cough Respiratory, thoracic and mediastinal
disorders
pseudomonas aeruginosa – growth on
cough swab
Pseudomonas infection Infections and infestations
pseudomonas aeruginosa Pseudomonas test Investigations
pseudomonas growth Pseudomonas infection Infections and infestations
continued
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TABLE 35 The MedDRA classifications for all AEs (continued )
AE description (verbatim) Preferred term SOC
pseudomonas isolated on cough swab at end
of trial intervention
Pseudomonas test positive Investigations
pseudomonas re occurrence Pseudomonas infection Infections and infestations








pyrexia Pyrexia General disorders and administration
site conditions
raised alanine transaminase Alanine aminotransferase
increased
Investigations
rash Rash Skin and subcutaneous tissue disorders
rash due to ciprofloxacilin Adverse drug reaction General disorders and administration
site conditions
rash on neck Rash Skin and subcutaneous tissue disorders
re growth of pseudomonas aeruginosa Pseudomonas infection Infections and infestations
re-growth of Pseudomonas – i.v. antibiotics
as in-patient
Pseudomonas infection Infections and infestations
recurrent L episaxis for about 2 months Epistaxis Respiratory, thoracic and mediastinal
disorders
reduction in lung function Pulmonary function test
decreased
Investigations
regrowth of pseudomonas aeruginosa Pseudomonas test positive Investigations
required added co-amoxiclav for cough Cough Respiratory, thoracic and mediastinal
disorders








respiratory syncytial virus positive Bronchiolitis Infections and infestations
segmental right middle lobe collapse/
conslidation consistent with acute plugging
or infection
Pneumothorax Respiratory, thoracic and mediastinal
disorders
sinus infection Sinusitis Infections and infestations
strep pyogenes – extra oral antibiotics Streptococcus test positive Investigations
sunburn with skin blistering Sunburn Injury, poisoning and procedural
complications
swollen nose Swelling General disorders and administration
site conditions
thrush Candida infection Infections and infestations
toe nails peeling – both feet Onychoclasis Skin and subcutaneous tissue disorders
transient discolouration of arms/legs Skin discolouration Skin and subcutaneous tissue disorders
upper arm pain Pain General disorders and administration
site conditions
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TABLE 35 The MedDRA classifications for all AEs (continued )
AE description (verbatim) Preferred term SOC
urticrial rash following ciprofloxacin and a
mixed nut bar. Subsequent doses of cipro
proved to have no adverse reaction
Urticaria Skin and subcutaneous tissue disorders
venous long line leaking from exit site on
flushing
Catheter management Surgical and medical procedures
viral illness Viral infection Infections and infestations
vomits Vomiting Gastrointestinal disorders
vomiting Vomiting Gastrointestinal disorders
wet cough Productive cough Respiratory, thoracic and mediastinal
disorders
wet cough increased sputum Productive cough Respiratory, thoracic and mediastinal
disorders
wheeze Wheezing Respiratory, thoracic and mediastinal
disorders
wheezy Wheezing Respiratory, thoracic and mediastinal
disorders
wheezy cough with colomycin Wheezing Respiratory, thoracic and mediastinal
disorders
wheezy with exercise (montekulast) Wheezing Respiratory, thoracic and mediastinal
disorders
CXR, chest radiograph; DIOS, distal intestinal obstruction syndrome; L, left; MAI, Mycobacterium avium complex infection;
PR, per rectum; R, right; RTI, respiratory tract infection; URTI, upper respiratory tract infection; UTI, urinary tract infection.
TABLE 36 Non-SAEs as recorded on the locked database
SOC Preferred term
Treatment group, n (%)





Events Patients Events Patients Events Patients
Ear and labyrinth
disorders
Ear discomfort 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Ear pain 0 0 (0.0) 2 2 (1.4) 2 2 (0.7)
Gastrointestinal
disorders
Abdominal pain 1 1 (0.8) 2 2 (1.4) 3 3 (1.1)
Abdominal pain upper 1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Constipation 1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Diarrhoea 6 5 (4) 3 3 (2.1) 9 8 (2.9)
Distal intestinal obstruction
syndrome
2 2 (1.6) 3 3 (2.1) 5 5 (1.8)
Haematemesis 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Nausea 1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Pancreatitis 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Paraesthesia oral 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Rectal haemorrhage 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Tongue discolouration 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Vomiting 3 3 (2.4) 0 0 (0.0) 3 3 (1.1)
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TABLE 36 Non-SAEs as recorded on the locked database (continued )
SOC Preferred term
Treatment group, n (%)









Administration site bruise 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Administration site pain 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Adverse drug reaction 1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Catheter site-related
reaction
1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Chest pain 1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Influenza-like illness 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Malaise 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Pain 1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Pyrexia 2 2 (1.6) 7 7 (4.8) 9 9 (3.3)
Swelling 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Immune system
disorders
Seasonal allergy 1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Infections and
infestations
Bacterial disease carrier 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Bronchopulmonary
aspergillosis allergic
0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Candida infection 1 1 (0.8) 5 5 (3.4) 6 6 (2.2)
Conjunctivitis 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Eczema infected 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Eye infection 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Foot and mouth disease 0 0 (0.0) 2 2 (1.4) 2 2 (0.7)
Gastroenteritis 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Haemophilus infection 2 1 (0.8) 0 0 (0.0) 2 1 (0.4)




4 3 (2.4) 6 6 (4.1) 10 9 (3.3)
Lower respiratory tract
infection
0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Mycobacterium avium
complex infection
0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Nasal vestibulitis 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Nasopharyngitis 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Oral candidiasis 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Otitis media 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Pneumonia 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Pseudomonas infection 7 7 (5.6) 2 2 (1.4) 9 9 (3.3)
Respiratory tract infection 1 1 (0.8) 2 2 (1.4) 3 3 (1.1)
Sinusitis 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Upper respiratory tract
infection
15 11 (8.7) 3 2 (1.4) 18 13 (4.8)
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TABLE 36 Non-SAEs as recorded on the locked database (continued )
SOC Preferred term
Treatment group, n (%)





Events Patients Events Patients Events Patients
Urinary tract infection 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Varicella 3 3 (2.4) 1 1 (0.7) 4 4 (1.5)
Viral infection 1 1 (0.8) 1 1 (0.7) 2 2 (0.7)




Fall 1 1 (0.8) 2 2 (1.4) 3 3 (1.1)
Skull fracture 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Sunburn 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Wrist fracture 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Investigations Alanine aminotransferase
increased
1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Blood glucose increased 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Chest X-ray abnormal 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Enterobacter test positive 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Haemophilus test positive 2 2 (1.6) 0 0 (0.0) 2 2 (0.7)
Klebsiella test positive 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Pseudomonas test 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Pseudomonas test positive 1 1 (0.8) 2 2 (1.4) 3 3 (1.1)
Pulmonary function test 0 0 (0.0) 2 2 (1.4) 2 2 (0.7)
Pulmonary function test
decreased
1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Stenotrophomonas test
positive
0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Streptococcus test positive 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Metabolism and
nutrition disorders
Decreased appetite 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Vitamin A deficiency 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Vitamin D deficiency 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)




Arthralgia 0 0 (0.0) 3 3 (2.1) 3 3 (1.1)
Back pain 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Flank pain 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Limb discomfort 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Musculoskeletal chest pain 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Musculoskeletal stiffness 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Myalgia 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Pain in extremity 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Tendonitis 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
continued
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TABLE 36 Non-SAEs as recorded on the locked database (continued )
SOC Preferred term
Treatment group, n (%)











Malignant melanoma 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Nervous system
disorders
Dizziness 1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Febrile convulsion 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Headache 3 2 (1.6) 0 0 (0.0) 3 2 (0.7)
Lethargy 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Migraine 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Product issues Device occlusion 2 2 (1.6) 0 0 (0.0) 2 2 (0.7)
Psychiatric
disorders
Enuresis 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Renal and urinary
disorders
Dysuria 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)





Bronchospasm 1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Cough 26 22 (17.5) 28 23 (15.8) 54 45 (16.5)
Epistaxis 1 1 (0.8) 2 2 (1.4) 3 3 (1.1)
Haemoptysis 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Nasal congestion 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Pharyngeal oedema 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Productive cough 5 5 (4) 8 8 (5.5) 13 13 (4.8)
Sputum increased 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)




Dermatitis diaper 1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Dry skin 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Eczema 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Onychoclasis 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Petechiae 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Photosensitivity reaction 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Rash 2 2 (1.6) 1 1 (0.7) 3 3 (1.1)
Skin discolouration 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Urticaria 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Total 135 64 (50.8) 144 75 (51.4) 279 139 (51.1)
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TABLE 37 Serious adverse events/SARs as reported in the locked trial database
SOC Preferred term
Treatment group, n (%)














Chest pain 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
General physical health
deterioration
0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Pyrexia 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Hepatobiliary
disorders
Hepatic failure 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Infections and
infestations
Bronchiolitis 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Croup infectious 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)




1 1 (0.8) 1 1 (0.7) 2 2 (0.7)
Lower respiratory tract
infection
0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Pseudomonas infection 0 0 (0.0) 3 3 (2.1) 3 3 (1.1)
Rhinitis 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Upper respiratory tract
infection
0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Viral infection 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Nervous system
disorders
Headache 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Psychiatric disorders Anxietya 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Renal and urinary
disorders




Dyspnoea 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Lung consolidation 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)
Pneumothorax 0 0 (0.0) 1 1 (0.7) 1 1 (0.4)




Rash pruritic 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Surgical and medical
procedures
Catheter management 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Vascular disorders Deep-vein thrombosis 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Thrombophlebitis 1 1 (0.8) 0 0 (0.0) 1 1 (0.4)
Total 11 10 (7.9) 21 14 (9.6) 32 24 (8.8)
a Event was that, after 5 weeks on the trial, the patient developed voices in their head, obsessive behaviours and
anxiety at night.
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Relationship Most likely cause,
if unrelated









Moderate Unexpected Unrelated Unlikely Disease under
study
Resolved








Mild Unexpected Unrelated Unrelated Disease under
study
Resolved
4 Oral Infections and
infestations




Moderate Unexpected Unrelated Unrelated Other illness Resolved








Moderate Unexpected Unrelated Unrelated Disease under
study
Resolved
6 Oral Infections and
infestations




Moderate Expected Unrelated Unrelated Other illness Resolved
7 i.v. Skin and
subcutaneous
tissue disorders






Moderate Expected Possibly Probably Resolved
8 Oral Infections and
infestations




Severe Unexpected Unrelated Unrelated Other illness Resolved








Mild Expected Probably Probably Resolved
with
sequelae





















Moderate Unexpected Unlikely Unrelated Other illness Resolved
13 Oral General disorders
and administration
site conditions




Moderate Unexpected Unrelated Unrelated Other illness Resolved
























16 Oral Infections and
infestations






























































Relationship Most likely cause,
if unrelated










Mild Unexpected Unrelated Unrelated Disease under
study
Resolved




Mild Expected Probably Probably Resolved



















Moderate Unexpected Unrelated Unrelated Disease under
study
Resolved
22 i.v. Renal and urinary
disorders




Moderate Unexpected Unrelated Unrelated Resolved
23 i.v. Hepatobiliary
disorders






Severe Unexpected Unrelated Unrelated Other illness Resolved
with
sequelae









































Moderate Expected Possibly Possibly Other illness Resolved









Moderate Unexpected Unrelated Unrelated Disease under
study
Resolved
29 i.v. General disorders
and administration
site conditions




Moderate Expected Possibly Unlikely Other illness Resolved
CI, chief investigator.
a SAE numbers 3 and 11 were allocated in error to AEs that did not meet the criteria for SAEs.
b Event was that, after 5 weeks on the trial, the patient developed voices in their head, obsessive behaviours and anxiety at night.
Note



















































































































































































































































































































































































































































TABLE 39 Clarification of AEs terms made by chief investigator and co-chief investigator






Agreed terminology to be
used for preferred term
SOC for agreed
terminology




















4 Swollen nose Swelling General disorders
and administration
site conditions
Nasal swelling General disorders
and administration
site conditions


























8 Nasal vestibulitis Nasal vestibulitis Infections and
infestations
Nasal vestibulitis Infections and
infestations

































































































Chest infection Infections and
infestations
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Appendix 6 Additional economic
evaluation information
Calculation of societal costs
Table 42 provides the societal unit costs used for the sensitivity analysis in the trial. Societal unit costs
covered patient aids paid for out of pocket by the carer/patient; any travel time, stratified by mode of




The car travel costs are summarised in Table 43. The cost per mile was converted to the cost per
minute using the mean speed of 25 miles per hour reported by the Department for Transport in
2018.71 Speed per minute was 0.42 miles per minute during free flow and 0.23 miles per minute with
adjustment for congestion, assuming a mean delay of 47 seconds per minute.
The cost estimates are based on the motoring costs per mile for domestic purposes reported by the
AA in 2014.72 The cost of personal transport did not change between 2014–17 according to the
Department for Transport, so the estimates from 2014 were assumed to be applicable to the 2017/18
cost year used in the analysis.73
TABLE 40 Logic for banding
Category Criteria
Band
1 1A 2 2A 3 4 5
Therapies Maximum number of total days of i.v. antibiotics 0 14 28 56 84 112 ≥ 113
Hospitalisations Maximum numbers of days in hospital 0 7 14 14 57 112 ≥ 113
TABLE 41 Cystic fibrosis specialty HRG costs
Band Measurement Unit cost (£) Source Detail
Band 1, adults ≥ 17 years Per year 3362 NHS reference costs 2016–1744 Table 39
Band 1A, adults ≥ 17 years Per year 5380 NHS reference costs 2016–1744 Table 39
Band 1A, children ≤ 16 years Per year 5778 NHS reference costs 2016–1744 Table 39
Band 1, children ≤ 16 years Per year 5685 NHS reference costs 2016–1744 Table 39
Band 2, adults ≥ 17 years Per year 6498 NHS reference costs 2016–1744 Table 39
Band 2A, adults ≥ 17 years Per year 8922 NHS reference costs 2016–1744 Table 39
Band 2A, children ≤ 16 years Per year 8968 NHS reference costs 2016–1744 Table 39
Band 2, children ≤ 16 years Per year 7492 NHS reference costs 2016–1744 Table 39
Band 3, adults ≥ 17 years Per year 15,337 NHS reference costs 2016–1744 Table 39
Band 3, children ≤ 16 years Per year 16,770 NHS reference costs 2016–1744 Table 39
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Bus
The bus travel costs are summarised in Table 44. The unit cost of bus transport was based on the
operating cost per passenger journey in English metropolitan areas in 2017/18.74 Given that bus
transport is predominantly publicly funded in England, it was assumed that this cost is reflective of the
cost paid by the passenger.
TABLE 42 Societal unit costs
Item Measurement Unit cost (£) Source Detail
Patient aids
Anti-allergy pillow Per item 8.00 Wilko (Wilko Retail Ltd,
Worksop, UK)69
Anti-allergy bed covers Per item 10.00 Wilko70
Peak flow medicine Per item 5.00 BNF 201743
Travel costs
Car Per minute 0.23 AA plc (Basingstoke, UK) Based on the motoring
costs per mile for
domestic purposes
Bus Per minute 0.08 Department for Transport Local bus transport
statistics reported.
3.5 miles per journey




Time lost from work
Carer/patient time Per hour 17.00 Office for National
Statistics49
Work per minute using
the mean hourly earnings
reported by the Office
for National Statistics49
Over-the-counter medicines
Various Per medicine/pill Various BNF 201743
TABLE 43 Travel costs for car
Item Cost per mile (£)
Cost per minute (£)
Without congestion With congestion
Standing charges (tax, insurance, capital) 0.35 0.15 0.08
Running costs (fuel, service, parts) 0.20 0.08 0.05
Total running costs 0.56a 0.23 0.13
a Rounded up to 0.56.
TABLE 44 Travel costs for bus
Item Cost (£)
Cost per passenger journey 1.23
Cost per minute 0.08
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The cost per minute was derived from the local bus transport statistics reported by the Department for
Transport in 2017/18. There were 4844 million journeys covering 16.9 billion miles, which corresponds
to 3.5 miles per journey.75,76 Assuming a mean speed of 25 miles per hour during free flow and 14 miles
per hour adjusting for congestion, the mean duration of a bus journey is 15 minutes.
Taxi
It was assumed that the mean length of a taxi journey is equivalent to the mean length of a bus
journey as described above (3.5 miles) lasting 15 minutes.
There is a large variation in regulated taxi fares across the UK. For example, the estimated cost of a
3.5-mile journey (including minimum charge) during daytime hours on a weekday is £6.30 in Glasgow,77
£8.00 in Liverpool,78 £8.25 in Plymouth79 and £8.90 in Manchester.80 The cost of a 3.5-mile taxi journey
was substantially higher in London (£12.40).81
The unit cost of a taxi journey depends on whether the journey was taken in or outside London, as
presented in Table 45.
Lost productivity
Lost productivity was estimated as the lost income from work per minute using the mean hourly
earnings reported by the Office for National Statistics,49 as recorded in Table 46.






London 12.40 0.83 Transport for London81
Outside London 8.00 0.53 Assumption (based on average
of Glasgow, Liverpool,
Manchester and Plymouth)
TABLE 46 Lost productivity
Category Per hour (£) Per minute (£) Source
Mean hourly earnings
excluding overtime
16.76 0.28 Office for National Statistics49
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FIGURE 33 Primary analysis: proportion infection free, NHS and PSS perspective costs, 15-month horizon, covariate
adjusted. (a) Incremental cost-effectiveness plane; and (b) CEAC.
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FIGURE 34 Primary analysis with sensitivity test using specialist HRG costs for CF patients. (a) Incremental cost-
effectiveness plane; and (b) CEAC.
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FIGURE 35 Primary analysis: proportion infection free, NHS and PSS perspective costs, covariate adjusted, GLM cost
model [link(log); family (Gaussian)]. (a) Incremental cost-effectiveness plane; and (b) CEAC.
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FIGURE 36 Primary analysis: proportion infection free, NHS and PSS perspective costs, covariate adjusted, GLM cost
model [link(log); family (Gaussian)]. (a) Incremental cost-effectiveness plane; and (b) CEAC.
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FIGURE 37 Primary analysis: clinical effect, NHS and PSS perspective costs, covariate adjusted, GLM cost model [link(log);
family (Gaussian)]. (a) Incremental cost-effectiveness plane; and (b) CEAC.
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FIGURE 38 Secondary analysis: 15-month horizon QALYs, NHS and PSS perspective costs, covariate. (a) Incremental
cost-effectiveness plane; and (b) CEAC.
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FIGURE 39 Secondary analysis: 24-month horizon QALYs, NHS and PSS perspective costs, covariate adjusted.
(a) Incremental cost-effectiveness plane; and (b) CEAC.
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FIGURE 40 Secondary analysis: 15-month horizon QALYs, NHS and PSS perspective costs, covariate adjusted, CF HRG
used. (a) Incremental cost-effectiveness plane; and (b) CEAC.
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FIGURE 41 Secondary analysis: 15-month horizon QALYs, societal perspective costs, covariate adjusted. (a) Incremental
cost-effectiveness plane; and (b) CEAC.
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FIGURE 42 Secondary analysis: 15-month horizon QALYs, NHS and PSS perspective costs, covariate adjusted, GLM cost
model [link(log); family (Gaussian)]. (a) Incremental cost-effectiveness plane; and (b) CEAC.
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FIGURE 43 Secondary analysis: 15-month horizon QALYs, NHS and PSS perspective costs, covariate adjusted, GLM cost
model [link(log); family (inverse Gaussian)]. (a) Incremental cost-effectiveness plane; and (b) CEAC.
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FIGURE 44 Secondary analysis: 15-month horizon QALYs, NHS and PSS perspective costs, CF HRG, covariate adjusted,
GLM cost model [link(log); family (Gaussian)]. (a) Incremental cost-effectiveness plane; and (b) CEAC.
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FIGURE 45 Secondary analysis: 15-month horizon QALYs, NHS and PSS perspective costs, CF HRG, covariate adjusted,
GLM cost model [link(log); family (inverse Gaussian)]. (a) Incremental cost-effectiveness plane; and (b) CEAC.
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